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ABSTRACT 
 
Lymphatic filariasis (LF) is a neglected tropical disease that affects over 120 million 
people worldwide and is caused by three filarial nematodes including Brugia malayi. Despite 
mass drug administration (MDA) to populations at risk for over 17 years, LF still remains a 
global health concern. Parasitism depends on specific interactions between the parasite and host. 
Our efforts of understanding these intricate interactions revealed a novel mechanism through 
which Brugia actively delivers small regulatory RNA and proteins to the host tissues via 
exosomes-like vesicles (ELV). Proteomics reveal stage and gender specific cargo, including 
proteins with potential immunomodulatory capacity. This suggests not only stage specific 
modulation of the host but also potential sexual dimorphism, and supports the hypothesis that 
these vesicles are released by the parasite to cater to its survival within the host. We have shown 
that these ELVs are functional and elicit a stage specific response in host macrophages, further 
supporting the above hypothesis. Further exploration of the possibility of exploiting these ELVs 
in disease control efforts revealed that exosomal release in these parasites is inhibited by current 
anthelmintics used to treat LF including ivermectin (IVM). Previous studies suggest a host 
component in parasite clearance by IVM and the fact that ELV release is inhibited by IVM not 
only supports this hypothesis but also provides evidence for how such a mechanism might take 
place. If our hypothesis that ELVs are released by these parasites to immunomodulate the host to 
aid in survival within the host is true, then inhibition of these vesicle by IVM leaves the parasites 
vulnerable to host defense mechanisms, thereby allowing effective parasite clearance. The use of 
ELV release inhibition as a platform for screening novel drugs resulted in the identification of a 
panel of L-type calcium channel inhibitors that block exosomal release in these parasites more 
potently than IVM. Current diagnostic methods for LF are suboptimal and here we demonstrate 
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proof of principle of using miRNA as biomarkers for more accurate diagnosis. Collectively our 
results reveal a novel mechanism in Brugia and demonstrate the potential of exploiting it in a 
wide spectrum of control efforts. 
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CHAPTER 1: GENERAL INTRODUCTION 
Neglected Tropical Diseases and Lymphatic Filariasis 
 
The World Health Organization (WHO) classifies seventeen diseases as Neglected 
Tropical Diseases (NTDs): Buruli ulcer, Chagas disease, Dengue and Chikunguya, Dracunculiasis, 
Echinococcosis, Foodborne trematodiases, Human African trypanosomiasis, Leishmaniasis, 
Leprosy, Lymphatic filariasis, Onchocerciasis, Rabies, Schistosomiasis, Soil-transmitted 
helminthiases, Taeniasis, Trachoma and Yaws. These are coined NTDs because they occur in low-
income populations in tropical countries and disproportionately few research dollars are allocated 
to investigate these diseases relative to their health and socioeconomic impact. NTDs are caused 
by a wide array of infectious agents ranging from viruses to bacteria to protozoa to parasitic 
helminths [3] that can be transmitted via a range of mechanisms, including vectors such as 
sandflies, blackflies, mosquitoes or snails [3]. Of these NTDs, Lymphatic filariasis, 
Onchocerciasis, Schistosomiasis, Soil-transmitted helminthiases, Trachoma and Dracunculiasis 
are known as “tool-ready” NTDs because they can potentially be controlled or eliminated via tools 
that are already in place such as mass drug administration (MDA) or other effective interventions 
[4]. 
Lymphatic filariasis (LF) is an NTD caused by filarial nematodes which puts 947 million 
people at risk worldwide in 73 countries where LF is considered endemic [5]. LF is caused by 
three filarial nematode parasites Wuchereria bancrofti, Brugia malayi and Brugia timori. These 
three species have different geographic distributions and vector mosquito species. Each parasite 
has its own genera of vector mosquitoes; Anopheles, Culex and Aedes for W. bancrofti, and mainly 
Mansonia and sometimes Anopheles for B. malayi while Anopheles is the primary vector for B. 
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timori. The vector species for W. bancrofti can be found in tropical areas across the world, whereas 
those for B. malayi are found only in Asia and those for B. timori only in Indonesia. While 
Bancrotian filariasis is the most common form of LF, B. malayi is the etiological agent of most of 
the remaining cases. These parasitic nematodes have a cyclodevelopmental life cycle, where they 
develop in a vector and become infective to a vertebrate host. When the infected female mosquito 
takes a blood meal, the infective third stage larvae (L3) are deposited on the skin within a droplet 
of saliva and once the mosquito withdraws they enter the body through the puncture wound. The 
L3 worms migrate to the lymphatic system where they develop into fourth stage larvae (L4) and 
then into adults after a subsequent molt. These adults mate and the females produce millions of 
microfilaria (mf) larvae. The mf circulate in the blood stream and are taken up by a mosquito 
during the blood meal. The mf rapidly penetrate the mosquito gut wall and migrate to the flight 
muscles where they develop into the first larval L1 stage then following molts, to the second L2 
stage and L3 larval stages. The L3s then leave the flight muscles and migrate to the proboscis of 
the mosquito where they can exit the mosquito during a blood meal and the cycle continues.  
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There are five clinical sub-categories of LF in endemic areas: (1) the percentage of the 
population who are not infected despite being continuously exposed (known as endemic normals, 
EN) [6], (2) infected but clinically asymptomatic, (3) those with acute infection [7], (4) those 
chronically infected [7] and (5) those with tropical pulmonary eosinophilia caused by 
hyperresponsiveness to the filarial parasites [8]. The majority of infected individuals are 
asymptomatic, however, the most noticeable symptom of LF results from chronic infection and is 
characterized by the gross swelling of extremities (lymphedema) and thickening of the skin and 
tissue of limbs. This condition is more commonly known as elephantitis and it affects 36 million 
people [4]. Elephantiasis develops only in about 30-40% of those infected with lymphatic filariasis 
Figure 1. The life cycle of Brugia malayi from Centers for Disease Control and  
Prevention (CDC), www.cdc.gov [1] 
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[9]. Development of elephantiasis is a two-step process. LF parasites release mediators that cause 
structural rearrangement of lymphatic vasculature, resulting in dilatation and tortuosity of lymph 
vessels [10-12]. This results in malfunctional lymph circulation and lymph build-up, which pre-
disposes infected individuals to secondary bacterial infections and accelerates the progression of 
pathology [13]. Another notion is that the proinflammatory immune responses against dying or 
dead adult parasites cause lymph buildup in the malfunctioning vessels and cause clinical 
manifestations [14, 15]. 
Of important note is that even though individuals who do not have elephantiasis appear 
visually asymptomatic, there may still be considerable damage to the kidneys, immune system and 
lymphatic system. Immune responses to the parasite can lead to acute adenolymphangitis (ADL) 
episodes of LF. Furthermore, a comprised immune response due to underlying lymphatic damage 
can cause secondary bacterial infections leading to inflammation of skin, lymph nodes and 
lymphatic vessels and eosinophilia. These acute attacks may last for weeks and sometimes lead to 
chronic LF.  
 
Prevention and treatment 
Transmission of the disease relies on many factors; the number of infected people or 
prevalence, the number of vector mosquitoes, and the frequency of human-vector contact, and each 
of these are being targeted individually to disrupt transmission. In 2000, the World Health 
Organization (WHO) launched the Global Program for Elimination of Lymphatic Filariasis 
(GPELF) to reduce the number of infected patients with LF. The goals of GPELF are two-fold. 
The first is to stop the spread of the infection through Mass Drug Administration (MDA), reducing 
infection below a threshold to prevent further transmission and demonstrate sustained reduction of 
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infection four years after stopping MDA. The second is morbidity management to alleviate the 
suffering of affected populations.  
Three MDA regimens are currently in use to treat LF: 6 mg/kg diethylcarbamazine citrate 
(DEC) + 400 mg albendazole or 150 μg/kg ivermectin + 400 mg albendazole in those areas that 
are co-endemic with Onchocerciasis [16]; or 400 mg albendazole in areas also co-endemic with 
Loiasis (African eyeworm) [17]. These regimens need to be administered for at least five rounds 
to be effective. The presence of these co-endemic diseases complicates drug regimens, which are 
discussed in detail below. 
 
(I) Diethylcarbamazine citrate (DEC)  
  
Figure 2. Chemical structure of Diethylcarbamazine from NIH 
PubChem Compound Data base; CID15432  [2] 
6 
 
Diethylcarbamazine (DEC) is an anthelmintic drug that is primarily used to treat diseases 
caused by filarial nematodes. Although its use is widespread, the exact mode of action is unclear. 
However, several mechanisms have been proposed. One is that it alters the arachidonic acid 
metabolism in both microfilaria (mf) and host endothelial cells, which can lead to the constriction 
of blood vessels and increased endothelial adhesions. This results in immobilization of mfs and 
allows host platelets and granulocytes to better adhere and exert cytotoxic activity against the 
parasites [18]. Another proposed mode of action of DEC is by inhibiting prostanoid production 
[19]. Filarial nematode parasites are known to constitutively release prostaglandins [20-22] which 
in the host are known to inhibit platelet aggregation [23], promote vasodilation of blood vessels 
[24] and increase immune suppression. DEC has been shown to inhibit prostanoid production, 
although it is not well understood whether it is the worm or host production that is affected by the 
drug. DEC has also been shown to increase nitrogen oxide induced mf clearance [21] but again, 
how it achieves this is not well understood. Nitrogen oxide prevents platelet aggregation and it is 
speculated that this might be one route of mf clearance. The observation that it has a rapid response 
in vivo where mf counts drop dramatically within minutes of treatment, yet there is no significant 
activity in vitro at comparable concentrations, suggests that some host factors influence the action 
of DEC [18]. 
Even though DEC has been widely used since 1947 to treat LF and is generally considered 
to be a safe drug, it has its limitations. It cannot be used in areas co-infected with Onchocerca due 
to the possibility of severe adverse immune response to O. volvulus mf in the eye. 
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(II) Ivermectin (IVM) 
 
 Figure 3. Chemical structure of Ivermectin from NIH PubChem    
 Compound. Data base; CID 6321424 [25] 
 
Ivermectin (IVM) is a member of the macrocyclic lactone compound family and in 
nematodes acts as a glutamate gated chloride channel (GluCl-) potentiator at low levels, which 
results in a small transient hyperpolarization of the membrane, or at high levels opens the GluCl- 
channel directly [26]. The most well described physiological effect of IVM on nematodes is an 
inhibition of pharyngeal pumping [27] caused by hyperpolarization of an inhibitory motor neuron 
in the pharynx. However, IVM also acts on somatic muscle and inhibits the neurotransmitter 
gamma-aminobutyric acid (GABA) mediated activated channels [28]. These direct effects of IVM 
are specific to the parasite since vertebrates do not have GluCl-s [26]. 
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IVM is a highly effective filarial nematode microfilaricide in vivo. However, studies 
performed on Onchocerciasis. volvulus, Dirofilaria. immitis, Acanthocheilonema viteae, B. 
pahangi and W. bancrofti have shown that it is barely efficacious in vitro at therapeutic 
concentrations [29-32]. This has led to speculation that the effect of IVM is not simply by its direct 
action on the nematode but also through a synergistic effect of the drug and the host immune 
system, resulting in rapid microfilarial clearance in vivo [33, 34]. Another hypothesis is that IVM 
could acting directly but its mode of action is not to produce gross neuromuscular or motor defects 
but rather more subtle phenotypes such as inhibition of mf release from females. However, studies 
on D. immitis and O. volvulus have shown that females exposed to IVM treatment shed mf at the 
same rate as untreated females [34], thus nullifying this speculation. 
IVM is highly effective against W. bancrofti microfilariae but lack of prolonged 
suppression of microfilarial production by W. bancrofti females [35] dampens its effectiveness in 
interrupting disease transmission. It is also effective against O. volvulus microfilariae which cause 
Onchocerciasis and D. immitis (canine heartworm) L3, L4 and juvenile adults although not mature 
adults, hence making it a valuable candidate for targeting multiple filarial nematode diseases. IVM 
also clears coinfection with a number of soil-transmitted helminths, including Ascaris 
lumbricoides and Strongyloides stercoralis, and some ectoparasites such as Sarcoptes scabies, 
posing an inter-phyla applicability. However, there are some limitations to the use of IVM. It 
cannot be used in areas co-infected with Loa loa since it results in severe adverse reactions such 
as coma and even death from the massive death of L. loa microfilariae. LF and Loiasis are co-
infected in 10 African countries and therefore, MDA cannot be initiated in these areas. Moreover, 
there is concern that IVM can penetrate the immature blood-brain barrier and cause neurotoxicity 
to children below five years of age or who weigh less than 15kg [36] and therefore there is some 
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reservation in administering IVM to this population demographic. As a result approximately 15% 
of the population are excluded from IVM treatment [37] and potentially serve as reservoirs for LF, 
contributing to continued transmission of the disease. Further studies investigating the safety of 
the drug can be helpful in ensuring maximum coverage is achieved. 
 
(III) Albendazole (Alb) 
 
Figure 4. Chemical structure of Albendazole from NIH PubChem Compound Data 
base; CID 2082 [38] 
 
Benzimadoles exert their anthelmintic activity by inhibiting the formation of β-tubulin, 
which is an essential component of microtubules. Tubulin needs to polymerize at the positive pole 
and depolarize at the negative pole in order for microtubules to form. Albendazole binds to the 
colchicine sensitive site of the positive pole of β-tubulin, thereby inhibiting the formation of 
microtubules [39]. In physiological terms this results in impaired glucose uptake and leads to 
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reduced parasite viability. Benzamioles have also been reported to inhibit egg production and 
muscle movement of parasite [40]. The higher affinity of benzimadoles to parasitic β-tubulin 
relative to mammalian β-tubulin results in drug selectivity for parasitic worms and effectiveness 
as an anthelmintic. [41]  
 
The coverage goals for mass drug administration targeting lymphatic filariasis is >65% of 
those in areas endemic for the disease [42]. Per the weekly epidemiological report published in 
September 2016 by the World Health Organization [5], a 58.8% coverage of the total population 
requiring MDA had been achieved by 2015. MDA was ongoing in 55 out of the 80 countries 
declared endemic at the beginning of GPELF in 2000. 18 countries including Malawi, Togo, 
Egypt, Yemen, Thailand, American Samoa, Kirirbati, Marshall Islands, Palau, Tonga, Vietnam 
and Wallis and Futuna had finished Phase one and were under post-MDA surveillance to validate 
elimination. 100% geographical coverage had been achieved in 13 countries by 2015, which scaled 
rapidly up to 23 in 2016. LF has been eliminated as a public health problem from Maldives, Sri 
Lanka, Cambodia, Cook Island, Niue, Vanautu while Gambia was reclassified as non-endemic. 
Among the 10 countries yet to start MDA in 2015 Central African Republic, Liberia and Brunei 
Darussalam were waiting to be confirmed for MDA implementation.  
Although MDA programs have been efficacious in reducing prevalence by approximately 
40% since their inception, there are rising concerns due to the limited applicability of current drugs 
and a concern of the emergence of resistance as with any other drugs that are so widely used [43]. 
Moreover, pregnant women in infected areas are excluded from treatment due to the absence of 
safety information on these drugs during pregnancy, serving as potential human reservoirs of the 
parasite [16]. 
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Alternative strategies for LF Control 
Of the factors influencing LF transmission, the frequency of host-vector contact is the most 
influential and controllable and can be reduced by using simple measures such as mosquito nets 
and repellents. Gleave et al. [44] have shown that host-mosquito convergence depends on the stage 
of larvae harbored by the mosquito. They demonstrated that mosquitoes harboring larvae younger 
than the infective L3 stage are five times less likely to converge with a host, whereas the likelihood 
of mosquitoes harboring infective stage L3s converging with a host is above average. This suggests 
both a suppressive and enhancing effect exerted by the larvae on the mosquito depending on the 
maturity of the infection [44]. There is also a considerable interest in implementing vector control 
to reduce the number of vector mosquitoes. In fact, several studies have been conducted to 
investigate this aspect [45-48]. Trial experiments to eradicate Bancroftian filariasis solely by 
vector control were carried out in Nagate village in Japan [45]. Residual spraying was done once 
a year for ten years starting from 1962 in combination with the application of larvicide once a 
week to potential breeding grounds during the breeding season of vector mosquitoes. After eight 
years of implementation, the microfilaremia positive population had decreased from 14% to 0.5% 
and the remaining carriers tested negative in 1971. They also demonstrated that the vector 
population could be reduced markedly by destroying breeding grounds where the population of 
Culex pipiens pallens vector mosquitoes diminished from 71.2 in 1961 to 0.6 in 1994 as a result 
of changing the open ditches collecting household waste water to underdrains. Moreover, mineral 
oils [48], polystyrene beads [47] and Spherix, a Bacillus sphaericus based biocide, have been 
successfully used as larvicides in open water areas serving as potential breeding sites. However, 
mosquitoes developed resistance against Spherix after 20-25 uses within a year reducing its value 
as an effective larvicide. Elimination of filariasis transmitted by Anopheles mosquitoes in Solomon 
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Islands and Togo by indoor spraying of dichlorodiphenyltrichloroethane (DDT) has also been 
reported and shows promise for this approach [46]. Another attractive extension of this application 
is an integrated approach to vector control, where control for vector mosquitoes are in place where 
LF is co-endemic with other mosquito-borne diseases such as malaria [49] or dengue [50]. Studies 
have been conducted to genetically modify mosquitoes such that they are refractory or carry a 
lethal gene. Paratransgenesis of symbiotic bacteria is also being considered as a method of vector 
control [51, 52]. 
Another interesting and promising control strategy is targeting the Wolbachia symbiont. 
The Wolbachia bacteria is an obligatory symbiont present in all human filarial nematodes except 
Loa loa [54] and has been shown to be important for parasite fertility, development and survival 
[55]. It is present in all life stages with abundance increasing as the parasite is transferred from the 
vector to the host and also as it develops into adulthood. It has been shown that antibiotic treatment 
to reduce Wolbachia population decreases adult lifespan, embryogenesis and microfilariae release 
[56]. Wolbachia are also present in insect vectors of these nematodes. In fact, Wolbachia cause 
four types of reproductive alterations in mosquitoes, namely cytoplasmic incompatibility resulting 
in sperm-egg incompatibility skewing the mosquito population to females infected with 
Wolbachia, feminization of genetic males, male-killing or killing male progeny of infected females 
and pathogenic induction resulting in unfertilized eggs [57]. The presence of Wolbachia in both 
the parasitic nematode and the vector present the possibility of being used as dual-use control 
measures. Doxycycline, an antibiotic that targets the Wolbachia symbiont, can be used as an 
alternative therapy. In fact, it is widely used in veterinary medicine to treat canine heartworm 
disease. However, this cannot be given to children under 9 years of age or pregnant and lactating 
mothers so all of them are excluded from MDA. This area is considered a promising field for novel 
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antifilarial drugs and efforts to identify anti-Wolbachia compounds continue. The Anti-Wolbachia 
Consortium (AWOL) is an international consortium funded by the Gates Foundation to identify 
such compounds that are suitable for MDA with a focus on repurposing existing antibiotics and 
some effective options are currently in development [58]. 
  
Current methods of diagnosis 
The rationale behind diagnosis for LF deviates somewhat from the norm in that it is not 
used to identify individuals who need treatment. Rather, it is used to assess the success of MDA 
programs and for post-treatment surveillance to ensure the disease does not resurface after 
treatment regimens have been concluded. Many methods have been used historically for LF 
detection with the most frequently used method being detection of microfilariae in a smear of 
finger-prick blood. Mf have nocturnal periodicity where they live in the lungs during the day and 
circulate in the peripheral blood at night [59]. Due to this nocturnal periodicity of mf, blood for 
the finger-prick method needs to be collected at night and therefore is inconvenient. Additionally, 
it introduces a degree of uncertainty or unreliability because absence of mf in the blood samples 
could be because the mfs had not yet entered the peripheral blood. In areas where blood cannot be 
collected at night, 2mg/kg diethylcarbamazine (DEC) can be administered which results in 
increased circulating mf in the peripheral blood within 30 – 45 minutes of administration. Another 
microscope-based detection method is by concentrating microfilariae from 1-2 ml of intravenous 
blood on to a 3 µm membrane filter and examining it on a microscope slide. Yet another method 
is by detection of microfilaria using a microhematocrit tube coated with acridine orange. This 
method allows for observation of mfs and their morphology. One major drawback of this method 
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is the need of a fluorescence microscope [60]. Sensitivity of microfilarial-based detection methods 
is limited because microfilariae are undetectable in pre-patent, light and post-patent infections. 
Circulating filarial antigen (CFA) can be detected in all microfilaraemic individuals and a 
proportion of amicrofilaraemic individuals with chronic manifestations of LF [61]. These tests 
detect antigens released by adult filarial worms, so they may be positive even in amicrofilaremic 
individuals [62]. The sensitivity of this test is such that it has been able to detect circulating antigen 
in individuals without clinical presentation who have been cleared of microfilariae after DEC 
administration post testing. CFA based tests are available in the form of enzyme-linked 
immunosorbent assays (ELISAs) and immunochromatographic card tests. These tests are highly 
sensitive and specific, are easy to produce and there is no need to draw night blood [63]. A major 
drawback of this method is that it is only available for detecting Wuchereria bancrofti antigens 
and not Brugian filariasis.  
Other detection methods augment the microscopic- and antigen-based approaches. 
Elevated eosinophil levels are often associated with filarial nematode infections and a marked IgE 
elevation can be supportive of a primary diagnostic method. However, it is difficult to develop an 
accurate relationship between eosinophilia and filarisis due to the frequent coexistence of other 
infections among individuals in endemic areas [64]. Visualization of the parasites themselves or 
the pathologies they cause can confirm a diagnosis. The rapid movement of adults also known as 
the “filarial dance” can be detected by ultrasonography of the scrotal lymphatics in men and the 
breast and retro-peritoneal lymphatics in women while X-rays of infected individuals show 
characteristic interstitial thickening and diffused nodular molting.  Studies are continuously being 
conducted to improve LF detection methods. The emergence of molecular tools for disease 
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diagnostics may be translated to LF detection. A recent study introduces qPCR as an assay 
sensitive enough to detect mf burden as low as 18mf/ml in a pool of 20 individuals [65] 
 
Brugia malayi as a Model for Studying Lymphatic Filariasis Agents 
The great majority of LF infections are caused by Wuchereria bancrofti but this parasite is not 
laboratory adapted whereas the ability of B. malayi to successfully infect monkeys and cats 
translates to the ability to maintain the B. malayi life cycle in a laboratory setting and therefore B. 
malayi is the primary LF model. In these terms, B. malayi is widely considered a good model for 
Lymphatic filariasis. Previous studies have shown that there is significant overlap in the antigens 
generated by the two species [66] and also that antibodies generated against W. bancrofti antigens 
in infected and immune individuals show significant cross reactivity with B. malayi [67]. This 
validates the use of B. malayi to study various aspects of these filarial nematodes, disease 
pathobiology and potential novel treatment and diagnostic avenues.  
 The use of B. malayi as the primary LF model was reinforced through the identification of 
several experimental hosts for B. malayi that allow economical large scale production of parasite 
materials. L3s injected subcutaneously in jirds (rodent Meriones spp) develop into L4s within 
about a week and into adults within about a month. The adults can survive up to about seven 
months. L3s injected subcutaneously into Mastomys rodents develop into adulthood and can 
produce mf; Mastomys rodents are, however, resistant to inter-peritoneal injections. L3 infections 
in macaques have been known to be able to produce mfs with the infection lasting to about one 
year. This availability of a vast array of experimental hosts allow for experimental modulation and 
further supports the use of B. malayi to study LF. 
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Host parasite interface in the context of Brugia malayi infection 
An immune response ranges in a spectrum between Th1 and Th2 depending on the type of 
T cell activation. Activated T cells produce cytokines of which IFN-γ is the main Th1 cytokine 
while IL-4, IL-5, IL-10 and IL-13 are produced in a Th2 response [68]. A Th1 response is 
proinflammatory and aids in the clearance of foreign particles. However, prolonged Th1 responses 
cause tissue damage and can be destructive to the host and therefore an anti-inflammatory Th2 
response that down regulates the Th1 response follows. Many changes in the immune system occur 
during a LF infection. An adaptive Th2 immune response with increased levels of IL-4, IL-5, IL-
9, IL-10 and IL-13 cytokines [68] and antibody isotypes IgG1, IgG4 is prototypical, along with 
expanded populations of eosinophils, basophils, mast cells and alternatively activated 
macrophages [69]. Infected individuals show elevated levels of IL-4. However, there does not 
seem to be a difference in the IL-4 levels between the different clinical groups in an endemic area 
(i.e asymptomatic, acute and chronic) [70]. The burst of IL-4 transcription within 24 hours of 
infection might explain the above observation because individuals in endemic areas are constantly 
exposed to L3 stage parasites [70]. Adult worms, especially females have also been shown to 
induce IL-4 production in mice [71]. In contrast, mfs induce proliferative and IFN-γ responses 
(which are more Th1-like than Th2) at the early stage followed later by increased IL-4 and IL-5 
production [71]. The fact that proliferative and IFN-γ responses were restored in infected 
individuals following ivermectin treatment, which clears mfs but not adults [72], further supports 
the role of mfs in proliferation suppression, although the mechanism of this Th1-Th2 switch 
remains to be elucidated. Studies done with Litomosoides sigmodontis, a mouse filarial parasite 
closely related to B. malayi have shown that increased IFN-γ and IL-5 are important for 
encapsulation and killing of adult parasites [73, 74] and could explain the importance of 
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maintaining elevated IL-4 levels (from the parasite’s perspective) for immunosuppressive 
containment of the parasite. Implantation of B. malayi adults in mice result in an increase in 
alternatively activated macrophages that suppress proliferative activity of lymphocytes upon 
contact [75]. The fact that this phenotype is not observed when dead parasites are implanted 
provides evidence that the immunosuppressive effect observed is actively exerted by these 
parasites [76]. A study investigating the role of filarial parasite in the induction of 
lymphangiogenesis and lymphatic differentiation reported endothelial rearrangement in response 
to antigens from adult B. malayi parasites and sera from infected patients [77]. This suggests that 
these parasites influence multiple host processes and systems for their benefit. 
The fact that parasites modulate the host to create an environment favorable for them is 
apparent. However, the mechanistic basis for this host manipulation is not clear. Some studies have 
speculated a role for secreted parasite proteins in host modulation [78-80]. A study done by 
Hewitson et al. (2008) revealed that Galectin 1 and 2 are the most abundant proteins secreted by 
Brugia [79]. Interestingly, they potentially have a role in immune evasion since mammalian 
galectins have been associated with downregulation of immune responses [81] and can suppress 
regulatory phenotypes of T cells [82]. They also identified leucyl aminopeptidase (Lap), the B. 
malayi homologue of ES-62 of a related rodent filarial nematode Acanthocheilonema viteae, which 
is known to modulate the immune response towards a Th2 response through interactions with B 
and T lymphocytes, dendritic cells, macrophages and mast cells [83]. Antioxidant proteins can 
detoxify damaging reactive oxygen and nitrogen intermediates produced by immune cells. 
Superoxide dismutase (SOD), glutathione peroxidase (gp29) and thioredoxin peroxidase 2 were 3 
such proteins that were detected in the Brugia secretome in this study. CPI-2, a cysteine-protease 
inhibitor, which potentially can dampen the immune response [84] was also identified in this study. 
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Lastly, B. malayi macrophage migration inhibitory factor, BmMIF-1 which has been demonstrated 
to be a chemotactic for human cells [85] was detected in this study. Another study published on 
the secretome the same year identified many of the above proteins as well [80]. Among them were 
MIF-1, galectin 1 and 2, CPI-2 and LAP. In addition to these proteins, they also identified another 
isoform of human MIF, MIF-2 in the adult stages. Yet another study on the B. malayi secretome 
was published the following year [78] which identified BmMIF-1 and galectins in the secretome 
of adult females and mfs. ES-62 and BmMIF-2 were also identified in the excretory-secretory 
(E/S) products of these stages and in L3s molting to L4s. Two antioxidant proteins identified 
previously, glutathione peroxidase and superoxide dismutase were also found in each life stage at 
different abundance levels. Peptides matching to LL20, an immunologically important antigen 
were found to be secreted in abundance by the molting L3s, adult females and microfilariae. A 
protease inhibitor-like protein, phosphatidyl-ethanolamine binding protein and a serine protease 
inhibitor were found as well in addition to the previously identified CPI-2 protease inhibitor.  
These proteomic studies have identified a number of proteins secreted by the parasite that 
have potential host modulatory functions. However, what is still unclear is how these effector 
proteins are released and the mechanisms by which they interact with host tissues. For example, 
are these proteins freely secreted into the host environment or are they somehow packaged for 
release and to prevent degradation? Is protein interaction with host cells non-specific or are these 
parasite-derived molecules targeted or trafficked to specific host cells? Recently there has been an 
explosion of studies revealing the role of exosomes in cell-to-cell communication and in disease 
pathogenesis. Exosomes represent a potential mechanism by which parasite proteins could be 
released into the host environment and delivered to target cells or tissues.  
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Extracellular Vesicles and Exosomes 
Intercellular communication is an essential phenomenon conserved throughout eukaryotes 
to regulate normal biological functions. Until recently, researchers had limited understanding of 
these communication pathways and often believed this to occur through cell-to-cell contact or 
interchange of specific secreted molecules, such as lipids, proteins or nucleotides. However, the 
recent discovery of extracellular vesicles (EVs) harboring bioactive molecules has advanced a new 
paradigm of cell-to-cell communication. EV were first identified in the 1940s as one of the pro-
coagulant components in blood [86]. Since then, EVs have been identified in various biological 
fluids including semen [87], urine [88], saliva [89] and breast milk [90]. EVs are a heterogenous 
population and generally include exosomes, microvesicles and apoptotic bodies, specific EV 
subtypes categorized by their size, biogenesis and cargo. Despite their different characteristics, 
these vesicles play a key role in cell-to-cell communication exerting their effects locally as well as 
over greater distances. Apoptotic bodies are the largest EVs (50-5000 nm) and are released when 
plasma membrane blebbing occurs during programmed cell death. In contrast, microvesicles and 
exosomes are much smaller in size and are generated by budding from the plasma membrane or 
derived from the endosomal pathway respectively. The current consensus on exosome particle size 
range is between 50 -150 nm in diameter, a size distribution that overlaps with that of microvesicles 
(50-2000 nm). Therefore when studying the function of exosomes and other EVs it is important to 
evaluate not only the size but also protein markers commonly enriched in these EV subtypes in 
order to differentiate exosomes from other similar vesicles. 
Membrane-derived vesicles are secreted across all kingdoms [91, 92]. Exosomes, or 
exosome-like vesicles, are secreted by eukaryotic organisms ranging from single cellular protists, 
to fungi, multicellular plants and most phyla of animals [93, 94]. Exosomes were first discovered 
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by Harding et al. in 1983 [95]. Briefly, in a study performed to investigate the mechanism of 
transferrin receptor turnover, the investigators discovered that the internalized colloidal gold-
conjugated transferrin (AuTf) particles were rarely present in the structures speculated to be 
lysosomes. Instead, AuTf particles were found predominantly in small vesicles within 
multivesicular bodies. They also observed that these multivesicular bodies fused with the plasma 
membrane and that the AuTf-labeled vesicles, which are now known as exosomes, were 
exocytosed. A paper by Pan and Johnstone was published around the same time complementing 
this discovery where they reported that sheep reticulocytes released vesicles of a uniform size 
containing transferrin receptors [96]. The term exosome was coined by Jonhstone et al. in 1987 
[97].  
 
Exosome biogenesis 
Biomolecules including proteins, lipids as well as immunomodulatory molecules such as 
antigens are taken up by cells via endocytosis. Following internalization these vesicles fuse to form 
early endosomes (EE) [98]. EEs are characterized by the presence of early endosomal antigen 1 
(EEA1) [99], Rab4 [100], -5 [101] and -14 [102] as well as transferrin receptor (TfR) [103] and 
have a mildly acidic pH (between 6.0 – 6.5) [104]. Since EEs lack degradative enzymes, the cargo 
in these vesicles can be recycled back to the cell surface when the tubular endosome buds off 
during membrane recycling. The internalized proteins are also sorted with some fated for recycling 
while others are transported to late endosomes (LE) for degradation via the lysosomal pathway. 
Switching of Rab5 for Rab7 leads to the transitioning of EE to LE [105]. LEs are circular and have 
a more acidic environment compared to early endosomes (pH = 4.9 - 6.0). In this environment 
recycling receptors are lost and the vesicular cargo is exclusively targeted for degradation. Acid 
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hydrolases can begin protein degradation although the high pH allows only a small percentage of 
degradation to occur in the LEs. When LE formation is initialized, they begin moving from the 
peripheral cytoplasm to the perinuclear area. This movement is initiated by dynein-dynactin via 
the Rab7 interacting lysosomal protein (RILP) [106]. Through bi-directional shuttling with the 
trans golgi network, lysosomal components are added to the LE while endosomal components such 
as Rab5 and other proteins associated with EEs are removed [107]. An important aspect in the 
maturation of endosomes is the formation of intraluminal vesicles (ILV’s). The Endosomal sorting 
complex required for transport (ESCRT), Alix and Vps4 among other protein complexes are 
required for the formation of ILV’s. A cluster of ILVs within the endosome forms what is known 
as a multivesicular body (MVB). 
Besides transporting the endosomal cargo to the lysosome for degradation, MVBs can also 
fuse with the cell membrane and release the ILVs outside the cell. These exocytosed ILVs are 
called exosomes. The mechanism by which exosomes are released has only become clear in the 
past few years. Switching of specific Rab proteins is thought to determine the fate of ILVs in the 
MVBs; Rab27b on the membrane of MVBs leads to the lysosomal degradation pathway [108]. 
Exosome secretion involves the presence of various Rab GTPases such as Rab27, Rab35 and 
Rab11. Importantly, switching of Rab27b to Rab27a is required for the release of exosomes in the 
intercellular environment [109]. This was shown by Ostrowski et al. (2010) who demonstrated 
that knockdown of Rab27a and Rab27b reduced exosome release while exogenous addition of 
Rab27a and Rab27b lead to greater numbers of peripheral vesicles or perinuclear endosomes 
respectively [109, 110]. A general scheme of exosome release involves the concerted action of the 
following mechanisms: 1) Inward budding of LEs to form ILVs containing cytosolic, ubiquinated 
proteins. 2) A number of budding incidences leading to a number of ILVs in what is now called 
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an MVB. 3) Recruitment of the ESCRT proteins ESCRT I (recognizes the ubiquinated cargo in 
developing MVB’s), II (involved in membrane budding of the LE’s to form ILV’s in the MVB) 
and III (involved in cleavage of MVB to release their cargo) as well as Alix and Vps4 among other 
proteins during the formation of MVBs. 4) For most cell types recruitment of Rab11 and Alix as 
well as flotillin and glycosphingolipids or lipid rafts leads to the docking and fusion of the MVB 
to the inner membrane of the cell and finally release of the ILV’s now - termed exosomes, outside 
the cell. [88, 111-113] The above steps are an over simplified version of exosome formation and 
release, indeed studies carried out in different cell types report different sets of proteins involved 
in exosome biogenesis and release. However, in general the proteins from the ESCRT and retromer 
complexes and their associated effector molecules are the main components that drive this 
phenomenon. While the above-mentioned phenomenon can be considered constitutive, exosome 
release can also be caused by stress stimuli including lipopolysaccharide (LPS) stimulation, heat-
shock and hypoxia [114-116]. 
 
Exosomes in host-parasite interactions 
While serving as communicators between cells within an organism, there are also reports 
suggesting that these structures have the capacity to serve as communication between species, 
specifically between parasites and their hosts. An emerging body of evidence suggests a role of 
exosomes (exosome-like vesicle, ELVs would be a better suited term for these vesicles since the 
biogenesis pathways have not yet been described) in pathogenesis of various helminth parasites 
[117-123]. Studies have shown that these parasite-secreted vesicles are being taken up by host 
cells, demonstrating proof of principle that these vesicles can serve as a mode of communication 
between the two species [118, 119]. Moreover, the discovery that microRNA (miRNA) and protein 
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molecules contained within these vesicles have the potential of manipulating host processes adds 
further support to this hypothesis. We recently demonstrated that ELVs secreted by B. malayi L3 
larval stage parasites are internalized by murine macrophages and that they are capable of 
triggering an inflammatory activation phenotype in these cells [119]. We also identified miRNAs 
and proteins with the potential of modulating host processes. The discovery of let-7 and cathepsin 
L-like proteins in these ELVs are prime examples of such molecules. The report by Buck et al. 
(2014), the only other report to date of ELVs secreted by nematodes demonstrated that the 
intestinal parasitic nematode Heligmosomoides polygyrus secretes exosomes containing miRNAs 
and worm Argonaute protein (WAGO) that are internalized by mouse small intestine epithelial 
cells and can suppress Type 2 innate responses in mice [118].  
 
miRNA Mediated Gene Regulation 
In eukaryotes, the default state of gene expression is “off” [124]. Gene silencing occurs at 
many levels: transcriptional repression by mechanisms such as acetylation, methylation, RNAi of 
chromatin; post-transcriptional regulation via small RNAs, riboswitches, alternative splicing; and 
translational repression of the protein via histone modification, phosphorylation of protein 
synthesis initiation factors. Post-transcriptional regulation via small RNAs is present in all 
eukaryotes except yeast. Bacteria and archae have the argonaute genes which are key components 
in small RNA pathways but there is no evidence yet that they have other small RNA machinery. 
There are three types of endogenous non-coding small RNAs that induce gene silencing; 
microRNA (miRNA), small interference RNA (siRNA) and piwi-interacting RNA (piRNA) [125]. 
miRNA induced gene silencing occurs mainly via repression with the regulatory small RNA 
binding to interaction sites on the target mRNA and therefore doesn’t require a 100% sequence 
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identity between the miRNA and target [126]. siRNA and piRNA induce gene silencing by 
enzyme-directed cleavage and therefore require exact or near exact sequence match with the target 
RNA [126, 127]. In mammals, small RNA regulation is post-transcriptional but in plants and yeast 
it can affect DNA by converting the chromatin to heterochromatin such that it isn’t easily 
accessible by the transcription machinery. Argonaute proteins interact with miRNA and siRNA 
for cytoplasmic post-transcriptional gene silencing while Piwi proteins interact with piRNA to 
silence transposable elements in the germline [128]. 
  
miRNA structure and biogenesis 
miRNA genes are transcribed into primary miRNA, also known as pri-miRNA. This was 
initially thought to be transcribed by RNA pol II [129] but a more recent report states that some 
genes are transcribed by RNA pol III [130]. The pri-miRNA is an imperfectly paired double 
stranded region containing a hairpin loop. The 5’ and 3’ ends of the pri-miRNA are then cleaved 
by the microprocessor complex which comprises of the DROSHA nuclease and the RNA-binding 
protein DGCR8 [131]. The resultant product is a 70-90nt region with a hairpin loop and is known 
as the pre-microRNA (pre-miRNA). This pre-miRNA is then translocated from the nucleus into 
the cytoplasm by a complex comprised of Exportin-5, Ran and GTP. Here regions of the pre-
miRNA including the loop are cleaved by a complex containing DICER 1 and TARBP2 or PRKRA 
and results in a double stranded region of 21-23nts with protruding single-stranded 3' ends of 2-3 
nt. The cleaved product is mounted on to a RNA-Induced Silencing Complex (RISC) with an 
argonaute protein. Here the passenger strand is removed and degraded; the other strand, known as 
the guide strand, moves on to exert its gene modulatory effects.  
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 Figure 5. Pictorial depiction of the miRNA Biogenesis pathway    
 reproduced with permission from Winter J. et al, 2009 [132]. 
  
The role of parasite-derived miRNA at the host parasite interface 
Studies have shown that like most eukaryotic organisms, B. malayi also expresses miRNA 
[119, 133, 134]. These miRNAs represent a powerful mechanism of regulation of endogenous 
gene expression in Brugia [134, 135] and it is possible that they also influence gene expression at 
the host-parasite interface. Indeed, miRNA contained within exosomes in other biological systems 
such as breast cancer  [136] and neurodegenerative diseases [137], have been shown to regulate 
gene expression in target cells. The only two reports on parasitic nematode exosome-like vesicles 
(ELVs), document miRNA contained within these vesicles [118, 119]. In our report [119], we 
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identified miRNA belonging to the let-7 class with potential immunomodulatory capacity. Let-7 
is constitutively present and functions as a molecular brake on cytokine release from macrophages 
[138]. Following infection, let-7 expression is downregulated allowing for the release of specific 
cytokines by macrophages. The discovery that B. malayi ELVs contain let-7 with direct homology 
to human let-7 allows us to speculate as to its function in filarial infection. It is possible that 
parasite-derived let-7 compensates for the diminished levels of endogenous let-7 thereby 
modulataing cytokine release by macrophages, allowing the parasite to establish itself within the 
host. Buck et al. (2014) also report a collection of miRNA contained within H. polygyrus exosomes 
[118]. They demonstrated that parasitic let-7 and mir-200 downregulated host Dusp1 which is a 
key regulator associated with dampening the proinflammatory response of the host. They also 
found that Il1rl1, a subunit of IL-33 a key alarmin cytokine associated with protection against 
multicellular parasite was downregulated by H. polygyrus exosomes. H. polygyrus exosomes also 
contain the worm Argonaute protein, suggesting that possibly the parasite is secreting these 
vesicles fully equipped to induce necessary gene manipulations. These examples indeed provide 
support that the hypothesis that parasitic nematodes may secrete exosome-like vesicles containing 
effector molecules including miRNA as a method of modulating the host to their advantage 
plausible.  
 
Leveraging parasite miRNA release in the context of lymphatic filariasis 
We have shown that miRNAs are packaged within ELVs and secreted into the host 
environment by filarial nematodes. It may be possible to exploit this mechanism to provide novel 
approaches in LF diagnostics and control efforts. Current methods of LF diagnosis are imperfect. 
Detection of mf in a smear of finger-prick blood is the main method of detection but is 
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inconvenient and poses unreliability issues due to the need to draw blood during the night due to 
nocturnal periodicity of mfs [59]. Another method is the detection of circulating filarial antigen 
[62] and even though this test is very sensitive, it is only available for detection of Bancroftian 
filariasis and not Brugian filariasis. Detection of the “filarial dance” by ultrasonography of the 
scrotal lymphatics in men [139] and the breast [140] and retro-peritoneal lymphatics in women 
[141] is yet another method of confirming an LF infection. Although accurate, a patent infection 
needs to have been established for this method of detection by which the window of prevention or 
administration of effective treatment has passed. miRNAs have been proposed as a diagnostic tool 
for a wide variety of diseases ranging from neurodegenerative diseases to cancers [137, 142-144]. 
For example, a study on manganese-induced neurodegenerative diseases demonstrated that forty-
three miRNAs were differentially expressed [137]. Of them twelve were significantly increased, 
some even as high as 15-fold, in Mn-induced exosomes, making them potential biomarkers for 
Mn-induced neurodegenerative diseases. Another study demonstrated that microRNA-126 and 
microRNA-182 can potentially be used to as biomarkers to identify urinary bladder cancer [144]. 
Likewise, identification of secreted miRNAs unique to each stage of B. malayi would enable the 
development of a non-invasive accurate detection platform, a liquid biopsy if you will, which not 
only detects the infection but also the maturity of it. We demonstrate the feasibility of this in 
chapter III of this thesis. 
 In this thesis we demonstrate that the filarial parasitic nematode B. malayi secretes 
exosome-like vesicles (ELVs) throughout its life cycle. Further we demonstrate that these vesicles 
harbor different cargo implying a stage and sex specific role of these ELVs. We show that ELVs 
of all life stages are being internalized by host cells, suggesting the potential of ELV-mediated 
host modulation by the parasite. We also show that ELV release decreases significantly in worms 
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treated with current anthelmintics, possibly uncovering one of the mechanisms of parasite 
clearance by these drugs. Further we identify compounds that inhibit ELV release more potently 
than current anthelmintics, suggesting the potential of employing ELV relsease as a screening 
platform for novel drug compounds. We also demonstrate proof-of-principal of using miRNA 
secreted by Brugia as biomarkers for identifying infection and disease maturity.  
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Abstract 
Lymphatic filariasis (LF) is a mosquito borne Neglected Tropical Disease caused by filarial 
nematodes including Brugia malayi. The interaction between host and parasite is critical for 
establishing and maintaining infection but is poorly understood. We have previously reported that 
exosome-like vesicles (ELVs) secreted by infective stage (L3) B. malayi parasites contain small 
RNA and protein effector molecules with the potential to manipulate the host immune system. 
Here we expand on this observation to report ELV secretion across the B. malayi life cycle and 
phenotypically profile ELV bioactivity. Nanoparticle tracking analysis and transmission electron 
microscopy describe ELV secretion by all parasite life stages examined. Further analysis by 
confocal microscopy and flow cytometry show ELVs are internalized by murine macrophages via 
phagocytosis. Proteomic profiles of ELVs released by the adult parasites contain canonical 
exosomal markers. Comparison of proteomic profiles reveal stage and gender specific cargo, 
suggesting targeted delivery of effector molecules catered to each life stage. Collectively our data 
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suggest a novel mechanism by which B. malayi may manipulate the host immune system. 
Targeting this interface in disease control efforts may potentiate disruption of infection and 
transmission of LF.  
 
Introduction 
Diseases caused by parasitic nematodes continue to have enormous global impact on the 
health of humans and animals. Lymphatic filariasis (LF) is a mosquito-borne Neglected Tropical 
Disease caused by the filarial nematodes Wuchereria bancrofti, B. timori and Brugia malayi, that 
puts over 947 million people in 55 countries where LF is considered endemic at risk [1]. The most 
recognizable symptom of LF is the gross swelling of extremities known as elephantiasis, caused 
by parasite obstruction of lymphatic vasculature; at least 36 million people suffer from this socially 
stigmatizing condition [2], making LF the second leading cause of permanent disability after 
leprosy [3]. Efforts to control LF rely heavily on Mass Drug Administration (MDA) programs in 
coordination with widespread surveillance of disease transmission. LF continues to be a global 
health concern despite sixteen years of MDA programs, and a sub-optimal drug portfolio is 
acknowledged to be a contributing factor [4]. There is a recognized need for novel therapeutics 
and control measures for LF and other parasitic nematode diseases but progress toward this goal 
is hindered by the limited understanding of general parasite biology.  
Successful parasitism depends on specific interactions between the parasite and host. 
Longevity of adult B. malayi parasites within the human host is remarkable and wouldn’t be 
possible without manipulation of the host to some extent by the parasite. Seminal work done by 
Buck et al. (2014) describe exosomes from Heligmosomoides polygyrus as a mechanism for host 
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manipulation by parasitic nematodes. Exosomes are a subtype of extracellular vesicles defined by 
their biogenesis pathway; inward budding of the late endosomes result in multivesicular bodies 
(MVB) [5]. The fate of these MVBs is two-fold, degradation by lysosomes or release of contents 
to the extracellular matrix by fusing with the cell membrane. Vesicles released in this manner are 
termed exosomes. They range between 30 – 120 nm and have a deflated-ball/ doughnut 
morphology when negatively stained. With the discovery that these specialized vesicles contain 
potently bioactive effector molecules and have been shown to have a role in cell-to-cell 
communication, there is a renewed interest in these extracellular vesicles and their cargo. In a 
recent study, we demonstrated that invasive Brugia L3 stage parasites secrete exosome-like 
vesicles (ELVs) containing small RNAs and proteins that have the capacity to regulate host 
processes [6]. 
Here we demonstrate pan-lifecycle secretion of ELVs by Brugia and show that they are 
being internalized by host macrophages which are early mediators of LF infection. We also report 
the site of ELV release in mf and the proteomic profile of ELVs from adult female and male stage 
parasites. Analysis of the proteomic profiles revealed canonical exosomal markers, adding 
confidence that the isolated vesicle population are B. malayi exosomes. Also of interest was the 
stage specific cargo contained within these vesicles with many immunomodulatory proteins 
identified in adult female ELVs. This stage and gender specificity suggests vesicle release is a 
regulated process via which the parasite releases effector molecules for targeted delivery within 
the host.   
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Results 
Exosome-like vesicles (ELVs) are released throughout the Brugia life cycle. 
In a previous study, we described the highly abundant release of a discrete ELV population 
from infective stage (L3) B. malayi [6]. ELV release from adult male and female nematodes, in 
contrast, was not definitive and led to the hypothesis that ELV secretion is primarily a strategy 
used by infective B. malayi larvae to facilitate host invasion and establishment of infection. To test 
this hypothesis we examined ELV release from all other intra-mammalian life stages of B. malayi. 
L4, adult male, adult female and microfilariae (mf) worms were incubated in culture media and 
secreted ELVs isolated, purified and quantified by nanoparticle tracking analysis using previously 
published protocols [6]. All life stages examined release extracellular vesicles of a size consistent 
with exosomes. The size distribution of the ELV fraction was homogenous with the mean size 
ranging from 50nm – 130nm (Figure 1A-E). The morphology of the parasite-derived vesicles also 
examined using electron microscopy and, consistent with our observations of B. malayi L3 ELVs, 
vesicles secreted by all life stages exhibited the accepted “cup-shaped” or “donut” morphology of 
exosomes [7-9] (Figure 1F). As with previous studies, we use the term exosome-like vesicles 
(ELVs) to describe these structures because although they present with the size and morphology 
of exosomes, uncertainty of vesicle biogenesis precludes unequivocal designation as exosomes. 
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Figure 1. Vesicles of a size and morphology consistent with the exosome literature are released 
by all life stages of Brugia malayi. Nanoparticle tracking analysis shows discrete populations of 
vesicle within the exosome size range are secreted by microfilaria (A), larval L3 (B), L4 (C), adult 
female (D) and adult male (E). Transmission electron microscopy reveals parasite-secreted 
vesicles within the expected size range. 
 
ELVs are released from microfilariae via the excretory-secretory pore. 
The mechanism by which exosomes are released by parasitic nematodes is unclear. To 
identify a site for ELV secretion by B. malayi we employed whole-mount indirect 
immunocytochemistry (ICC) interfaced with confocal scanning laser microscopy using primary 
anti-Alix antibodies. ALG-2-interacting protein X (Alix) is an ESCRT associated protein found 
in many exosomes and is widely accepted as an exosomal marker [10, 11]. Strong anti-Alix 
immunoreactivity was observed in B. malayi microfilariae preparations but not in L3, adult 
male or adult female preparations. Immunoreactivity was highly focused around the Excretory-
Secretory (ES) pore (Figure 2) suggesting this structure may be the site of ELV release in 
42 
 
microfilariae. The ES pore is the terminus of the parasite excretory system that may be 
considered functionally equivalent to the vertebrate renal system, and vesicle release via this 
system may be expected given its partial glandular arrangement [12, 13]. A lack of anti-Alix 
immunoreactivity in the L3 and adult preparations does not mean, however, that ELV secretion 
in these stages is not via the ES pore. It may be that ELVs released by these stages do not 
express Alix, or that a technical obstacle in whole mount ICC in the larger worm stages proved 
obstructive. Knowledge on the L3 and adult ELV protein content allows us to perform a more 
specified IHC to show ELV release. Custom antibodies against selected proteins we know are 
contained within these ELVs as revealed by the proteomic analysis can be generated and used 
to perform IHC to detect the site of ELV release by the L3 and adults. In case the IHC fails, 
running a western on ELV preparations (if there are some to spare) using these antibodies will 
help confirm whether it was a technical issue related to IHC and Brugia. IHC with antibodies 
raised against CD63 (considered a universal exosome marker) were also unsuccessful 
suggesting a shortcoming in IHC, rather than variance in exosomal marker expression, 
underpinning the lack of immunoreactivity in L3 through adult stages. If the IHCs on these 
stages failed due to technical problems related to IHC and Brugia as anecdotally evidenced, in 
situ hybridization can be an alternative technique used. The RNA content of the L3 life stage 
ELVs is currently available via work previously published by our lab. RNA probes can be 
generated against a selected few of these RNA targets and in situ hybridization can be done to 
visualize ELV release. 
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Host macrophages internalize Brugia ELVs by phagocytosis. 
Exosomes deliver their contents to target cells via different mechanisms; endocytosis by 
recipient cells, receptor mediated processes, and the fusion of vesicle and recipient cell plasma 
membranes [14-17]. Previously we reported that ELVs released by B. malayi L3 parasites are 
internalized by host macrophages [6]. Here we wanted to test whether all life stage ELVs (mf, L3, 
Figure 2. Brugia microfilaria release ELVs via the Excretory/Secretory pore. 
Confocal scanning laser micrograph of whole mount B. malayi microfilaria showing 
immunoreactivity against Alix (green), a canonical exosome marker, is focused 
around the excretory/secretory (E/S) pore. The preparation is counterstained with 
Hoechst 33342 (blue) and Phalloidin 647 (purple) to help identify major 
anatomical features. 
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L4, adult male and adult female) are internalized by host macrophages and identify a mechanistic 
basis for this internalization.  
Figure 3. ELVs from all life stages are internalized by J774A.1 murine macrophages as seen by 
confocal microscopy (A-D) and flow cytometry (E).  Cells were stained with Phalloidin 647 
(purple) to visualize the actin skeleton and counter-stained with Hoescht 33342 (blue) to visualize 
nuclei (A)ELVs were stained with PKH67 (green) before adding to the cells (B). Overlays of these 
channels demonstrate internalization of ELVs from all the life stages by the macrophages (C) as 
confirmed via flow cytometry (E).  A 3-dimentional cartoon image magnified 5X is shown for 
clarity (D). 
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The interaction of fluorescently labeled B. malayi ELVs with J774A.1 murine macrophages was 
visualized using confocal microscopy and quantified with flow cytometry. ELVs released by all 
parasite life stages are taken up by J774A.1 macrophages (Fig. 3). All macrophages took up 
parasite ELVs to some extent (Fig. 3E) and there was no significant difference in the uptake of 
ELVs from the different life stages. 
In an effort to characterize the mechanisms of this ELV internalization, J774A.1 
macrophages were pretreated with chemical inhibitors of discrete endocytic pathways before 
incubation with fluorescently labeled parasite ELVs. Pretreatment with Dynasore, a dynamin 
inhibitor and therefore inhibitor of dynamin-dependent uptake pathways [18], completely blocked 
ELV internalization (Fig. 4B-E) strongly suggesting that ELV uptake occurs via dynamin-
dependent processes, that is to say, via either phagocytosis, clathrin-mediated endocytosis or 
caveoli-mediated endocytosis, or a combination thereof. ELV uptake was not inhibited in 
macrophages pretreated with Chlropromazine, a clathrin-mediated endocytosis blocker [19, 20] 
(Fig.4G-J), or by Genistein, an inhibitor of caveoli-mediated endocytosis [21] (Fig. 4M-P), 
suggesting that ELV uptake does not occur by these pathways. This leads to the conclusion that B. 
malayi ELVs are internalized by J774A.1 macrophages mainly via phagocytosis.  
Our ability to selectively inhibit chosen endocytic pathways using these compounds in this 
experimental model was confirmed by measuring their ability to inhibit the internalization of 
explicit controls for each endocytic pathway i.e. a microsphere phagocytic tracer for phagocytosis 
(Fig. 4A, B), labeled transferrin for clathrin-mediated endocytosis (Fig. 4F, G) and labeled cholera 
toxin b for caveoli-mediated endocytosis (Fig. 4L, M).  
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Figure 4. ELV uptake is mainly via 
phagocytocis. Cells were pre-treated with 
chemical compounds that selectively inhibit 
endocytic pathways phagocytosis (B-E), 
clathrin-mediated endocytosis (B-E, G-J) and 
caveoli-mediated endocytosis (B-E, M-P) and 
incubated with ELVs stained with PKH67 
(green) (C, H, N). Nuclei of the cells were 
stained ith Hoescht 33342 (blue) and the actin 
skeleton with phalloidin 647 (purple). Cells 
were incubated with Phagocytic tracers (A, B), 
transferrin (F, G) and cholera toxin b (L, M) as 
indicators of blockage by the respective 
inhibitors.  An overlay of the three channels (D, 
I, O) and 3D depiction of the merged channel magnified 5X (E, J, P) show varying degrees 
of internalization when treated with these chemical inhibitors.  
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Adult ELV proteomics reveals proteins involved in exosome biogenesis and 
immunomodulation. 
Our overarching hypothesis is that ELVs are a mechanism of host immunomodulation 
employed by the parasitic nematode B. malayi. In support of this, we have shown that ELVs are 
being released by all parasitic life stages and that these ELVs are being internalized by host 
immune cells. In an attempt to delineate the function of these ELVs, we examined the protein 
content of adult male and female ELVs. Vesicles were purified from culture media as described, 
and following protein isolation and tryptic digestion, samples were subjected to nano-scale LC-
MS/MS. Proteins were identified using Mascot to search Brugia, Ascaris and Caenorhabditis 
protein datasets, then parsed into Scaffold to generate a non-redundant list of proteins with host 
contaminant proteins subtracted. A total of 84 distinct proteins were identified in the adult female 
ELV preparation (Table 2) and 21 in the adult male vesicles (Table 1). The combined protein 
profile of adult ELVs revealed proteins commonly associated with exosomes and proteins 
considered canonical exosome markers; Rab GTPases such as Rab 11, Rab 27, Rab 35 and Rab 7 
are involved in membrane transport and fusion [22-24] and the presence of all four of these proteins 
in the vesicle population provides support that these vesicles are indeed exosomes. Other proteins 
commonly found in exosomes, for example cytoskeleton proteins such as actin, ERM (ezrin, 
radixin and moesin) proteins and tubulin [22], lipid rafts such as GPI proteins (DAF-21 also known 
as CD55) [25] and molecular chaperones such as heatshock protein HSP-1 (also known as HSP70) 
[26, 27] were also present in the vesicle population. These proteins are commonly found in 
exosomes across a broad species range and are considered typical of this specific extracellular 
vesicle subtype. These data strongly support our hypothesis that Brugia secrete exosomes and 
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provide confidence that downstream identification of vesicle function can be attributed to this 
vesicles subtype rather than, for example, plasma membrane blebs.  
Amongst the most abundant proteins identified in the adult female profile were proteins 
with known immunomodulatory properties. Galectins are a 15-member family that have been 
shown to be involved in many functions related to immunomodulation. Galectin-1 and 2 were 
identified in the adult female ELV proteome and have previously been shown to have 
immunomodulatory roles such as phagocytic recognition [28], inhibition of proinflammatoy 
cytokines [29] and shift T cells towards a Th2 paradigm [30]. Another interesting protein identified 
is annexin. This is a protein family of diverse functions ranging from membrane transport and 
fusion [31] to exerting anti-inflammatory effects [32, 33] which, depending on the annexin 
identified, suggests a function in exosome biogenesis or the canonical Th2 response associated 
with LF respectively. Macrophage migration inhibitory factor-1 (MIF-1) is another interesting 
protein that was identified. MIF-1 is the Brugia homolog of human MIF-1, the first cytokine to be 
identified [34]. It was one of the most abundant exosome proteins suggesting an active role of the 
molecule. MIF has been found in Brugia secretions and shown to promote differentiation of 
macrophages towards alternative activation (immunosuppressive phenotype) in the presence of IL-
4 [35]. HSP-70, while serving as an exosomal marker has also been shown to have 
immunomodulatory capacity in tumor cells where soluble HSP-70 activates monocytes to secrete 
proinflammatory cytokines, while the membrane-bound form has been reported to be a target of 
cytosolic attack by natural killer cells [36].  
  
49 
 
Table 1. The proteomic profile of adult female ELVs reveal proteins with immunomodulatory 
capacity.   
Identified Proteins NSAF(AF) 
Galectin-2 0.0605 
BMA-ACT-5 0.0596 
Annexin 0.0569 
Galectin-1 0.0462 
Triosephosphate isomerase 0.0379 
Macrophage migration inhibitory factor 
homolog 0.0379 
BMA-ERM-1 0.0348 
BMA-UBQ-2 0.0335 
BMA-HSP-1 0.0309 
BMA-RAB-8 0.0261 
Uncharacterized protein 0.0255 
BMA-RAB-1 0.0247 
Uncharacterized protein 0.0244 
Bm3210 0.0228 
thioredoxin peroxidase 0.0223 
Glyceraldehyde-3-phosphate dehydrogenase 0.0221 
BMA-RAP-1 0.0217 
BMA-RAB-11.1 0.0213 
BMA-DAF-21 0.0206 
L-lactate dehydrogenase 0.0195 
BMA-AQP-7 0.0190 
Tubulin beta chain 0.0182 
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BMA-RAB-35 0.0166 
Galectin 0.0160 
Sugar transporter family protein 0.0160 
Malate dehydrogenase 0.0126 
BMA-GPA-16 0.0125 
Tubulin alpha chain 0.0123 
GTP-binding nuclear protein Ran 0.0119 
Bm5356 0.0116 
Uncharacterized protein 0.0114 
Histone H4 0.0103 
Mechanosensory protein 2 isoform a 0.0089 
Bm13965 0.0085 
Uncharacterized protein 0.0075 
Pyruvate kinase 0.0075 
Bm13659 0.0074 
ras-related protein Rab-7 0.0071 
Fructose-bisphosphate aldolase 0.0071 
Bm2511 0.0071 
Bm9132 0.0065 
BMA-UMPS-1 isoform a 0.0064 
BMA-GPB-1 isoform a 0.0062 
Elongation factor 1-alpha 0.0056 
Bm3648 0.0055 
BMA-RME-1, isoform a (Receptor Mediated 
Endocytosis) 0.0054 
BMA-ARF-1.2 0.0054 
Bm6727 0.0052 
Table 1. Continued 
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BMA-ATGP-1 0.0048 
Ras related Rab-27 0.0047 
Nucleoside transporter family protein 0.0047 
BMA-GST-1 0.0047 
Annexin 0.0047 
Bm8928 0.0044 
Transketolase 0.0042 
BMA-MCA-2, isoform d (calcium ATPase) 0.0041 
BMA-EGL-30 0.0040 
Transaldolase 0.0032 
Bm795 0.0030 
macroglobulin complement component 
family protein 0.0027 
Sodium/potassium-transporting ATPase 
subunit alpha 0.0025 
Bm1994, isoform a 0.0025 
Adenosylhomocysteinase 0.0024 
Bm13661 0.0023 
cytochrome b superfamily 0.0022 
BMA-LGC-21 ligand gated ion channel 0.0022 
Protein kinase C 0.0021 
2,3-bisphosphoglycerate-independent 
phosphoglycerate mutase 0.0020 
Transmembrane amino acid transporter 
protein 0.0019 
Bm5460, isoform b 0.0018 
Bm15985 0.0013 
Bm Neprilysin 0.0012 
Table 1. Continued 
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AP complex subunit beta 0.0010 
Apolipophorin 0.0005 
 
Of particular interest in the proteomic data was the comparison between proteins identified 
in the male and female preparations. 84 proteins were identified in the female sample whereas only 
21 were identified in the male sample. Further, whilst the female sample included exosome 
markers as well as proteins with potential immunomodulatory properties, these 
immunomodulatory proteins were largely absent from the male profile.  Two interpretations can 
be drawn from this. One is that perhaps the depth of sequencing of the male sample was not as 
good as the female preparation and therefore this analysis doesn’t reflect the comprehensive profile 
of proteins contained within adult male ELVs.  However, the male profile was repeated twice with 
similar vesicle numbers to the female sample, and protein extractions generated protein yields that 
were not only comparable to the female preparation but also more than exceeded protein 
requirements for nano-scale LC-MS/MS.  Moreover, the vesicles were pooled from multiple worm 
incubations and therefore represent good biological coverage. The other interpretation would be 
that this is a representative analysis of male ELVs and that they contain limited functional cargo 
relative to female exosomes. Whilst these findings must be investigated further to validate, the 
lack of immunomodulatory proteins in male ELVs suggests exosome release may serve sexually 
dimorphic functions; female ELVs may be more effective at host immunomodulation than male 
vesicles. Differential pathobiology for male and female Brugia has not been reported in the 
literature but may also have not been explicitly investigated. It is not clear why male and female 
parasites would have discrepant functional roles in maintaining infection but a loss of 
immunomodulation in males may simply be a result of redundancy. Male and female worms 
Table 1. Continued 
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associate closely in infected lymphatic vasculature and it might be expected that males would 
benefit from host immunomodulation driven by female 
 Table 2. The proteomic profile of adult male ELVs reveal mainly structural 
proteins. 
Identified Proteins NSAF 
Histone3 0.4710 
BMA-ACT-5 0.4261 
Bm4628 0.1656 
ATP synthase subunit 
alpha 0.1029 
BMA-RAB-11.1 0.0885 
BMA-RAP-1 0.0867 
BMA-HSP-1 0.0694 
BMA-RAB-1 0.0660 
Tubulin beta chain 0.0546 
BMA-ARF-1.2 0.0434 
Bm13659 0.0396 
Tubulin alpha chain 0.0364 
BMA-GPA-16 0.0222 
Bm9583, isoform b 0.0209 
Bm5196, isoform a 0.0194 
Uncharacterized protein 0.0190 
BMA-GPB-1, isoform a 0.0164 
Adenosylhomocysteinase 0.0126 
BMA-DAF-21 0.0110 
Bm1994, isoform a 0.0067 
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Figure 5. GO annotation of molecular function of adult female ELV proteins. 
Figure 6. GO analysis of adult male proteomics based on molecular function 
GTP binding guanyl ribonucleotide binding
guanyl nucleotide binding dopachrome isomerase activity
lactate dehydrogenase activity L-lactate dehydrogenase activity
intramolecular oxidoreductase activity, ... phenylpyruvate tautomerase activity
fructose-bisphosphate aldolase activity intramolecular oxidoreductase activity, ...
L-malate dehydrogenase activity GTPase activity
6-phosphofructokinase activity glutathione transferase activity
phosphoglycerate mutase activity phosphofructokinase activity
aldehyde-lyase activity nucleoside-triphosphatase activity
oxidoreductase activity, acting on the C... phosphopyruvate hydratase activity
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Discussion 
Exosomes are a subtype of extracellular vesicle secreted by eukaryotic organisms ranging 
from single-celled protists to fungi to multicellular plants and most phyla of animals [37, 38]. 
Initially thought to be a mechanism of waste disposal, exosomes have gained renewed interest as 
mediators of cell-to-cell communication with the discovery that their cargo can contain potently 
bioactive nucleotide and protein effectors [31, 39-43]. There is an emerging body of evidence that 
parasitic worms, including nematodes and platyhelminths, release exosomes into the host milieu 
and that these exosomes contain potential effector molecules that may function at the host parasite 
interface [44-50]. We have previously shown that larval L3 stage B. malayi, a filarial nematode 
and etiological agent of Lymphatic filariasis (LF), release exosome-like vesicles (ELVs) 
containing known effector proteins and microRNAs (miRNA) with host homology [6]. Our 
overarching hypothesis is that filarial nematodes, including B. malayi, use ELVs to release effector 
molecules that facilitate the establishment or maintenance of parasitemia, specifically by actively 
directing the host response to infection. Here we provide evidence to support this hypothesis. 
We previously described ELV release from the infectious L3 larval stage of B. malayi but 
here we show that ELV release is a conserved phenomenon across the entire mammalian host 
phase of the parasite life cycle. ELVs are secreted by mf, L3, L4 adult male and adult female 
worms with a size range between 50 -130 nm in diameter.  This ELV size distribution falls within 
the range of 30 – 180 nm released from discrete life stages of other parasitic helminth species [44-
52] and is consistent with the broader exosome literature. If parasite derived ELVs operate at the 
host-pathogen interface, the consistent pattern of ELV release reported here would suggest it is a 
conserved strategy adopted by all stages. It would be expected, however, that although the broad 
strategy is conserved, the specific modulatory properties of ELVs would change depending on 
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parasite life stage and host. ELVs released by L3 B. malayi, for example, in the mosquito host 
would likely have properties distinct from ELVs released by adult worms in human lymphatic 
vasculature since the host processes requiring modulation and potential host cues and stimuli are 
different. The variance in ELV size reported here points to some morphological differences in 
Brugia stage-specific ELVs but functional variance is more likely to arise from differences in 
structural components and cargo and such developmental regulation of vesicles has been suggested 
in parasitic flatworms [53]. Therefore, a trans-life cycle characterization of the molecular content 
of ELVs (including proteins and small RNAs) and the array of host phenotypic changes in response 
to them is important to fully understand the role of ELVs in parasitemia. 
The mechanisms of ELV release by parasitic helminths, as separate from their cellular 
biogenetic pathways, remain undefined. In parasitic flatworms, a model of vesicle release from the 
apical membrane at the tegumental surface is supported by transmission electron microscopy [46, 
47, 53, 54]; but may not be the only route of secretion [55]. In contrast to the flatworm tegument, 
the nematode cuticle is a relatively impervious interface. Composed primarily of collagens and 
cuticulins overlaid by a lipid- and glycoprotein-rich coat [56], the filarial cuticle is capable of small 
molecule transport [57, 58] but not dynamic vesicle release, turning the focus to other structures. 
Buck et al. (2014) note that extracellular vesicles secreted by Heligmosomoides polygyrus are 
enriched with intestinal proteins suggesting secretion from the digestive tract and in the same study 
observed vesicles associated with intestinal tissue preparations. Other routes may be relevant and 
our identification that the excretory-secretory (ES) pore is highly immunoreactive to exosomal 
markers in microfilariae suggests at least one other avenue. The fine structure of the ES system in 
filarial nematode larvae has been variously described [59-62]. Excretory and glandular cells empty 
into an ampulla structure, which connects to the ES pore via a channel, with close association of 
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neuronal elements suggesting regulated release via a valve-like structure. Microfilarial ELV 
release by this valve-like structure suggests that it is a regulated process, and not mere 
uncoordinated expulsion of vesicles to the environment, hence a process of biological importance 
to the parasite. Anatomical differences in this general apparatus between life stages suggest 
increased importance of the structure in larval parasites [63], which may account for our observed 
exosomal marker immunoreactivity in mf but not later stages. If Brugia mf release ELVs via the 
ES pore it provides a basis to speculate a link between ELVs and ivermectin (IVM) mode of action. 
The microfilaricidal activity of IVM is unclear and it has been suggested that IVM may work at 
therapeutic concentrations by disrupting the parasite’s ability to regulate the host immune system 
[64, 65]. Moreno et al. (2010) showed that ivermectin-sensitive glutamate-gated chloride channels 
were expressed around the ES pore of Brugia mf and that IVM treatment reduced secretion from 
this structure. Consistent with our overarching hypothesis, IVM may inhibit ELV release from the 
mf ES pore, depriving the parasite of the host immunomodulatory property of the vesicles and 
allowing effective clearance. This poses an important avenue for filariasis control where parasitic 
load can potentially be reduced by targeting a mechanism such as ELV release which is universal 
across the Brugia life cycle. Analysis of the effect of IVM on ELV release in Brugia will be 
required to support this hypothesis.  
Internalization of exosomes from various cell types have been shown to occur through 
different endocytic pathways [14, 66-68]. Even though uptake of parasitic helminth ELVs by 
various mammalian cell lines have been shown before [44, 46, 49-51], the mechanistic basis of the 
internalization pathway of these ELVs has, until now, not been elucidated. Here we show that 
ELVs from across the Brugia life cycle are internalized via phagocytocis. Internalization by 
phagocytocis requires recognition via specific opsinin receptors, scavenger receptors or toll-like 
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receptors (TLRs) [69], suggesting that B. malayi ELVs may contain special surface recognition 
molecules to ensure internalization. This again suggests that ELVs are released to serve a specific 
purpose within the host.  
  
Profiling of adult male and female ELV protein components, added to our previous 
proteomic analysis of L3 ELVs [10] allows us to build a picture of the diversity of ELV structure 
and cargo across the Brugia life cycle. A cohort of proteins is shared across all ELV preparations 
and these molecules tended to be structural or markers of ELV biosynthesis, for example, actin 
and β tubulin, HSP-70 and elongation factor-1. The identification that classical exosomal markers 
are found in the ELV profile of L3, adult male and female preparations is important since it 
supports our designation of the vesicles under investigation as exosomes. Other subtypes of 
extracellular vesicle may be released by these parasites such as microvesicles and membrane blebs 
or apoptotic bodies, and the size profile of these vesicles may often overlap such that reliance on 
morphology to discriminate is unreliable. The presence of exosomal markers provides another 
layer of identification and provides a platform for downstream functional characterization. To this 
end, adult female ELVs were enriched with proteins that have previously been described as 
immunomodulatory whereas adult male ELVs lacked such proteins. A Cathepsin L-like protease 
was the only protein with known immunomodulatory capacity that was identified in the L3 ELV 
proteome [6]. These findings support our hypothesis that B. malayi release exosomes to facilitate 
the establishment or maintenance of parasitemia, specifically by actively directing the host 
response to infection. Our data focus the functional role of host immunomodulation of adult 
females since these ELVs contain candidate effector proteins whereas the male ELVs do not. This 
is not to say male ELVs do not contain any potential immunomodulatory molecules since we did 
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not examine small RNA cargo in this study. Previously we described the miRNA complement of 
L3 ELVs and identified miRNA with host homology that may affect host immune cell gene 
expression [10]. Further we noted that there were global differences in the small RNA cargo 
between L3, adult female and adult male ELVs. It Is possible that host immunomodulatory small 
RNAs are carried by male ELVs with the goal of manipulating host gene expression. Small RNA-
seq analysis will be required to gain further insight into the small RNA cargo of stage- and sex-
specific ELVs. However, the current findings do suggest sexual dimorphism in ELV structure and 
function and further emphasize the diversity and functional plasticity of parasite exosomes.  
Comparison of the ELV proteome with previous Brugia secretome data [70-72] yielded 
some interesting observations. Just eight proteins identified in the present study overlapped with 
the consensus secretome, however this group was among the most abundant in the ELV proteome. 
For example, Hewitson et al. (2008) found that galectin-1 and 2 were among the most abundant 
proteins in the Brugia secretome [32] and galectin -2 was the most abundant protein in our study 
followed closely by galectin-1. Conversely, around 20 proteins identified in our study were absent 
in the consensus secretome. One reason for this disparity between identified proteins could merely 
reflect a difference in abundance. It could be that due to the sheer abundance of freely secreted 
protein, those packaged in ELVs are masked during whole secretome analysis. This is not to say 
that ELV proteins are of less importance. Rather, it could be a directed mechanism mounted by 
the parasite to exert specific effects. While freely secreted proteins are more easily subjected to 
degradation, those contained in ELVs are protected by the surrounding membrane. Moreover, 
packaging proteins within ELVs allows the parasite to send them to targetted destinations, 
increasing the probability of it achieving the desired function. Additionally, a difference in protein 
extraction and preparation methods could also partially explain this difference.  
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In summary, we have showed that ELVs are released across the Brugia life cycle, that they 
are internalized by host macrophages, that the protein cargo in these ELVs are stage- and sex-
specific and that they indicate host immunomodulatory function. These data collectively support 
our overarching hypothesis that filarial nematodes, including B. malayi, use ELVs to release 
effector molecules that facilitate the establishment or maintenance of parasitemia, specifically by 
actively directing the host response to infection. We add to the emerging body of evidence that 
exosomes/ELVs are a mode of communication not only between cells of an organism but also 
between species. 
 
Materials and Methods 
Exosome-like vesicle (ELV) isolation  
All B. malayi stages used in this study were obtained from the NIAID/NIH Filariasis 
Research Reagent Resource Center (FR3) at the University of Georgia, USA. 600 L4 and 60 adult 
male and 60 adult female stage parasites were cultured in RPMI 1640 (Thermo Fisher Scientific, 
Waltham MA) containing 10 g/L glucose (Thermo Fisher Scientific) and pen-strep (penicillin 0.4 
units/mL, streptomycin 0.4 mcg/mL; Thermo Fisher Scientific) at 37°C, 5% CO2. Microfilariae 
(mf) were purified using established protocols and cultured in identical media at room temperature. 
Culture media was collected and replaced at 24 hr intervals for ELV purification for as long as the 
worms maintained the same level of activity as when they were received (i.e. approximately 3-5 
days for adult females and 10 days for adult males). The culture media in which the L3s (600) 
were received in, was processed for ELV isolation and no further incubations were performed 
since we previously showed that the homogeneity of ELVs secreted by this life stage rapidly 
61 
 
deteriorates in culture. ELVs were purified via differential centrifugation. Culture media aliquots 
were centrifuged at 12,000 x g for 45 minutes at 4°C and filtered through 0.22 μm filters to remove 
debris then ultracentrifuged at 120,000 x g for 1.5 hours to pellet the ELVs. The ELV were washed 
with cold 1X dPBS (Thermo Fisher Scientific) and consolidated into 1.5 ml ultracentrifuge tubes 
(Beckman Coulter, Brea, CA) and centrifuged for 55,000 rpm for 2 hours at 4°C. All but 25 – 50 
µl media were removed and the purified ELV preparations were quantified by Nanoparticle 
Tracking Analysis using NanoSight LM14 (Malvern Instruments, Malvern, UK). ELV samples 
were stored at -80°C.  
 
Electron microscopy of ELVs 
An aliquot of the ELV purification was mixed with uranyl acetate 2% (w/v), incubated for 
5 min at room temperature and applied to carbon-coated copper grids. Images were taken at 80kV 
using a JEOL 2100 200-kV scanning and transmission electron microscope (STEM) with a 
Thermo Fisher Noran System 6 elemental analysis system. 
  
Localization of ELV secretion 
Microfilariae immunohistochemistry was performed as previously described. In brief, 
microfilariae were collected by centrifugation at 1000 X g for 5 minutes and washed in RT 1X 
dPBS. The worms were immersed in 4% PFA (Electron Microscopy Sciences, Hatfield, PA) in 
dPBS and freeze-cracked by immersing the tube in liquid Nitrogen for 2-3 minutes, thawing in a 
37°C water bath and repeating the process twice more. They were then fixed for 4 hours at 4°C. 
The fixed worms were collected by centrifugation, washed with PBST (0.1% Triton-X 100 in PBS) 
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and permeablized overnight in fresh 2-mercaptanol solution (5% 2-mercaptoethnanol, 1% Triton, 
120mM Tris, pH 7) at 37°C. Following thorough washes in PBST, the worms were incubated in 
antibody diluent (AbD; 0.1% BSA, 0.1% NaN3 in PBST) overnight. Next, they were incubated 
with anti-Alix rabbit primary antibody (diluted 1:1000 in AbD) (Millipore) at 4°C for 2 days, 
washed in AbD three times and incubated in AbD overnight. The same procedure was followed 
for the incubation in donkey anti-rabbit secondary antibody (Invitrogen) at 1:1000 dilution in AbD. 
Following an overnight wash in AbD, the worms were incubated in 1:100 Phalloidin 647 (Life 
Technologies, Carlsbad, CA) and 1:100 Hoechst 33342 (Invitrogen, Carlsbad, CA) at 4°C 
overnight. The worms were washed in AbD the next day and mounted using Flouromount aqueous 
mounting medium (Sigma-Aldrich, St Louis, MO) and visualized by a Leica SP5 X MP 
confocal/multiphoton microscope system. 
 
ELV uptake assay 
5 x 105 J774A.1 cells were grown for 24 hrs on coverslips commercially coated with Poly 
D-lysine (Fisher). ELV preparations were stained with the green lipophilic dye, PKH67 (Sigma-
Aldrich) according to manufacturer’s instructions. In short, the ELV pellet was homogenized in 
125µl of diluent C. Next 0.5µl of the dye was added to 125µl of diluent C and pipetted several 
times to mix well. This mixture was then added to the ELVs homogenized in diluent C and 
incubated for 5 minutes. The reaction was inactivated by adding 250 µl of heat inactivated FBS 
for 1 minute. 0.5-1ml 1X PBS was added and ultracentrifuged for 1 hour at 55,000 rpm to pellet 
the ELVs. 1 x 107 of stained ELVs of each life stage were added to cells grown on coverslips and 
incubated at 37°C for an additional 24 hrs. The internalization pathway of these ELVs was 
explored using endocytic inhibitors to selectively block each pathway. Cells were incubated in the 
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presence of 200 µM Dynasore (Sigma-Aldrich), 30 µM Chlorpromazine (Sigma-Aldrich) or 300 
µM Genistein (Sigma-Aldrich) 1-2 hours prior to the addition of PKH labelled ELVs along with 
0.1µm Fluoresbrite Carboxy NYO microspheres (PolySciences Inc., Warrington, PA) transferrin 
from human serum (Molecular probes), Alexa Fluor 555 conjugate (Life Technologies) and 
Cholera toxin subunit B, Alexa Fluor 555 conjugate CtxB (Life Technologies) with respective 
treatments to control for inhibition. 
Cells were prepared for Immunocytochemisry 24 hours post-treatment as previously 
described. Briefly, media were removed and cells were washed with 1X dPBS heated to 37°C, 
followed by a 30 minute incubation at room temperature in 4% PFA heated to 37°C. All washes 
and incubations from this point onwards were done on a rocker at room temperature. Cells were 
washed for 10 minutes with 1X dPBS, followed by two more 10 minute washes. Cells were then 
incubated in 1:200 Phalloidin 647 (Life Technologies,) for 30 minutes followed by three 10 minute 
washes with 1X dPBS. 1:500 Hoechst 33342 was added to the cells and incubated for 10 minutes 
and washed twice in 1X dPBS. Coverslips were mounted on slides using Flouromount aqueous 
mounting media (Sigma-Aldrich) and visualized by a Leica SP5 X MP confocal/multiphoton 
microscope system.  
 
Proteomic analysis 
Protein was extracted from adult female and microfilarial stage exosome-like vesicles 
(System Biosciences). Samples were heated at 100°C for 15 minutes, lysate clarified by 
centrifugation and protein concentration determined by Qubit fluorometry (Invitrogen). 8µg of 
extracted protein from each sample was processed by SDS-PAGE using 10% Bis Tris NuPage 
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mini-gel (Invitrogen) in the MES buffer system. In-gel digestion with trypsin was done at 37°C 
for 4 hrs using a ProGest robot (DigiLab). The processed sample was analyzed by nano LC-
MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher Q Exactive. The 
mass spectrometer was operated in data-dependent mode, with the Orbitrap operating at 60,000 
FWHM and 17,500 FWHM for MS and MS/MS respectively. The fifteen most abundant ions were 
selected for MS/MS. Data were searched against a copy of the B. malayi UniProt database using a 
locally running copy of MASCOT. The search was restricted using the following parameters; 
maximum missed cleavages = 2, fixed modifications = carbamidomethyl (C), variable 
modifications = Oxidation (M), Acetyl (N-term), Pyro-Glu (N-term Q) and Deamidation (N, Q), 
a peptide mass tolerance of 10 ppm, and a fragment mass tolerance of 0.02 Da. Mascot DAT files 
were parsed into the Scaffold software for validation, filtering and to create a nonredundant list 
per sample. Data were filtered using at 1% protein and peptide FDR and requiring at least two 
unique peptides per protein. Adult female and male proteomic profiles were subjected to gene 
ontology (GO) analysis. GO terms from all the exosome proteins were compared to the distribution 
of GO terms from the entire B. malayi proteome. GO terms that occur in the exosome dataset more 
often than expected (as tested by the Fisher exact test) are said to be “enriched.” 
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CHAPTER 3. INVESTIGATING THE ROLE OF BRUGIA MALAYI EXOSOME-LIKE 
VESICLES (ELV) AT THE HOST PARASITE INTERFACE 
 
Introduction 
Lymphatic filariasis (LF) is a debilitating, socially stigmatizing disease that is a major 
cause of socioeconomic burden in developing countries [1-3]. Of the three etiological agents of 
LF, Wuchereria bancrofti, Brugia malayi and B. timori, W. bancrofti is responsible for 90% of 
cases and B. malayi for most of the remainder [4]. Although different filarial nematode species, 
these parasites share a common life cycle differing only in the vector and definitive host range. 
The infective third larval stage (L3) of these parasites enters the human host via the puncture 
wound left behind by the mosquito following a blood meal. The L3s encounter a diversity of host 
cell types during their migratory journey from the puncture wound to the lymphatic vasculature 
where they develop into L4 stage parasites and then mature adults. The adults mate and the females 
produce microfilariae, which enter the blood stream to be taken up by a mosquito during a 
subsequent blood meal. For the duration of infection, the parasite is constantly exposed to host 
immune system components. Given the diverse range of barriers, sensors and response 
mechanisms of clearance present, it is remarkable that parasitic nematodes can still successfully 
evade these defense mechanisms and not only enter the host but also reside within it. 
An immunosuppressive Th2 response is prototypical of LF infection [5, 6]. A few studies 
have focused on identifying how this immune response is generated with a focus on monocytes 
and macrophages since these cells are critical coordinators of the early immune response to filarial 
infection. Studies exposing monocytes to live microfilariae [7] and microfilarial lysate [8] have 
shown that these parasitic materials induce an alternative activation phenotype characterized by 
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elevated levels of IL-10 and ARG-1 among others. Interestingly, the study using microfilarial 
lysate reported that stimulation impairs the differentiation process of macrophages and their ability 
to produce cytokines. This is an important observation because impaired macrophages dampen the 
immune responses mounted against the parasites. Another study showed that macrophages 
diverted the Th1 immune response toward Th2 in the face of filarial infection by regulation of 
CD4+ T cells [9]. Yet another study investigating the changes in macrophages during LF infection 
observed that cytokine production is not inhibited although cellular proliferation is [10]. It is 
apparent that the phenotype and function of macrophages are affected during LF infection, 
however, how the mechanisms mediating this modulation are unclear. One effort to characterize 
parasite-directed host modulation has focused on the molecules secreted by the parasites, revealing 
proteins that may play a role. Secretion of various molecules such as macrophage inhibitory factor 
[11], ES-62 [12] and cystatin [13] that have the capacity of modulating antigen presenting cells 
has been reported but a mechanism for bridging how these proteins exert their effects is not well 
understood. An explosion of recent studies has described the role of exosomes in cell-to-cell 
communication [14-16] and in disease pathogenesis, including in helminth infection. These 
extracellular vesicles represent an intriguing possible mechanism by which Brugia may package, 
secrete and deliver effector molecules to target host cells. Here, we present a novel potential 
immunomodulatory mechanism employed by the filarial nematode B. malayi. We hypothesize that 
B. malayi has adopted ELVs as a mechanism to fight and evade immune responses mounted by 
the host, ensuring its survival within the host.  
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Results and Discussion 
Host macrophage phenotypes elicited by Brugia ELVs are stage-specific and reveal 
immunomodulatory capability. 
Macrophages are early mediators of the immune response to LF infection [17]. Previously 
we noted differences in the cargo of vesicles secreted by L3, adult male and adult female worms 
(Chapter II and [18]). Such variation in cargo may be functionally relevant, reflecting that the host 
parasite interface is stage specific and would similarly require stage specific effector molecules. 
Therefore, we hypothesized that ELVs of different B. malayi life stages would elicit qualitative or 
quantitative differences in macrophage phenotype.  
Macrophage activation spans a spectrum between classical activation (M1, CAMΦ) and 
alternative activation (M2, AAMΦ) phenotypes [19]. The classical activation phenotype is well 
defined and includes the release of proinflammatory cytokines, such as IL-6 [20], and increased 
transcription of iNOS, the enzyme necessary for digesting arginine into NO and citrulline [21]. 
Our previous studies suggest B. malayi L3 ELVs elicit an activation profile that is orientated 
towards the classical end of the macrophage activation spectrum [18]. Therefore we exposed 
murine J774A.1 macrophages to Brugia mf, L3, L4, adult male and adult female ELVs and 
examined the phenotypes of the macrophages within the context of classical activation. 
Macrophage incubation with L3 stage ELVs produced a strong increase in IL-6 production (mean 
value 852pg/ml; mean fold change over control 17.1) that was comparable in magnitude to the 
lipopolysaccharide (LPS; 100 ng/mL) positive control (mean value 1077pg/ml; mean fold change 
over control 20.3) (Fig. 1A). No other life stage ELV preparation stimulated IL-6 production 
suggesting host macrophage classical activation is specific to the L3 stage even though all life 
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stage ELVs are internalized by macrophages (chapter II). In broad terms this pattern of L3 specific 
activation was also seen when a Greiss assay was used to quantify nitrite production (Fig. 1B) and 
qPCR to quantify changes in iNOS transcription (Fig. 1C) in response to ELV exposure. L3 ELVs 
produced significant increases in nitrite levels (mean value 17.66mM) and iNOS transcription 
(mean fold change 14.6 over control) but no effect was observed with other life stage ELVs. 
J774A.1 activation requires internalization of ELVs since pretreatment of the macrophages with 
Dynasore (200 µM) abrogated the observed response in each assay by over 80% (Fig. 1D). 
Pretreatment with 5-(N-Ethyl-N-isopropyl) amiloride (EIPA; 200 µM), an inhibitor of 
phagocytocis and macropincytosis [22] also reduced nitrite production at a similar efficacy, 
supporting our conclusion that internalization occurs primarily by phagocytosis. Differential 
stimulation of macrophages by ELVs across the Brugia life cycle, despite the same level of 
internalization (Chapter II) suggests stage-specific stimulation via differential cargo or ELV 
surface proteins, further emphasizing their specific roles within the host.  
 
Contrary to the immunosuppressive response typically associated with helminth 
infection in vivo [5, 6], infective stage L3 Brugia ELVs elicit a response more suggestive of a 
classical activation phenotype in J774A.1 macrophages. Wang et al. (2015) demonstrated that 
exosomes from adult Schistosoma japonicum worms drive a classical activation phenotype in 
macrophages. Similarly, exosomes derived from cancerous MDA-MB-231 and MCF7 cells also 
induce proinflammatory cytokines including IL-6, GCSF and TNF-α, whereas exosomes from 
non-malignant MCF10A cells do not [23], suggesting that an inflammatory response is not 
necessarily generated by exosomes of all origin. A proinflammatory response results in high traffic 
of cellular components to and from the site of infection, and parasites have been known to utilize 
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this for dissemination away from the infection site [24]. This leads us to speculate whether ELVs 
from the L3 stage elicit a classical phenotype to aid in transport of the parasite within the host.  
 
 
Figure 1. B. malayi ELVs induce stage specific activation profiles in host 
macrophages. Macrophages were incubated with ELVs from different life stages. 
Increases in IL-6 production through ELISA (A), NO through Griess assay (B) and iNOS 
trhough qPCR (C) indicate classical activation of macrophages in response to L3 stage 
ELVs but not those secreted by other stages.  The proinflammatory effects are diminished 
when cells are pretreated with phagocytic inhibitors dynasore (Dyn) and N-Ethyl-N-
isopropyl) amiloride (EIPA) (D). 
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Phenotypic plasticity of macrophages is well established in that M1 or M2 activated cells 
can revert to the contrary phenotype (i.e. from M1 to M2 or from M2 to M1) in response to 
appropriate immunomodulatory stimuli [25, 26]. We employed this characteristic to investigate 
the hypothesis that B. malayi ELVs have immunomodulatory properties. J774A.1 macrophages 
were driven towards an M2 activation phenotype using IL-4 before exposure to L3 ELVs. The 
ensuing macrophage response was profiled via Griess assay. L3 ELVs were not only able to drive 
macrophages from an M2 to M1 phenotype, demonstrating their immunomodulatory properties 
but also the magnitude of the response was significantly higher than that of undifferentiated 
macrophages to L3 ELVs. This demonstrates an active modulatory effort by the L3 ELVs. The 
significance of this lies in that the macrophages encountered by these parasites in vivo are more 
likely to be activated than naïve and therefore the parasites need to be equipped to revert an already 
established macrophage phenotype in their favor in order to establish and maintain infection.  
 
Brugia ELVs elicit a similar activation profile in RAW 264.7 murine macrophages.  
Thus far we have established that B. malayi ELVs modulate J774A.1 murine macrophages 
and elicit an M1-like phenotype in a stage-dependent manner. It may be possible that these effects 
are specific to the J774A.1 cell line and are not representative of the broader parasite-macrophage 
interaction. To test this hypothesis, we repeated select experiments using RAW 264.7 
macrophages, another murine macrophage line. In general, the responses of RAW 264.7 
macrophages to B. malayi ELVs mirror those of J774A.1. RAW 264.7 cells internalize all B. 
malayi life stage ELVs examined (mf, L3, L4, adult male and adult female; Figure 3). The 
activation profile was also similar; treatment with L3 ELVs elicited potent increases in IL-6 
production with a fold increase of approximately 3000 over control, nitrite levels with a fold 
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increase of approximately 30 over control and a fold increase over control of over 600 of iNOS 
transcription, all indicators of a classical or M1 type phenotype (Figure 4A-C). Other life stage 
ELVs did not stimulate this response. These data corroborate our findings with J774A.1 
macrophages and suggest a stage-specific interaction of filarial nematode ELVs with host 
macrophages in the murine model. 
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Figure 2. B. malayi L3 ELVs demonstrate immunomodulatory capacity. B. malayi L3 
ELVs were added to J774A.1 cells and the response was measured using a griess assay. 
J774A.1 macrophages were classically activated upon exposure to B. malayi L3 ELVs. 
LPS, a compound known for driving a classical activation phenotype in macrophages was 
used a s a positive control. A subset of J774A.1 macrophages were pretreated with IL-4 to 
drive them towards an alternative activation phenotype prior to adding L3 ELVS. 
Interestingly, these alternatively activated macrophages were driven towards a classical 
activation phenotype upon exposure to L3 ELVs, demonstrating immunomodulatory 
capacity of L3 ELVs. 
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Figure 3: B. malayi ELVs are internalized by RAW 264.7 macrophages as seen by confocal 
microscopy. RAW 264.7 macrophages were incubated with ELVs from different life stages of B. 
malayi to visualize uptake by these cells. Cells were stained with Phalloidin 647 (purple) to 
visualize the actin skeleton and counter-stained with Hoescht 33342 (blue) to visualize nuclei. 
ELVs were stained with PKH67 (green) before adding to the cells. Overlays of these channels 
demonstrate internalization of ELVs from all the life stages by the macrophages (top panel).  A 3-
dimentional cartoon image magnified 5X is shown for clarity (bottom panel).  
 
 
 
Figure 4: B. malayi ELVs trigger activation patterns similar to J774A.1 cells in RAW 264.7 
macrophages. RAW 264.7 macrophages were incubated with ELVs from different life stages of 
B. malayi and the response was measured via (A) IL-6 ELISA, (B) Griess assay and (C) 
qRTPCR of iNOS transcription, markers of classical activation. All showed marked increased in 
the face of L3 ELVs but not ELVs from other life stages. The magnitude of response was 
comparable to that of LPS, a known classical activator. 
77 
 
Brugia ELVs are internalized by Human Lymphatic Endothelial Cells (HLEC) 
The L3 larval stage parasites migrate to the lymphatics where they molt into the L4 larval 
stage and subsequently into adults. On par with our overarching hypothesis that ELVs are a 
mechanism of host immunomodulation by B. malayi, we hypothesized that ELVs from all life 
stages (mf, L3, L4, adult male and adult female) will interact with human lymphatic endothelial 
cells (HLEC). To test this hypothesis, the interaction of fluorescently labeled B. malayi ELVs with 
HLECs was visualized using confocal microscopy. Due to limited availability of sample only the 
internalization of L3, AF and AM ELVs were tested. ELVs released by all three life stages were 
internalized by HLECs (Fig. 4A-D). This internalization profile by HLECs of ELVs is expected 
given that all parasitic life stages are likely to encounter these cells in the natural host. In fact, a 
body of evidence suggests this interaction is not simply passive and that marked lymphatic 
rearrangement occurs during Brugia infection [27, 28]. Bennuru and Nutman (2009) reported that 
lymphangiogenesis can be observed in response to B. malayi antigens in an antigen specific 
manner [27]. Babu et al. (2012) further demonstrate a Toll-like receptor mediated increase of 
vascular endothelial growth factor [28]. Our observation that ELVs from these life stages are being 
internalized by HLECs might provide a mechanistic basis for the lymphatic rearrangement 
observed during LF. Further development of functional assays will help inform whether Brugia 
ELVs play a role in lymphangiogenesis and of other functions of these ELVs in the context of 
HLECs. 
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Figure 4: L3 and adult B. malayi ELVs are internalized by human lymphatic endothelial 
cells (HLEC). HLECs were exposed to L3, adult female and adult male ELVs and visualize 
via confocal microscopy. Cells were stained with Phalloidin 647 (purple) to visualize the 
actin skeleton and counter-stained with Hoescht 33342 (blue) to visualize nuclei, ELVs 
were stained with PKH67 (green) before adding to the cells. Overlays of these channels 
demonstrate internalization of ELVs from these life stages by the macrophages. 
 
In conclusion, we demonstrate that B. malayi ELVs are internalized by macrophages and 
HLECs which are all cells these parasites encounter en route to the lymphatic vasculature. Further, 
we show that there is a clear difference between host macrophage responses to larval and adult 
ELV. We also demonstrate that infective stage ELVs are pro-inflammatory in nature and have 
immunomodulatory capacities. These data imply parasite-derived ELVs are potential bioactive 
agents with a specific purpose tailored to benefit the life stage from which they are released and 
its survival within the host. Description of this mode of communication between the parasitic 
nematode B. malayi and the human host also open interesting avenues for drug targeting and 
filariasis control. 
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Materials and Methods 
ELV uptake assay 
5 x 105 J774A.1, RAW264.7 and human lymphatic endothelial (HLEC) cells were grown 
for 24 hrs on coverslips commercially coated with Poly D-lysine (Fisherbrand). ELV preparations 
were stained with the green lipophilic dye, PKH67 (Sigma-Aldrich) according to manufacturer’s 
instructions. In short, the ELV pellet was homogenized in 125µl of diluent C. Next 0.5µl of the 
dye was added to 125µl of diluent C and pipetted several times to mix well. This mixture was then 
added to the ELVs homogenized in diluent C and incubated for 5 minutes. The reaction was 
inactivated by adding 250 µl of heat inactivated FBS for 1 minute. 0.5-1ml 1X PBS was added 
and ultracentrifuged for 1 hour at 55,000 rpm to pellet the ELVs. 1 x 107 of stained ELVs of each 
life stage were added to cells grown on coverslips and incubated at 37°C for an additional 24 hrs. 
The internalization pathway of these ELVs was explored using endocytic inhibitors to selectively 
block each pathway. Cells were incubated in the presence of 200 µM Dynasore (Sigma-Aldrich), 
30 µM Chlorpromazine (Sigma-Aldrich) or 300 µM Genistein (Sigma-Aldrich) 1-2 hours prior to 
the addition of PKH labelled ELVs along with 0.1µm Fluoresbrite Carboxy NYO microspheres 
(PolySciences Inc., Warrington, PA) transferrin from human serum (Molecular probes), Alexa 
Fluor 555 conjugate (Life Technologies) and Cholera toxin subunit B, Alexa Fluor 555 conjugate 
CtxB (Life Technologies) with respective treatments to control for inhibition. Cells were analyzed 
via flow cytometry and confocal microscopy 24 hours post-treatment.  
Cells were prepared for flow cytometry as follows. Cells were washed with FACS buffer 
(0.1% BSA, 0.1% NaN3 in PBS) heated to 37°C, scraped and resuspended in 1% PFA. Samples 
were analyzed by the BD Biosciences FACSCanto machine. 
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Cells were prepared for Immunocytochemisry 24 hours post-treatment as previously 
described. Briefly, media were removed and cells were washed with 1X dPBS heated to 37°C, 
followed by a 30 minute incubation at room temperature in 4% PFA heated to 37°C. All washes 
and incubations from this point onwards were done at room temperature on a rocker. Cells were 
washed for 10 minutes with 1X dPBS, followed by two more 10 minute washes. Cells were then 
incubated in 1:200 Phalloidin 647 (Life Technologies,) for 30 minutes followed by three 10 minute 
washes with 1X dPBS. 1:500 Hoechst 33342 was added to the cells and incubated for 10 minutes 
and washed twice in 1X dPBS. Coverslips were mounted on slides using Flouromount aqueous 
mounting media (Sigma-Aldrich) and visualized by a Leica SP5 X MP confocal/multiphoton 
microscope system.  
 
Macrophage activation assays: 
Changes in nitrite production, iNOS transcripttion and IL-6 cytokine release were measured 
to determine the activation profile of J774A.1 and RAW264.7 macrophages in response to ELVs. 
5 x 105 cells were grown overnight and were subjected to different treatments for an additional 24 
hours; Cells were treated with 100 ng/ml LPS (EMD Millipore, Billerica, MA) and 10 ng/ml IL-4 
(PeproTech, Rocky Hill, NJ) as positive controls for classical and alternative activation 
respectively as well as 1 x 107 ELV preparations from different life stages with or without 
endocytic inhibitors 200 µM Dynaore and 200 µM EIPA (Tocris Bioscience, Bristol, UK). Nitrite 
levels were measured using Griess reagent (Sigma-Aldrich) as follows. Standards were prepared 
by adding Nitrite (2 µl of 0.1M sodium nitrite to 1ml of media) in 5 µl increments to media with 
each standard totaling 100 µls. 100 µl of Griess reagent was added to 100 µls of standards and 
samples (cell culture supernatants) and incubated on a shaker for 10 minutes for the color to 
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develop. Air bubbles were removed and the plate was read on a SoftMaxPro plate reader at 540 
nm wavelength. Urea assays (BioAssay Systems, Hayward, CA) were also performed according 
to manufacturer’s instructions on media collected. RNA lysates for iNOS and Arginase I qPCR 
were prepared and converted to cDNA using the Cells-to-cT kit (Thermo Fisher Scientific). The 
qPCR was performed in a GeneAmp 5700 machine for 95°C for 10 mins followed by 40 cycles of 
30 seconds at 95°C and 45 seconds at 60°C using 5’ GCCACCAACAATGGCAACA 3’ forward 
and 5’ CGTACCGGATGAGCTGTGAATT 3’ reverse primers to amplify the iNOS mRNA 
transcript. β-actin served as an internal control (Forward primer: 5’ 
GGCTGTATTCCCCTCCATCG 3’ and reverse primer 5’ CCAGTTGGTAACAATGCCATGT 
3’). Changes in the levels of IL-6 were measured using the Mouse IL-6 ELISA Ready-SET-Go! 
Kit (Affymetrix, Santa Clara, CA). 
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CHAPTER IV. FILARIAL NEMATODE ELVS: EFFECT OF ANTHELMINTICS ON 
VESICLE RELEASE AND THEIR USE AS BIOMARKERS 
 
The data presented in this chapter is contributing to two manuscripts in preparation. The data 
describing the effect of calcium channel inhibitors on ELV release will form part of a currently 
untitled manuscript in collaboration with John Siekierka’s group at Montclair State University, NJ, 
validating a family of calcium channel blockers as novel antifilarial drugs. The data evaluating the 
use of secreted miRNAs as biomarkers of filarial disease will be published part of a broader study 
examining small RNA release from B. malayi. A running title for this manuscript is: "Comparison 
of secreted and endogenously expressed microRNAs (miRNAs) in the filarial nematode 
parasite, Brugia malayi." Zamanian M., Harischandra H., Day T.A. and Kimber M.J. 
 
Introduction 
Lymphatic filariasis (LF) is a widespread Neglected Tropical Disease that is caused by the 
mosquito-borne parasitic filarial nematode worms Wuchereria bancrofti, Brugia malayi and 
Brugia timori. It is a major public health problem with nearly 947 million individuals at risk of 
infection in 54  tropical and subtropical countries worldwide [1] resulting over US $100.5 billion 
economic burden for treatment, cost of healthcare and potential income loss [2]. The key 
component of LF control and elimination programs is mass drug administration (MDA) to reduce 
the infection levels in at-risk populations and interrupt disease transmission. The preventative 
chemotherapy drugs currently used in these MDA programs are either albendazole and 
diethylcarbamazine (DEC) or albendazole and ivermectin (in areas co-endemic with 
onchocerciasis). Although these drugs are generally regarded as safe and have been widely used 
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as anthelmintics to target filarial nematode parasites, their physiological modes of action are still 
not well understood [3]. Illustrating this, Ivermectin is a highly effective microfilaricide in that its 
effect can be seen as early as one day post treatment, leading to complete clearance of Bancroftian 
microfilariae and about 90% of Brugian microfilariae by one week after treatment [4]. Ivermectin 
exerts its effects by acting as a glutamate gated chloride channel (GluCl-) potentiator [5, 6] but 
how this results in rapid microfilaricide activity is not well understood. Studies have shown that 
high doses of ivermectin paralyze nematode muscle but therapeutic concentrations have no 
apparent effect [6, 7]. This has led to the hypothesis that a host component is responsible for the 
rapid clearance observed in vivo [8, 9]. Hinting at another mechanism of action, Moreno et al. 
(2010) showed ivermectin inhibits protein release from the excretory-secretory pore of B. malayi 
[10]. This is interesting because analysis of the Brugia secretome identified proteins that could 
potentially have a host immunomodulatory role [11-13] and the Moreno et al. (2010) study adds 
support to the hypothesis that the anthelmintic effects of ivermectin are partly due to synergistic 
effects between the host and parasite. A thorough understanding of how ivermectin and other 
antifilarial drugs exert their effects is not only important in optimizing their use but also to inform 
the constant search for more efficacious compounds that can be used to combat this socially 
stigmatizing disease.  
In addition to chemotherapy, surveillance and diagnostics form a critical component of LF 
control programs to both evaluate the effectiveness of MDA and to provide an informed basis for 
continued implementation. Current methods for monitoring and evaluation of LF infection have 
largely relied on the detection of microfilariae (mf) stage parasites in a blood smear [14], however, 
such diagnostic methods are sub-optimal and carry inherent problems that may contribute to 
continued disease prevalence. Given that mf nocturnal periodicity, blood for these tests must be 
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collected at night and is therefore inconvenient and presents reliability issues. Although detection 
of antigenemia and W. bancrofti antibodies in human populations have been developed as sensitive 
and accurate approaches to identify adult and mf infection [15], they are ineffective at recognizing 
larval stage parasites during patent infection. This is a significant obstacle because these stages are 
vulnerable to chemotherapeutics whereas adults are not, such that early diagnosis would allow a 
curative therapeutic intervention rather than one that simply manages the infection. Hence, to 
bridge this gap, there is an urgent need to develop affordable, reliable and quantitative diagnostic 
tests for the early detection of LF.  
Exosomes are nano-sized vesicles (50-150 nm) of endosomal origin that are released into 
the extracellular space by many cell types [16, 17] and are widely distributed in various body fluids 
[18-22]. Exosomes have been shown to contain a diverse range of bioactive molecules including 
proteins, mRNA and miRNA [23-26]. Importantly, these exosomally packaged miRNAs are 
emerging as novel regulators of cellular function and interest has emerged over the years in 
exosome research because of the potential role for these extracellular vesicles in disease 
pathogenesis and biomarker discovery [19, 27-29]. Although proteins secreted by Brugia with 
potential immunomodulatory properties have been reported [11-13], the mechanism by which 
these proteins may be delivered to target cells and exert their effect has not been elucidated. Given 
the role of exosomes in cell to cell communication in various biological contexts [30-33], we 
hypothesize that exosome-like vesicles are a mechanism by which Brugia can package and release 
parasite-specific effector molecules (both protein and miRNA) to modulate the human host and 
successfully establish and maintain infection. Extending this hypothesis, if vesicle release is a 
critical mechanism for parasite pathogenicity and disrupting the process may have therapeutic or 
prophylactic benefit. Additionally, blood-based assays for circulating vesicle-bound extracellular 
87 
 
RNAs could prove particularly fruitful as biomarkers in diagnosing LF. A recent study has 
identified stage specific, differentially expressed miRNAs in B. malayi [34] and we have 
previously shown that B. malayi exosome-like vesicles released into the host contain a diverse 
small RNA (microRNA, miRNA) cargo [23] which suggest a potential role in host manipulation 
through ELVs. 
In this current study, we apply our central hypothesis that Brugia release exosome-like 
vesicles containing protein and small RNA effectors that modulate host biology. We demonstrate 
that Brugia vesicle release is inhibited by current anthelmintics used to treat LF, confirming this 
is a druggable biology and suggesting a novel mechanism of anthelmintic activity. Further, we 
explore the use of specific miRNA molecules secreted into host biofluids as novel, stage-specific 
biomarkers of filarial nematode infection.  
 
Results and Discussion 
Current anthelmintics inhibit ELV release. 
Ivermectin (IVM), diethylcarbamazine (DEC) and albendazole (ALB) are the 
chemotherapeutic drugs currently used in mass drug administration (MDA) programs to treat 
Lymphatic filariasis (LF). Linking the parasite and host derived mechanisms, Moreno et al. (2010), 
showed that ivermectin sensitive glutamate-gated chloride channels were expressed around the ES 
pore of Brugia mf and that ivermectin treatment reduced protein secretion by this stage. It has been 
speculated that this reduced protein secretion may facilitate host mechanisms to clear the parasites. 
Our previous work led to the identification of the ES pore as a site of ELV release in microfilariae 
(Chapter 1). In light if this and our previous findings that Brugia malayi ELVs have 
immunomodulatory properties [23], we hypothesized that ivermectin may function in part by 
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inhibiting ELV release of these parasites, thus making them vulnerable to host defense 
mechanisms. To test this hypothesis, we incubated Brugia malayi mf, L3, AF and AM parasites 
with ivermectin, as well as the other anthelmintics DEC and albendazole and quantified ELV 
release. Interestingly, ELV release across the Brugia life cycle was potently inhibited by IVM 
(Figure 1) and might reveal a new mode of action for IVM induced parasite clearance. We 
hpothesize that Brugia parasites modulate the host via molecules secreted in ELVs such that the 
host is unable to mount an immune reaction effective enough to clear the parasites. The fact that 
IVM inhibits ELV release supports this hypothesis in that by inhibiting ELV release, IVM prevents 
the parasite from modulating the host immune system, making the parasite vulnerable to host 
defense mechanisms. Interestingly, DEC and ALB also inhibited ELVS release although host 
mediated parasite clearance has not been associated with these drugs, especially abendazole. The 
conclusions that can be derived from this observation are two-fold: 1) that there may be a host 
driven component that has not been discovered driven by inhibition of vesicle release or 2) the 
inhibition of vesicle release is a non-specific consequence of drugs that disrupt neuromuscular 
function, which is still an interesting observation because it demonstrates that vesicle release is a 
regulated process, controlled by the worm. An interesting observation was that all drugs effectively 
blocked adult ELV release eventhough none are effective adulticides. The reason for this could be 
that it is too challenging to expel the adult worm from the host due to the sheer mass of it. Niche 
could also factor into this. For example, the adults are in the lymphatics whereas larval stages are 
circulating and relatively accessible. 
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Figure 1. Current anthelmintics inhibit ELV release across the B. malayi life cycle. 
Worms were incubated with anthelmintics used to treat lymphatic filariasis (A) 
albendazole, (B) diethylcarbamazine and (C) ivermectin, media was collected and 
exosomes were purified. Quantification of exosomes via nanosight particle analysis 
showed inhiition of ELV release across the life cycle by all three drugs.  
 
Calcium channel blockers inhibit ELV release 
Drugs that alter Ca homeostasis in flatworms, for example praziquantel are currently being 
used as anthelmintics to treat Schistosomiasis suggesting that Ca homeostasis is a good, druggable 
target for helminths. Here we wanted to extend this principle to filarial nematodes and investigate 
the potential of targeting ca metabolism in parasite to inhibit vesicle release. A class of voltage-
dependent L-type calcium channel blockers has recently been identified as a source of potential 
novel antifilarial drug candidates in a diversity library compound screen (John Siekierka, personal 
communication). Family members rapidly paralyze adult female and mf stage parasites and also 
inhibit mf release from adult females. Given the potent neuromuscular effects on B. malayi and 
inhibition of mf release, we wanted to test the hypothesis that L-type calcium channel blockers 
also inhibit other similar release mechanisms such as ELV release by Brugia. To test this 
hypothesis, we incubated B. malayi mf and L3 parasites with the most potent L-type calcium 
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channel inhibitors identified in the above study, namely amlodipine, benedipine, isradipine, 
nisoldipine and lacidipine. We also incubated worms with DMSO control and ivermectin for 
reference. All compounds potently inhibit ELV release in mf (Figure 2A), with the most potent 
compounds being amlodipine, benedipine, isradipine and nisoldipine. All four compounds 
inhibited ELV release more than 95% which was significantly higher than the inhibition by 
ivermectin which was approximately 60% (Figure 2C). Interestingly, the ELV inhibition pattern 
of L3 was markedly different from that of mf. Lacidipine, which was the least potent inhibitor of 
mf ELV release (Figure 2A), was the most potent ELV inhibitor of L3 stage parasites over control 
(Figure 2B), followed by amplodipine, ivermectin and nisoldipine. There was no significant 
difference in the inhibition over ivermectin in any of the compounds (Figure 2D). These data 
provide indicate that L-type calcium channel blockers are potent inhibitors of ELV release in larval 
stage B. malayi parasites. Moreover, they demonstrate differences of patterns of pharmacological 
inhibition between the two larval stages that could underpin different physiological mechanisms 
of ELV release between different life stages. Although we demonstrated that ELV release in 
microfilarial stage parasites occurs via the excretory-secretory pore, we were unable to visualize a 
site of release for the other life stages and postulated one reason may be that other life stages do 
not release ELV via this structure. It is possible that the different pharmacological profiles revealed 
in this study reflect the different sensitivities to L-type calcium channel blockers in different 
parasite structures; ES pore in the case of mf, intestinal tract (for example) in the case of L3. 
Knowledge on the L3 and adult ELV protein content will allow us to perform a more targeted 
immunochemistry (IHC) approach to show localize ELV release in distinct parasite life stages. 
Stage- or sex-specific ELV proteomic analysis, as performed in Chapter 2 of this thesis, will 
position us to identify stage- or sex-specific markers of ELV release that may allow selective 
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visualization of ELV release sites through IHC. Alternative approaches that may also be valuable 
to this end include in situ hybridization or variants such as RNAscope technology. These 
techniques may permit the visualization of the small RNA cargo contained within filarial nematode 
ELVs [103].  
Our observation that ELV release is a ‘druggable’ process, and that we can assay for 
compounds that affect this process, is also significant. If inhibition of vesicle release proves to be 
a valuable paradigm upon which to base novel anthelmintic discovery, we have established that 
known anthelmintic drugs can elicit a potent phenotype, defined that phenotype, and established a 
baseline assay for lead compound screening. This initial assay will require refinement; it is 
impractical and decidedly low throughput to screen hundreds of individual parasite with a single 
drug/concentration, collect vesicles by ultracentrifugation and quantify by nanoparticle tracking 
analysis. A major improvement would be to incorporate more sensitive methods to detect and 
quantify vesicle release, and the automation of such methods. This would allow fewer parasites to 
be used per treatment and may enable transition towards a plate based assay. Exciting 
developments to this end are emerging from the interface of biology and engineering with 
microfluidics and lab-on-a-chip type devices showing promise for sensitive vesicle detection 
approaches [35].  
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Figure 2: L-type calcium channel blockers potently inhibit ELV release by mf and L3 
stage parasites. (A) Mf and (B) L3 parasites were incubated with chosen L-type calcium 
channel inhibitors. They were also incubated with ivermectin for reference. ELVs were 
purified from media and quantified via nanosight particle tracking analysis. Significance 
of ELV release inhibition against ivermectin was analyzed for both (C) mf and (D) L3 
stages. 
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Investigating the potential of secreted miRNA as biomarkers 
Among the different methods of LF diagnosis, confirming the presence of mf in finger-
prick blood is the current gold standard. However, due to nocturnal periodicity of mf, blood for 
this method needs to be drawn between 10 p.m. and 2 a.m. making the approach both inconvenient 
and unreliable. A more reliable test is the immunochromatographic card test or ELISA based assay 
on circulating filarial antigens. These tests are only available for W. bancrofti and not yet available 
for B. malayi [36]. An emerging body of studies investigate the potential of specific molecules to 
serve as biomarkers for different disease conditions such as various types of cancers and 
neurodegenerative diseases [29, 37-39]. In fact, serological markers CEA, CA 125 and CA 19.9 
are currently being used in follow up visits for patients with prostate cancer [40, 41]. An attractive 
aspect of using liquid biopsies i.e. molecules circulating biological fluid [42], is the non-
invasiveness in obtaining samples. In Chapter 2 of this thesis we demonstrated stage specific cargo 
contained within B. malayi ELVs. Identification of secreted miRNAs unique to each stage of B. 
malayi might enable the development of a non-invasive, accurate detection platforms, a parsite-
specific liquid biopsy if you will, which not only detects the infection but also it’s maturity. The 
goal of the present study was to explore this idea and develop novel diagnostic assays based on 
identification of parasite-derived extracellular small RNA packaged in exosome-like vesicles. Four 
parasite-derived miRNAs were identified as specific to the parasite and not found in the  circulating 
host miRNA pool using a robust bioinformatics pipeline established in our lab. Our hypothesis 
was that these parasite-derived miRNA will have differential expression between B. malayi 
infective and adult life stages, demonstrating proof-of principle that they may have biomarker 
potential.  
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We were able to reproducibly amplify all four miRNAs (lin4, unk2, mir100d and bantam) 
from worm culture media. (Figure 3). This suggests that all four miRNAs are being actively 
secreted by these worms and therefore, have the potential of being used as a biomarker to identify 
patent LF infections. Of these, there was a significant increase in the level of mir100d miRNA 
secreted by adult females when compared to that of L3 and adult male secretions (Figure 4C). The 
fact that the amount of secreted mir100d varies between life stages is interesting because it implies 
mir100d has the potential of serving as a candidate to predict the maturity of the infection. 
Although the other three candidates lin4, unk2 and bantam are all secreted by the parasite, there is 
no apparent difference in secretion levels between the life stages and therefore, have the potential 
of being used to identify LF infection but not the stage of infection. Identification of more targets 
that are differentially secreted by the larvae and adults will enable the development of a robust 
qPCR based infection identification platform that can be used reliably to predict infection.  
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Figure 3: miRNA targets are differentially expressed between tissue (solid) and secretory 
samples (clear). The expression of four miRNA targets (A) lin4, (B) unk2, (C) mir100d and (D) 
bantam were analyzed. miRNA targets unk2, lin4, bantam and mir100d secreted by B. malayi 
parasitic nematodes were detected in culture media of (A) L3, (B) AF and (C) AM life stages.  
 
Figure 4. miRNA targets unk2, lin4, bantam and mir100d secreted by B. malayi parasitic 
nematodes were detected in culture media of (A) L3, (B) AF and (C) AM life stages.  
 
 
Materials and Methods 
ELV release assay 
Brugia malayi microfilariae (mf) and infective L3 stage larvae were obtained from the 
NIAID/NIH Filariasis Research Reagent Resource Center (FR3) at the University of Georgia, 
Athens GA. Mf were filter purified using standard protocols. Briefly, they were centrifuged at 
2000 rpm for 10 minutes and resuspended in 5 mls of 1X dPBS (Life Technologies). The mf 
suspension was overlaid on 5 mls of Histopaque (Sigma Aldrich?) in a 15 ml tube and centrifuged 
at 2000 rpm for 15 minutes to separate worms from host contaminants. The worms were then 
washed twice in 10 mls of dPBS and centrifuged at 2000 rpm for 5 minutes. Red blood cells were 
lysed by adding 3 mls of water for 15 seconds. 12 mls of 1X dPBS was added and centrifuged for 
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5 minutes at 200 rpm. Purified worms were cultured in RPMI 1640 (Life Technologies) containing 
10 g/L glucose and pen-strep (penicillin 0.4 units/mL, streptomycin 0.4 mcg/mL) at room 
temperature. L3 worms were cultured in identical medium at 37°C in the presence of 5% CO2. 
For the ELV release assay, one million mfs, 100 L3s, 10 adult male and 10 adult female 
parasites per treatment were cultured in 1.3, 1.3, 3 and 10 mls of media containing the test 
compound at 1µM final concentration or DMSO (vehicle) control respectively. Culture media was 
collected after 24 hrs and ELVs purified via differential centrifugation as described previously 
[23]. Briefly, media was centrifuged at 12,000 x g for 45 min at 4°C and filtered through 0.22 μm 
filters to remove debris followed by ultracentrifugation at 55,000 rpm for 2 hrs at 4°C in 1.5 ml 
ultracentrifuge tubes to pellet secreted ELVs. Supernatant was aspirated leaving a residual media 
volume of 25 μL and the purified ELV preparations were re-suspended to 500 µl using cold 1X 
dPBS (Life Technologies). Nanoparticle Tracking Analysis (NanoSight LM10, Malvern 
Instruments, UK) was used to quantify the purified ELV preparations. 
 
Biomarker qPCR assay 
L3, adult female and adult male worms were cultured for 24 hours in RPMI 1640 (Life 
Technologies) containing 10 g/L glucose and pen-strep (penicillin 0.4 units/mL, streptomycin 0.4 
mcg/mL) at 37°C in the presence of 5% CO2. Microfilariae (mf) were culture in identical media at 
room temperature. RNA was extracted from culture media using the Norgen total urine kit as per 
manufacturer’s instructions. RNA was also extracted from IP fluid collected from infected and 
uninfected jirds (Meriones spp). RNA preparations were DNAse treated using the Turbo DNASe 
kit (Ambion) and converted to cDNA using the miRNA cDNA synthesis kit (Quanta Bioscineces). 
qPCR analysis was done to validate in silico findings of four parasite-derived sequences identified 
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by Dr. Mostafa Zamanian using a robust bioinformatics pipeline. The qPCR was performed in a 
GeneAmp 5700 machine at 95°C for 5 mins followed by 40 cycles of 30 seconds at 95°C and 45 
seconds at 60°C using the universal primer (Quanta Biosciences) and the following gene specific 
primers. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
Lymphatic filariasis (LF) is a debilitating, socially stigmatizing neglected tropical disease 
which puts 947 million people at risk worldwide [1]. It is caused by filarial nematodes Wuchereria 
bancrofti, Brugia malayi and Brugia timori of which the infective larval stage is transferred to 
humans via a mosquito bite. The L3 larval stage migrates to the lymphatics where it molts twice 
and matures into adults. These adults mate and the female nematode produces millions of 
microfilariae. There are no vaccines for this disease. Chemotherapy through mass drug 
administration (MDA) programs 
and prevention measures are the 
only solution. However, even 
after 15 years of MDA, 
Lymphatic filariasis still remains 
a global health concern. 
Successful parasitism depends on 
specific interactions between the 
host and the parasite and our 
efforts of delineating these 
interactions resulted in the 
identification of a novel 
mechanism by which these 
parasites may manipulate the host 
to its benefit (Figure 1).  
 
 
 
Figure 1. A proposed model by which exosome-like vesicles (ELVs) 
secreted by the filarial nematode, Brugia malayi, are released into the 
host environment and interact with host cells to facilitate infection. 
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The immune profile of a Lymphatic filariasis infection is mainly immunosuppressive. 
Although secretome studies have identified proteins with immunomodulatory capacity [2-4], 
neither how these proteins enter the respective cells nor how immunosuppression is achieved has 
been known to date. Exosomes are extracellular vesicles containing effector molecules. Previously 
thought to be a mechanism of waste disposal, with the discovery that these vesicles harbor 
bioactive molecules exosomes have gained renewed interest during the past few years. Previously 
we found that infective L3 stage B. malayi release exosome-like vesicles (ELVs) that contain 
putative host effector molecules including microRNAs (miRNAs) with the potential to manipulate 
host gene expression [5]. Further, these ELVs were internalized by host macrophages, early 
mediators of the host immune response for filarial infection [6-8]. Our overarching hypothesis is 
that filarial nematodes, including B. malayi, use ELVs to release effector molecules that facilitate 
the establishment or maintenance of parasitemia, specifically by actively directing the host 
response to infection. In Chapter 3 of this thesis we describe data that support this hypothesis. 
We have demonstrated that vesicles bearing characteristics of exosomes are secreted by all 
life stages of the parasitic filarial nematode B. malayi. No other study thus far has demonstrated 
this phenomenon throughout the life cycle; all studies on parasitic helminth ELV release have 
focused a single life stage, mostly adults [9-15] and one on the fourth larval stage [16]. Pan life 
cycle secretion suggests that ELV release is a conserved process. The proteomic profile of adult 
and infective L3 larval stage ELVs contained canonical exosomal markers and proteins of 
endocytic pathway origin, providing evidence that the observed vesicles are exosomes and not 
another form of extracellular vesicles. Previous studies on parasitic nematode ELVs have 
discussed the possibility of the release of heterologous vesicle population and therefore question 
whether the effects seen are due to exosomes or a different subset of extracellular vesicle; our 
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observations suggest a homologous exosome population as discussed in chapter 2 in this thesis 
and functional assays attribute the effects observed to ELVs.  
Previous studies on the Brugia secretome [2-4] have revealed proteins with 
immunomodulatory capacity such as galectins and yet how these proteins enter cells nor how they 
exert their effect is unknown. We hypothesized that Brugia employ ELVs as a mode of transferring 
these effector molecules to host cells, thereby aiding in host manipulation. Indeed, analysis of the 
proteomic content of the ELVs revealed immunomodulatory cargo supporting this hypothesis; 
Adult female ELVs were abundant in proteins with immunomodulatory capacity such as 
macrophage migration inhibitory factor, galectins, annexin, DAF-21. The proteomic profiles of 
the different B. malayi life stages compare well with the existing profiles of ELVs from other 
helminths [11-13, 16, 17]. They all contain structural proteins such as actin, tubulin, nuclear 
proteins such as histones, peroxiredoxins such as thioredoxin peroxidase, and exosomal proteins 
such as HSP70. Interestingly, thioredoxin peroxidase which has been shown to be contained in 
these ELVs and annexin which was shown in D. dendriticum, S. Japonicum and S. mansoni [12, 
13, 17] ELVs are the only immunomodulatory proteins identified in other ELV proteomic studies, 
while our current study on adult ELVs identified many other immunomodulatory proteins 
contained within them. Also of interest was the stage and gender specificity of the cargo within 
these ELVs; the proteomic profiles of L3 and adult male ELVs were mainly of structural proteins, 
unlike the female profile. Not only does this demonstrate stage specific secretion, hence possibly 
stage specific host modulation but also possibly sexual dimorphism. Our studies uncovered new 
information that adds to the wealth of knowledge in the field of nematode biology and parasitology. 
Here, we have identified a mechanism by which effector molecules are released from the parasite 
and delivered to the host. The fact that the release of these effector molecules is via a regulated 
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defined process provides further support of specific functions and targeted delivery. It has also 
uncovered a host of novel molecules that can be targeted in drug discovery efforts. Moreover, this 
is the 1st report of ELV secretion of a medically relevant human parasite and the second of a 
parasitic nematode. A recent report on the secretion of exosomes harboring effector molecules by 
the intestinal parasitic nematode Heligsomoides polygyrus [9] suggest exosome release is a process 
shared among nematodes and warrants further investigation with other nematode species. 
We also demonstrated that B. malayi ELVs are internalized by host macrophages and 
lymphatic endothelial cells. Previous studies have shown that exposure to B. malayi parasites can 
induce specific immune responses. A Th2 response with elevated levels of anti-inflammatory 
cytokines like IL-4, IL-5, IL-10 and IL-13 is prototypical of a Lymphatic filariasis infection [18]. 
Studies have shown that L3 larval stage parasites [19] and adult worms induce IL-4 production 
[20]. Moreover, mfs initially induce a more Th1-like response later followed by increased IL-4 
and IL-5 production [20, 21]. In addition to changes in the immune system, studies have also 
shown that these parasites induce endothelial rearrangement [22]. Although it is apparent that these 
parasites influence multiple host processes how this is achieved has not been elucidated to date. 
Interaction of parasitic ELVs with host cells suggest a mechanism for effector delivery to these 
tissues and explains how parasites might be mediating their host. Exosome-like vesicles (ELVs) 
released by the infective larval stage (L3) B. malayi trigger the classical activation pathway in 
murine macrophages upon internalization. However, no other stage elicits such a response. This 
stage specific activation of host cells in response to internalization suggests that ELVs are released 
by the parasite to cater to each stage and suggests its importance in establishing and maintaining 
infection. A recent study on Heligmosomoides polygyrus corroborates our findings [23] and 
suggest exosome mediated host manipulation might be a mechanism employed by parasitic 
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nematodes. This is an interesting paradigm and studies on other parasitic nematode species are 
essential to investigate the universality of this process. This would help explore the possibility of 
developing disease control methods targeting multiple nematode diseases, which would be useful 
for areas co-endemic with many. 
Further, In Chapter 4, we demonstrated that ELV secretion by B. malayi parasites can be 
significantly decreased by anthelmintics.  Previous efforts to delineate the mechanisms of action 
of anthelmintics have suggested a host component to the effective larval clearance observed in 
vivo [24-27] although neither what it is nor how it achieves this clearance has been explained to 
date. Our finding that anthelmintics decrease Brugia ELV secretion might provide a mechanistic 
basis for how this is achieved, partially if not completely, adding another piece to the puzzle of 
how these parasites manipulate host mechanisms. Our hypothesis is that the parasite releases ELVs 
packaged with effector molecules that can manipulate and combat defense mechanism mounted 
by the host in response to the parasites, enabling them to establish and maintain infection. The 
immunomodulatory proteins contained within these ELVs, as revealed by the proteomic analysis, 
provides support in favor of this hypothesis. Furthermore, we identified calcium channel blockers 
that inhibit ELV secretion more potently than ivermectin. If ELVs are a method of host 
manipulation, then the discovery of compounds targeting this process more potently than available 
anthelmintics is very exciting. It also suggests that ELV release could represent a novel screening 
platform for the next generation of anthelmintics.  
Early detection of the disease is important to help keep it at bay. Here we demonstrated 
that secreted miRNA can be isolated from host mileu and detected via a qPCR platform. This 
discovery is important because it demonstrates proof-of-principle of using secreted miRNA as 
biomarkers to detect infection. ELV antigens are protected against degradation over freely 
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circulating macromolecules due to being enclosed within a vesicle and can therefore circulate 
throughout the body unharmed to reach distal organs. This characteristic enables the use of ELVs 
as liquid biopsies for identification of the disease. Different cargo within ELVs allow us to exploit 
this further to establish stage-specific biomarkers to identify disease progression, providing 
medical practitioners the option to optimize treatment on a case by case basis. Accurate 
identification is important to ensure it’s targeted and treated so that infected individuals cannot 
serve as reservoirs for parasites, prolonging transmission. Targets that can accurately identify the 
presence of L3s in patients would be of paramount importance since most LF infections are 
asymptomatic and this allows for detection prior to a patent infection being established. 
Furthermore, adult parasites could be residing in patients even though microfilaria cannot be 
detected in blood samples. This scenario cannot be detected by the traditional finger-prick method 
since it probes for microfilariae but can be identified by miRNA biomarkers specific to the adult 
stage. In a hypothetical world, treating these patients will help minimize the damage inflicted by 
the parasites. Having said that, the 3 antifilarial drugs currently being used are only larvicidal and 
therefore, will have no effect against the adult parasites. For this reason, there is no use in treating 
non-patent infections at the present but once an adulticide is discovered, it will be important that 
these infections are also treated. For the time being, it is important however, that these patients are 
routinely checked for repeated infections so that they can be treated early if microfilariae re-
surface. 
Since MDA is carried out to populations at risk, diagnosis of LF is mainly to evaluate the 
effectiveness of the MDA treatments. Blood can be drawn at random from populations to check 
for the presence of miRNA biomarkers that indicate not only the presence or absence of infection 
but also potentially the stage of it. There are many advantages to this method. It is a more 
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convenient method than the conventional finger-prick method because blood drawings are not 
constrained to evenings. In the conventional method, absence of microfilariae in the blood sample 
can leave a degree of uncertainty; microfilariae have nighttime periodicity and it could be that they 
had not yet surfaced at the time blood was drawn. The biomarker method is more reliable and 
accurate because nighttime periodicity has no effect on circulating miRNA. It is also less time 
consuming and therefore, can serve as a high throughput screening method; even up to 384 samples 
can be run on a single plate. Moreover, no special skills are needed to conduct this screening 
process. Another advantage is that it can be developed further to identify markers of various 
diseases at the same time using a single sample. This is a cost-effective and more efficient method 
when diagnosis of multiple diseases is concerned. A major disadvantage is that this screening 
method requires the access to a qPCR machine and one will most probably not be available at 
every diagnostic center in these areas. Another disadvantage might be that it is difficult to parse 
out the parasitic miRNA or the biomarker from host material at low levels and therefore, could 
lead to inaccurate conclusions. A recent study questioned the applicability of parasitic miRNA as 
biomarkers due to the difficulty of parsing out parasitic miRNA from host biofluid [28]. Similar 
studies in Brugia infected hosts will help inform the transferability of these conclusions to the 
Brugia model. 
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Future experiments 
It is important to analyze the proteomic profile of the microfilariae and the fourth larval 
stage parasite ELVs as well in order to identify cargo specific to those stages and fully understand 
the role of ELVs in pathogenesis. Our previous study showed that the infective L3 larval stage 
parasite ELVs contained miRNA with potential immunomodulatory capacity [5]. These may be 
critical regulators of host gene expression in this model and therefore it is also important to identify 
the small RNA cargo of all other stages. This information will be important in furthering the 
understanding of the role of these vesicles and the identification of stage specific cargo that can be 
exploited in disease control and drug discovery efforts as discussed below. 
The fact that these ELVs are internalized by J774A.1 and RAW 264.7 murine macrophages 
and Human Lymphatic Endothelial Cells (HLEC), which all life stages of B. malayi interact with 
within the human host strengthens the hypothesis that the ELVs are secreted by the parasite for 
host immunomodulation. Demonstration that ELVs elicit stage specific differential activation 
profiles in the murine macrophage model further suppots this hypothesis. Although the usage of 
murine models is accepted for the study of early LF infection by larval stage B. malayi, it is not 
the best model for studying adults due to their inability to survive to adulthood in these animals. 
Therefore, an important next step will be to investigate the response to ELVs in a more translatable 
model such as human macrophage cell lines such as THP-1 and U937, or macrophages from 
athymic nude mice (C3H/HeN) in which a related species, Brugia pahangi has been reported to 
survive to adulthood [29]. Moreover, although studying the interaction between parasite ELVs and 
explicit macrophage lines is necessary to define the specificity and outcome of this particular host-
parasite interaction, taken in isolation, these phenotypes may not reveal the global effect of ELV 
secretion on the host immune response. Therefore it is also important to examine the global 
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response to ELV secretion using a whole animal murine model for a comprehensive understanding 
of this interface. C57/BL6 mice can be footpad injected with ELVs purified from different life 
stages of B. malayi. Draining lymph nodes can be collected and changes in the global cytokine 
profile can be explored using MCYTOMAG-70K, MILLIPLEX MAP Mouse 
Cytokine/Chemokine Magnetic Bead Panel Immunology Multiplex Assay on the Luminex 
platform. This high throughput assay will allow the simultaneous identification and quantification 
of chemokines/cytokines, allowing us to explicitly describe the global response to parasite ELVs. 
Since we looked at only classical activation profiles in cells, a more inclusive cytokine array should 
be used in this experiment that will also check for cytokines associated with the alternative 
activation pathway. The control mice will be injected with PBS. Lymphotoxin α or retinoic acid-
related orphan receptor (Ror)-γt knock-out mice can be used as an additional control. These mice 
will also be injected with ELVs but since they lack or have reduced lymph nodes, the cytokine 
profile in these mice should be more closely related to control mice than the ELV injected mice, 
hence attributing any changes in the cytokine profile to ELVs. Further, immunohistochemistry can 
be performed on cross sections of lymph nodes. The staining patterns of different cytokines can 
provide additional information about the immune response generated. Moreover, dendritic cells, 
T cells, B cells, monocytes granulocytes can be isolated from the lymph nodes and assessed for 
morphological changes, which could further inform which cells are involved in generating the 
immune response observed. One of the biggest advantages of looking at the effect of ELVs in the 
whole mouse model is that it provides direct evidence of immunomodulation by ELVs as opposed 
to a cell based method. A disadvantage of this method is that it is terminal.  
Another option would be to inject ELVs and collect blood from the ocular vein or 
submandibular and look for cytokines in the serum. An advantage of this method is that a time 
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course study can be done using the same mice, which has many advantages; it provides more 
information such as when a robust immune response is generated, how long it lasts. It is also cost-
effective and reduces the mouse to mouse variation if the same set are used. I believe this method 
would indeed identify immunomodulation as long as it is optimized for the amount of ELV injected 
and when the reaction is monitored. Whether the amount of ELVs that need to be injected to 
observe a change in the cytokine profile is physiologically relevant is a different question that 
needs to be addressed. 
While ELVs might be employed by B. malayi to manipulate the host immune system, their 
immunomodulatory characteristics suggest these very ELVs may be exploited therapeutically to 
provide protection against filarial nematode infection. Controlling filarial infection relies 
exclusively on chemotherapy. Issues with drug efficacy, regimen, safety and resistance make a 
broadly protective approach to disease control highly appealing. This is a novel concept and has 
not been demonstrated in a medically relevant human filarial parasite to date. Historically, efforts 
to develop vaccines against Brugia have used both attenuated parasite and sub-unit approaches. 
Irradiated L3 infective stage larvae [30], ALT-1 and ALT-2 major gene product of the L3 stage 
[31] and recombinant Trehalose-6-Phosphate Phosphatase [32] antigens have all yielded varying 
degrees of protection against the L3 stage, with the Bm-TPP experiments also leading to reduced 
microfilarial load [32]. A study on the protective effects of excretory-secretory products of the L3 
larval stage of B. pahangi, a related species to B. malayi, observed similar results with no effect 
against the adult parasites [33]. Whilst these efforts have successfully elicited protective effects 
against the infective stage, their poor efficacy against adult parasites mean that although 
transmission can be reduced, it cannot be halted. Moreover, suboptimal vaccines pose a threat. 
Previous studies with L. sigmodontis, a filarial parasite closely related to B. malayi, reported that 
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phenotypic plasticity can occur in response to host immune responses and that they can adjust their 
development based on environmental cues as soon as they enter the host [34]. Therefore, it is 
important to target a mechanism that is universal across the life cycle so that parasites that escape 
the initial defense will still be targeted. The Th-1/ Th-2 response in endemic normal individuals 
makes the discovery of the proinflammatory nature of ELVs that much more interesting. The 
antigenic nature of Brugia ELVs suggest the potential of mounting a rapid response in the face of 
repeated infection and therefore, validate them as potential novel vaccine candidates. Specialized 
adhesion and recognition molecules on ELVs may associate with antigen-presenting cells more 
efficiently and will be more effective in cross-priming since ELVs are a known mechanism for 
transporting antigens between cells [35, 36]. ELV antigens are protected against degradation over 
freely circulating macromolecules due to being enclosed within a vesicle and can therefore 
circulate throughout the body unharmed to reach distal organs. This further opens up the possibility 
of pre-exposure to potential antigens identified in the future encapsulated within these ELVs to 
ensure minimal degradation and optimal delivery to cells. Moreover, ELVs are secreted by diverse 
parasitic nematodes [5, 9] and therefore, vaccines developed with this approach have the potential 
of being used for trans-species control. We believe parasite ELVs are attractive novel protective 
antigens and warrant further studies to investigate the possibility of exploiting these structures for 
therapeutic benefit.  
A recent study conducted using exosomes secreted by an intestinal parasitic nematode 
Heligmosomoides polygyrus, showed that mice injected with exosomes secreted by these parasites 
demonstrated protective effects against larval challenge [23]. An earlier study with Leishmania 
spp. (a single celled parasite that is also known to secrete ELVs) has also similar protective effects 
upon reinfection when pre-exposured to Leismania ELVs has a protective effect upon reinfection 
111 
 
[37]. B. malayi L3 larvae or adults can be surgically implanted into the peritoneal cavity of 
vaccinated or control animals as previously described [38]. Jirds (Meriones spp) can be used in 
these studies because of the permissiveness of them to Brugia infection and the ability of these 
parasites to develop into adulthood within this host as have been shown by studies where L3 larvae 
inoculated into the peritoneal cavity of jirds developed within this location [39, 40]. Short-term (2 
weeks post immunization) and long term (5 months post immunization) effects can be observed to 
confirm that any initial clearance observed with the short –term study is clearance due to 
immunological memory and not just due to the persistent inflammation from the vaccine. The 
viability of the inoculated and implanted parasites and other measures of parasitemia in the ELV-
challenged jirds can be compared to control animals at several time points; 2 weeks, 4 weeks and 
4 months post immunization. The expected result would be reduced parasitemia and worm burden 
in the animals pre-exposed to ELVs. The importance of this study lies in the demonstration of 
proof-of-concept that vaccines may be generated using B. malayi ELVs to prime the immune 
system, which can then be administered to human or animal populations at high risk for filarial 
nematode disease. Priming the immune system in this way will result in reduced susceptibility to 
the parasite, helping disrupt transmission of the disease. 
In conclusion, we identified a novel mechanism by which B. malayi, one of the etiological 
agents of Lymphatic filariasis might be manipulating the host to its benefit via exosome-like 
vesicles (Figure 1). We have also demonstrated differential cargo and host activation patterns of 
these vesicles, lending support for stage and gender specific roles of these vesicles. Furthermore, 
we showed the antigenic nature of these vesicles. Our discoveries not only further the 
understanding of nematode biology and parasitology but also have demonstrated a novel 
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mechanism of host manipulation, suggest a mechanism of anthelmintic mode of action and 
uncovered a host of molecules that can be targeted in disease control and drug discovery efforts. 
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APPENDIX I – IDENTIFICATION AND CHARACTERIZATION OF NEMATODE G 
PROTEIN-COUPLED RECEPTORS  
  
Introduction 
Lymphatic filariasis (LF) is a debilitating and socially stigmatizing neglected tropical disease 
(NTD) caused by parasitic nematodes including Brugia malayi. In 2000, the world health 
organization launched a Global Programme to Eliminate Lymphatic Filariasis (GPEFL) by 2020 
through mass drug administration (MDA). Although the MDA program has celebrated some 
success [1], the chemotherapeutics being used are suboptimal. All three drugs used are only 
effective against larval stages and therefore can merely reduce prevalence and not completely 
disrupt transmission. Ivermectin and diethylcarbamazine (DEC) cannot be used in certain areas 
where LF is co-endemic with certain other NTDs due to severe adverse reactions if administered 
to those with loiasis and onchocerciasis respectively. Due to these reasons, there is an urgent need 
for novel anthelmintics for B. malayi.  
Acetylcholine (ACh) functions as a major neuro-transmitter in both vertebrates and 
invertebrates [2]. The two types of cholinergic receptor in nematodes are the ligand gated chloride 
channels, which are comprised of the nicotinic ACh receptors (nAChRs) and the acetylcholine 
gated chloride channels (ACC), and the slower acting muscarinic ACh receptors (mAChRs – in 
nematodes these are referred to as G protein-linked acetylcholine receptors, or GARs) [3]. A 
number of current anthelmintics such as pyrantel, morantel and levamisole target nAChRs [4], 
acting as selective agonists at the receptors to increase cation conductance, eliciting membrane 
depolarization and muscle contraction thereby facilitating parasite expulsion. The widespread use 
of such anthelmintics to control primarily gastrointestinal parasites in both human and veterinary 
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medicine has ensured that the pharmacology and physiological importance of nematode nAChRs 
are well characterized. However, there are significant knowledge gaps in our understanding of the 
pharmacology and physiological importance of the other types of nematode cholinergic receptor, 
in particular, the GARs. 
Despite our limited understanding of nematode GARs, there is evidence supporting the 
argument that parasitic nematode GARs are strong candidates as novel anti-nematodal drug 
targets. GARs are reported to be expressed in the body wall and pharyngeal muscle of the model 
free-living nematode Caenorhabditis elegans [5]  and may be involved in regulating or modulating 
locomotory and feeding behaviors in nematodes. These processes have historically been prioritized 
as targets in the development of novel anthelmintics. Further, C. elegans GARs also have a role in 
mating behavior and egg laying [6]. Whilst no known anthelmintics disrupt parasite reproductive 
biology as their primary mechanism of action, compounds targeting this process would have 
potential in controlling parasite infection through breaking the parasite life cycle – an overall 
strategy that has proven effective in LF control. Lastly, as members of the wider G protein-coupled 
receptor (GPCR) superfamily, GARs have specific advantages from a drug development 
perspective. GPCRs are highly druggable proteins and are targeted by a diverse array of 
therapeutics for many diseases [7]. A broad range of high throughput platforms and technologies 
allow screening and pharmacological analysis of these receptors, facilitating the quest for 
compounds that act against specific GPCRs. Lastly, although GARs appear pharmacologically 
distinct from vertebrate mAChRs, they do share responsiveness to acetylcholine – a fact that may 
allow the exploitation of established chemical libraries that include small molecules used to target 
cholinergic GPCRs. 
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The goal of this study was to identify and characterize parasitic nematode GARs using the 
filarial nematode B. malayi, and provide new information on their role in parasitic nematode 
physiology. B. malayi genomic data was queried using C. elegans GAR sequences as bait to 
identify fragments of GAR-encoding genes which were extended using RACE PCR to elucidate 
the full length sequence of a GAR-3 homolog, termed Bmgar-3. Bmgar-3 homologs were also 
identified in the genomes of other parasitic nematode species. The expression pattern of BmGAR-
3 and the Ascaris homolog were examined using a combination of RT-PCR and western blot to 
reveal specific temporal and spatial expression; GAR-3 homologs showed increased expression in 
male worms of both species. An auxotrophic yeast expression system was used to 
pharmacologically characterize BmGAR-3 but positive functional expression could not be 
consistently replicated despite exhaustive optimization efforts. Similarly, functional expression in 
HEK cells interfaced with a novel phosphorylation assay to reveal receptor activation yielded 
inconsistent results. Our data point to issues expressing nematode GPCRs in heterologous cell 
lines that must be addressed before parasitic nematode GPCRs can be exploited as novel 
anthelmintic drug targets. 
 
Results and discussion 
Identification of BmGAR-3, the Brugia malayi GAR-3 homolog 
Three G protein-coupled acetylcholine receptors (GARs) have been identified and 
characterized in the model worm, Caenorhabditis elegans [2, 8, 9]. Our hypothesis is that B. malayi 
possesses a similar GAR complement. To identify B. malayi GAR-encoding genes, we used a 
tBLASTn search of the Brugia draft genome using the three C. elegans GAR sequences as bait. 
We identified three fragments with homology to the C. elegans receptors [WGS reads BRBCS25TJ 
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(putative BmGAR-1) and BRKPQ43TF (putative BmGAR-3), and XM_001893774 (putative 
BmGAR-2)]. To extend these fragments into full-length sequence we used RACE (Rapid 
Amplification of cDNA Ends) PCR using primers designed from the genomic data. We extended 
the known Bmgar-1 and Bmgar-2 sequences but were not able to identify complete transcripts for 
these two genes. However, we were able to generate a full-length transcript for Bmgar-3 (Figure 
1A). This transcript included a 1803 nt open reading frame encoding a 601 aa protein. A reciprocal 
BLAST returned GAR-3 homologs as the most similar proteins, strongly indicating that this 
molecule is the B. malayi GAR-3 homolog. 
 
BmGAR-3 sequence analysis 
G protein coupled receptors (GPCR) have a characteristic seven transmembrane (TM) 
domain arrangement. Crossing the membrane seven times generates an amino terminus and 
extracellular region with three extracellular loops, an intracellular region with three intracellular 
loops and a carboxyl terminus [7, 10]. The greatest homology between GPCRs and GPCR families 
lies in the TM domains, while they differ the most at the amino and carboxyl termini and third 
intracellular loop [7]. Throughout the GPCR sequence there are key conserved motifs that are 
related to receptor functions, such as ligand binding and G-protein interaction sites. For example, 
the DRY motif at the end of the third intracellular loop is a highly conserved sequence [11] that 
functions in receptor conformation, ligand binding and G-protein interaction [12] . Our hypothesis 
is BmGAR-3 encodes a B. malayi acetylcholine responsive GPCR. To test this hypothesis we 
examined the encoded BmGAR-3 protein for features consistent with this designation. To describe 
transmembrane topology, the BmGAR-3 sequence was analyzed using TMHMM 2.0 (cbs.dtu.dk), 
an online tool for transmembrane helix prediction. This model takes into account hydrophobicity, 
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the charge of each residue (positively charged residues are more abundant in the intracellular or 
extracellular regions [13]), helix length and the GPCR “grammar” where the cytoplasmic and non-
cytoplasmic loops must alternate [14]. TMHMM 2.0 output identified seven TM domains in 
BmGAR-3 (Figure 1B). The predicted extracellular orientation of the N terminus (low N-in value 
= 0.048), intracellular orientation of the C terminus, and presence of these seven TM domains 
corresponds well with the standard structure of GPCRs and supports the hypothesis that BmGAR-
3 is a GPCR (Figure 1C). The sequence of Bmgar-3 was then aligned to C. elegans gar-3 using 
CLC DNA Workbench 6 software to assess the homology between the two receptors (Figure 1A). 
The highest conservation of sequence is found across the seven TM domains (underlined in black) 
with the lowest homology across the long third intracellular loop (underlined in orange) and the 
N- and C-termini. The highly conserved DRY motif was also observed (196-198 aa). Collectively, 
these sequence features strongly support the hypothesis that BmGAR-3 is indeed a GPCR. 
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Figure 1. Analysis of BmGAR3 sequence. (A) alignment of BmGAR3 with C. 
elegans GAR3. (B) Probability values of the sequence matching to GPCR structure. (C) 
Topolgy of BmGAR3 as predicted by TMHMM2.0 
B 
C 
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Muscarinic acetylcholine receptors (mAChRs) are the family of acetylcholine GPCRs in 
vertebrates. We have shown that GARs are structurally and functionally distinct from mAChR 
[15], an important consideration if GARs are to be exploited as novel anthelmintic drug candidates. 
However, both GARs and mAChRs are GPCRs that are activated by acetylcholine and other 
cholinergic ligands. Sequence features of mAChRs that are important for cholinergic ligand 
binding are known. Our hypothesis is that BmGAR-3 is a GPCR that responds to acetylcholine. To 
support this hypothesis we examined the BmGAR-3 sequence for features that are important for 
ligand binding and which are shared with mAChRs. There are 11 amino acid positions important 
for acetylcholine binding in mAChRs (Table 1, Figure 2). Ten of these amino acids are conserved 
in BmGAR-3 (denoted by red asterisks), with the only difference being substitution of the valine 
at position 266 to an alanine in BmGAR-3 (highlighted by the black asterisk). The cysteine residues 
at position 175 and 255, engaged in a disulfide bond, are another key characteristic of muscarinic 
receptors and are also present in BmGAR-3, shown by the yellow circles. This high conservation 
of critical ligand interaction residues with mAChRs supports the prediction that BmGAR-3 is an 
acetylcholine GPCR.  
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Figure 2. BmGAR-3 chare characteristics with muscarinic acetylcholine receptors. 
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Table 1. Amino acids important for muscarinic ligand binding. 
Amino acid Position 
(S) 154 
(W) 179 
(D) 182 
(Y) 183 
Valine (V)* 266 
(T) 270 
(W) 559 
(Y) 562 
(N) 563 
(Y) 585 
(Y) 589 
 
Expression analysis of BmGAR-3 and a related receptor  
Current chemotherapeutics used to treat LF are only effective against larval stages. An 
anthelmintic with macrofilaricidal properties would be of great value and help expedite the 
eradication process of LF. Acetylcholine is the primary excitatory neurotransmitter in nematodes 
and GARs mediate potent contractile activities, affecting worm body wall muscle [16], egg laying 
[17], and pharyngeal muscle [5]. Given the expression of GARs throughout the C. elegans life 
cycle, their putative physiological significance to adult nematode biology, and the conservation 
between C. elegans and B. malayi, we hypothesized that BmGAR-3 would be expressed in all B. 
malayi life stages. To test this hypothesis, we explored the spatial and temporal expression patterns 
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of Bmgar-3 via semi-quantitative RT-PCR where target gene expression at each stage was 
normalized to Bm-tph-1, a stably expressed internal reference gene. Bmgar-3 was expressed in 
infective L3 larvae, adult female (AF) and adult male (AM) life stages but could not be amplified 
from microfilaria (mf) or the L4 larval stage (Figure 3A). Notably, relative expression levels of 
Bm-gar-3 were higher in the adult stages compared to the larval L3, and markedly higher in adult 
male preparations than adult female. Enrichment in adult worms and specifically in the male 
suggests Bmgar-3 may function in worm reproductive behaviors. This is consistent with C. elegans 
where GARs are known to have a functional role in worm reproduction [17, 18]. To support this 
transcriptional data, we commercially raised polyclonal antisera against BmGAR-3 using 
extracellular epitopes in the third and sixth TM domains. Western blot analysis revealed reactivity 
in adult male and adult female protein preparations at the expected size. As with the RT-PCR 
findings, BmGAR-3 protein expression was higher in male worms than female (Figure 3B). We 
also used the BmGAR-3 antisera in whole worm immunocytochemical studies to determine tissue 
localization of BmGAR-3. Unfortunately, despite significant optimization studies, no specific 
staining was observed in Brugia preparations and we were unable to elucidate spatial expression 
patterns. We know the BmGAR-3 antisera works in Western blot so failure of the 
immunocytochemical approach is likely due to technical challenges of performing 
immunocytochemistry on B. malayi worms and subsequent anecdotal evidence from other 
investigators in the field supports this.  
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In an effort to determine tissue-specific spatial expression patterns of GAR-3 homologs, 
we transitioned to the pig gastrointestinal nematode, Ascaris suum. During our reciprocal BLAST 
analysis of Bmgar-3 we identified a putative GAR-3 homolog in Ascaris, which we called AsGAR-
3. Significant AsGAR-3 identity in the BmGAR-3 epitope regions (Figure 4A) led us to speculate 
if we could use the BmGAR-3 antisera to specifically localize AsGAR-3. Using Ascaris as a model 
also allows us to exploit the much larger size of this parasite; it is possible to dissect multiple tissue 
types from these worms and individually assay them for protein or transcript expression [15]. 
Western blot analysis of Ascaris tissue revealed specific immunoreactivity of the expected size in 
female body wall muscle preparations (Figure 4B). Refinement of these tissue preparations and a 
shift to AsGAR-3 transcript analysis using RT-PCR showed that As-gar-3 is expressed in the 
pharynx of female worms, and in the body wall muscle and pharynx of male worms (Figure 4C). 
Similar to Bm-gar-3, transcript expression is higher in male preparations and expression is 
restricted to distinct subsets of parasite tissue. Although the Western blot and RT-PCR results are 
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somewhat incongruous, they suggest roles for AsGAR-3 (and by extension BmGAR-3) in specific 
worm behaviors that may have sex-specific relevance.  
 
 
Pharmacological characterization of BmGAR-3 
Although nematode GARs are GPCRs that respond to cholinergic ligands, they have 
limited structural homology to mAChRs, are phylogenetically distinct to mAChRs, and our 
hypothesis is that they have a different pharmacological profile to mAChRs. Supporting this 
hypothesis, Kimber et al. (2009) functionally characterized a GAR from Ascaris (AsGAR-1) and 
found different pharmacology to mAChRs. Specifically, some mAChR agonists had no effect and 
all mAChR anatagonists were ineffective. To test the hypothesis that BmGAR-3 is 
pharmacologically different from its most closely related mACh (M5), we attempted to 
functionally express BmGAR-3 and human M5, and directly compare agonist and antagonist 
profiles. We used an auxotrophic yeast functional expression system (Figure 5 A and B) where 
auxotrophic S. cerevisiae strains are transformed with GPCRs of interest and receptor activation 
is reported by yeast growth in histidine-deficient media. Initial optimization efforts on M5 using 
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this system were encouraging. The M5 receptor showed strong agonist-driven growth in response 
to carbachol (10-4M; Figure 5C). BmGAR-3 was more challenging; over 100 individual 
transfection positive clones from multiple yeast strains were assayed for activity and whilst 
agonist-driven growth could be generated in some clones (Figure 5D), it could not be maintained 
over repeated experiments despite exhaustive efforts (Figure 5E). Included in our optimization 
experiments was the transfection with BmGAR-3 codon optimized for yeast expression (Figure 
5F). This also failed to generate agonist-driven yeast growth, however, we were able to isolate a 
number of constitutively active clones. These cells expressed a constitutively active BmGAR-3, 
that is, the receptor was always active and driving yeast growth even in the absence of ligand. 
Whilst unsuitable for agonist studies, these receptors could be useful for identifying inverse 
agonists, compounds that elicit the opposite response to agonists rather than simply acting as 
antagonists. We screened the constitutively active BmGAR-3 with a panel of compounds known 
to act as inverse agonists at mAChRs. None of these compounds showed dose-dependent activity 
at BmGAR-3 (Figure 5G). This observation is not unexpected since we previously found mAChR 
antagonists were mostly ineffective against the Ascaris GAR, AsGAR-1 in the same yeast 
expression system. 
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Figure 5: Auxotrophic yeast pheremone pathway (A) without and (B) with modifications to be 
employed as a screening platform for pharmacological compounds. (C) Muscarinic receptor M5 
is potently expressed in the yeast system. (D and E) BmGAR3 showed poor reproducibility. 
(F)BmGAR3 was codon optimized for yeast. (G) Dose response curves for uscarinic 
agonist/inverse agonists. 
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Pharmacological characterization in a mammalian expression platform. 
Mitogen-activated protein kinase (MAPKs) pathways are one of the major pathways activated by 
G protein coupled receptors [19, 20]. The most prominent MAP kinases are extracellular signal-
related kinases (ERK1 and 2 also known as p44mapk or MAPK3 and p42mapk or MAPK1 
respectively) [19, 21], stress activated kinases or Jun N-terminal kinase (SAPK/JNK), p38MAPK 
and big MAPK (BMK) [19, 22]. Unphosphorylated ERK is tethered to the cytoplasm in a 2-kinase 
complex together with raf kinases and MEK1/2. Upon activation, ERK is released from this 
complex and phosphorylates downstream reactions [21]. Signaling of the ERK/MAPK pathway 
has previously been studied in HEK293T cells [20, 23] and led us to hypothesize that it can be 
lobbied to heterologously express GARs of our interest to pharmacologically characterize them. 
C. elegans gar-3 was cloned into pcDNA3.1, a mammalian cloning vector and transfected into 
HEK293 cells. Carbachol was added and cells were collected after 5 and 10 minutes of exposure, 
lysed and processed. Both total and phosphorylated ERK were measured. Total ERK was constant 
between treatment groups (Figure 6A). However, nearly a two-fold difference was observed in 
phosphorylated ERK in the CeGAR3 transformed cells over no drug and untransfected cells. This 
suggested that the ERK/MAPK system in HEK293 cells is a viable assay for the pharmacological 
characterization of GARs.  
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Figure 6. C. elegans GAR3 is expressed in HEK293 cells as shown  
by (A) total ERK and (B) phosphorylated ERK assays. 
 
Next, we cloned Bmgar-3 into pmaxgfp, a mammalian expression vector expressing gfp and 
transfected into HEK293 cells (Figure 7). Empty pmaxgfp vector and M5, which was the most 
closely related muscarinic receptor, were also transfected as controls. Transfection and expression 
efficiency of the vector and receptors were observed at different time points. Some expression of 
the empty vector was observed after incubating for 16hrs at 37°C, but no expression was observed 
in either the M5 or Bmgar-3 transfected cells (Figure 7A). pmaxgfp empty vector transfected cells 
were highly expressed after 32hrs of incubation at37°C although the receptor transfected cells were 
barely expressed (Figure 7B). Following anecdotal evidence that temperature shifts can activate 
nematode GPCRs, a parallel experiment was carried out where the cells were transferred to 30°C 
after the first 16hrs and were incubated for 16hrs at 30°C (Figure 7C). Indeed, this drastically 
improved the expression of M5. However, it had no effect on BmGAR-3 expression. Uncertainty 
whether this poor expression efficacy would translate into the pharmacological assays halted 
further experimentation with this system. If time was not of the essence, the next logical step would 
have been to select the cells that expressed the fluorescently tagged Bm-gar3 gene by 
Fluorescence-activated cell sorting (FACS) and use the same number of control cells to do 
experiments with. Furthermore, a stably transfected cell line containing Bm-gar3 could also have 
been established by selecting cells containing the Bm-gar3 gene by FACS and growing them on 
media with neomycin. Since the plasmid has a G418 neomycin resistant gene, only plasmids that 
have been successfully be transfected will grow on the selective media. This cell line could have 
then been used for future exeriments.  
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Figure 7. Expression patterns of HEK293 cells transfected with empty vector control, muscarinic 
receptor M5 and BmGAR3 at (A) 16hrs at 37°C, (B) 32hrs at 37°C and (C) 16hrs at 30°C.   
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Abstract 
 
Lymphatic filariasis (LF) is a socio-economically devastating mosquito-borne Neglected 
Tropical Disease caused by parasitic  filarial nematodes. The interaction  between the para- 
site and host, both mosquito and human, during infection, development and persistence is 
dynamic and delicately balanced. Manipulation of this interface  to the detriment of the para- 
site is a promising potential avenue to develop  disease therapies but is prevented by our 
very limited understanding of the host-parasite relationship. Exosomes are bioactive small 
vesicles (30–120  nm) secreted by a wide range of cell types and involved in a wide range of 
physiological processes. Here, we report the identification and partial characterization of 
exosome-like vesicles (ELVs) released from the infective L3 stage of the human  filarial par- 
asite Brugia malayi. Exosome-like vesicles were isolated  from parasites in culture media 
and electron  microscopy and nanoparticle tracking analysis were used to confirm that vesi- 
cles produced by juvenile B. malayi are exosome-like based on size and morphology.  We 
show that loss of parasite viability correlates with a time-dependent decay in vesicle size 
specificity and rate of release. The protein cargo of these vesicles is shown to include com- 
mon exosomal protein markers and putative effector proteins. These Brugia-derived vesi- 
cles contain small RNA species that include microRNAs with host homology, suggesting a 
potential role in host manipulation. Confocal microscopy shows J774A.1,  a murine macro- 
phage cell line, internalize  purified ELVs, and we demonstrate that these ELVs effectively 
stimulate  a classically activated macrophage phenotype in J774A.1.  To our knowledge, this 
is the first report of exosome-like vesicle release by a human parasitic nematode and our 
data suggest a novel mechanism by which human  parasitic  nematodes may actively direct 
the host responses to infection. Further interrogation  of the makeup and function of these 
bioactive vesicles could seed new therapeutic strategies and unearth stage-specific diag- 
nostic biomarkers.
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Author Summary 
 
Lymphatic filariasis is caused by parasitic nematodes that invade and occupy the host lym- 
phatic system. The extent of lymphatic filariasis is staggering, with over 120 million people 
infected in 73 endemic countries and an estimated 40 million people suffering from a 
range of disfiguring and debilitating clinical manifestations of this disease. The mecha- 
nisms by which these medically important parasites navigate the host immune response to 
establish infection are not yet fully understood. In this study, we identify exosome-like ves- 
icles (ELVs) that are abundantly released from infective stage L3 Brugia malayi, an etiolog- 
ical agent of human lymphatic filariasis. We show that these vesicles have a narrow size 
distribution and morphology consistent with classical exosomes, and that they contain 
common exosomal protein markers, putative effector proteins, as well as small regulatory 
RNAs. We show that ELVs are enriched with microRNAs that are perfectly conserved 
between parasite and host, suggesting a potentially novel mechanism by which filarial 
worms can actively manipulate host gene expression. We demonstrate that parasite ELVs 
are internalized by macrophages and elicit a classically activated phenotype in these host 
cells. The discovery of exosome-like vesicle release by human nematode parasites newly 
enlightens the roadmap to understanding the pathology of LF and related helminthiases. 
These vesicles also present promising new targets for intervention and diagnostics. 
 
 
 
Introduction 
 
The parasitic filarial nematodes Wuchereria bancrofti, Brugia malayi and B. timori are etiologi- 
cal agents of Lymphatic filariasis (LF), a chronic and debilitating disease infecting over 120 mil- 
lion people in 73 endemic countries [1]. Adult parasites reside in the lymphatic vasculature of 
infected individuals and release larvae called microfilariae, which are taken up by vector mos- 
quitoes during the blood meal. Parasites rapidly develop within the mosquito, molting twice to 
the infective L3 stage [2, 3] before transmission to the definitive host during a subsequent 
blood meal. Following penetration of the vertebrate host via the puncture wound left by the 
mosquito, L3 stage parasites migrate to the lymphatics and undergo further growth and devel- 
opment, molting to the L4 stage and again to adulthood. The longevity of patent infection is 
remarkable; adults live for at least 8–10 years by general consensus. The ability of larval stages 
to successfully invade the host, and for adult worms to maintain infection for such an extended 
period of time, suggest filarial worms have developed strategies to both facilitate the establish- 
ment of infection and evade or manipulate the host immune response. Although the immuno- 
modulatory capabilities of infecting larval and adult stage filarial worms have been well 
documented and reviewed [4–8], the parasite effector molecules responsible for manipulating 
host biology and their mechanisms of release have been difficult to define. Actively secreted 
proteins have historically been considered the principal candidates and several secreted pro- 
teins have been identified with demonstrable bioactivity at the host-parasite interface [9–12]. 
Adding to these, the characterization of parasitic nematode secretomes has revealed a complex 
array of potential proteinaceous effectors [13–16]. Other types of effector, including molecules 
expressed on the parasite surface may have a role [17] and the emergence of small noncoding 
RNAs as cell-to-cell agents of genetic regulation [18–22] hint at exciting alternative 
mechanisms. 
Exosomes are a subtype of extracellular vesicle categorized by size (30–120 nm diameter) 
and defined by a particular biogenic pathway [23]; exosomes are formed by inward budding of 
vesicles in the late endosomal pathway to create multivesicular endosomes that fuse with the
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plasma membrane to effect release [24, 25]. Originally thought to be a means of cellular waste 
disposal, exosomes are now considered highly bioactive extracellular vesicles that facilitate cell- 
to-cell communication and are the focus of renewed investigation. The cargo of exosomes is 
complex and variable, containing bioactive proteins, functional mRNA, miRNA and other 
small non-coding RNA species [18, 26], likely reflecting both source and target environments. 
Fusion of the exosome to a target cell delivers this heterogeneous bioactive cargo and selectively 
alters the biology of the target tissue [19, 21, 26, 27]; the isolation of exosomes from circulatory 
systems and an array of biofluids suggests effector sites can be far from the point of release. Par- 
asites are known to release exosome-like vesicles [27–30] and it is compelling to hypothesize 
that bioactive molecules secreted by parasitic nematodes, packaged in exosomes, function as 
cell-to-cell effectors in the host-parasite interaction. Indeed recently, extracellular vesicles 
secreted by the gastrointestinal nematode Heligmosomoides polygyrus, containing proteins and 
small RNA species, have been shown to alter gene expression in host cells and suppress innate 
immune responses in mice [26]. 
Here we show that larval and adult stage B. malayi secrete prodigious quantities of extracel- 
lular vesicles in vitro whose size and morphology are consistent with exosomes. These exo- 
some-like extracellular vesicles (ELVs) contain small RNA species, including specific miRNA 
and are enriched in miRNA that are identical to host miRNAs with known immunomodula- 
tory roles [31–34]. The protein cargo of the vesicles is relatively scant but includes bioactive 
proteins, proteins with putative RNA binding properties and proteins commonly associated 
with exosomes [35]. The parasite ELVs are internalized by host macrophages and elicit a classi- 
cally activated phenotype in these cells. The demonstration that filarial nematodes secrete exo- 
somal RNA and proteins that potentially function at the host-parasite interface is significant. 
Defining this parasite effector toolkit exposes an array of new molecules that may be exploited 
in novel LF control strategies. 
 
 
Results and Discussion 
Infective-stage B. malayi release exosome-like vesicles 
 
In order to ascertain whether exosomes are released by B. malayi, extracellular vesicles were 
isolated from parasites incubated in culture media using a filtration and ultracentrifugation 
protocol. We focused our initial discovery efforts on larval and adult stage parasites. L3, adult 
male, and adult female B. malayi were incubated in vitro for 24 hour periods under standard 
culture conditions, and purified vesicle preparations were evaluated with electron microscopy 
(EM). Infectious stage L3 parasites in culture release abundant 50–120 nm microvesicles con- 
sistent with the classical “deflated ball” morphology of mammalian and non-mammalian exo- 
somes reported in the literature [36] (Fig 1A & 1B). We refer to these as exosome-like vesicles 
(ELVs) throughout this manuscript, in recognition that they cannot be unequivocally desig- 
nated as exosomes, rather than another class of extracellular vesicles, because their biogenesis 
has not been determined. Preparations from adult stage B. malayi were more heterogenous 
and dilute, not allowing for the definitive categorization of putative exosome-like vesicles 
(Fig 1C). This, despite the fact a much higher mass of total parasite tissue was used for adult 
preparations as compared to larval preparations. These data suggest ELV release to be a pre- 
dominantly larval phenomenon in B. malayi, a working hypothesis supported by analysis of 
RNA associated with the vesicles. We therefore chose to focus our subsequent experiments on 
L3 stage parasites. A compelling overall hypothesis for the function of B. malayi ELVs is that 
they mediate the secretion and trafficking to host cells of effector molecules that facilitate para- 
sitism and the observation that ELV secretion occurs primarily in those parasite stages that 
infect the host and establish parasitemia is consistent with this narrative.
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Fig 1. Electron microscopy confirms secretion of exosome-like vesicles in intra-host stages of B. malayi. TEM images of L3 (A and B) and adult 
female (C) ELV preparations are shown. L3 vesicles take on a distinct morphology  often reported in the literature. Adult isolations are more heterogenous 
and may require further optimization to achieve uniform vesicle preparation. White arrows show canonical L3 ELVs (B) and putative adult ELVs (C). This 
provides evidence for the release of exosome-like vesicles in the human-infective L3 stage of the parasite and much of the rest of the work we report is 
focused on vesicles derived from this larval stage. 
 
doi:10.1371/journal.pntd.0004069.g001 
 
 
 
 
Time course profile of exosome-like vesicle release from infectious 
stage B. malayi 
To more accurately resolve the dynamics of ELV release in L3 B. malayi, we used a nanoparticle 
tracking analysis (NTA) system to measure vesicle output in a 72 hr in vitro time course. 
Media was collected from 300 worms after three successive 24 hr incubation periods, vesicles 
were purified by ultracentrifugation as before and individual vesicle preparations were ana- 
lyzed via NanoSight LM10 as shown in Fig 2 (sample recording: S1 Video). Day 1 (0–24 hr in 
culture) preparations reveal a prolific ELV release rate (> 9,000 ELVs/parasite/min) with a 
very narrow size distribution centered at *90 nm. Day 2 (24–48 hr in culture) preparations 
show an essentially equivalent rate of release, but a stark broadening of the size distribution. 
Day 3 (48–72 hr in culture) preparations are associated with significantly lower levels of release 
(<4,000 ELVs/parasite/min) and an even wider multimodal size distribution. These data
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Fig 2. Particle tracking analysis reveals prolific larval  Brugia exosome-like vesicle release rate. Profile of ELVs isolated from culture media incubated 
with 300 L3 parasites for successive 24 hr incubations. The size distribution of L3-derived ELVs from Day 1 (left), Day 2 (center) and Day 3 (right) incubations 
are shown (mean  ± SD). Calculated vesicle release rates are provided in tabular format. ELV rate of release and size specificity decay in a time-dependent 
manner in vitro. * re-scaled based on dilution for comparison to 0–24 hour (1:20) dilution. 
 
doi:10.1371/journal.pntd.0004069.g002 
 
 
 
suggest an overall time-dependent decay in vesicle rate of release and size specificity, which 
correlates to decreased L3 viability in vitro. The release of considerable quantities of precisely- 
sized ELVs in viable worms (Days 1–2) is followed by the release of smaller quantities of a 
broader size range of particles that potentially include larger membrane vesicles and apoptotic 
blebs (Days 2–3). This suggests an active and regulated mechanism of ELV release in healthy 
and viable L3 stage parasites, as opposed to a passive mode of noisy cellular deterioration. 
 
 
 
The protein cargo of Brugia exosome-like vesicles 
 
The protein content of B. malayi ELVs was determined using nanoscale liquid chromatography 
coupled to tandem mass spectrometry (nano LC/MS/MS). A total of 32 proteins each contain- 
ing at least two unique peptides were identified using MASCOT (Table 1). Specific proteins 
identified within the pellet included characteristic markers of exosomes including Hsp70, elon- 
gation factor-1α, elongation factor-2, actin, and Rab-1. In addition, over 80% of the proteins 
identified are orthologous to proteins identified in mammalian exosome proteomes, strongly 
suggesting that these vesicles are exosome-like in nature and supporting our ELV designation 
here. Interestingly, this set of vesicle-specific proteins is entirely distinct from the proteins pre- 
viously identified in pre- and post-molt L3 secretions [37].
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Table  1. Annotation of Brugia ELV proteome. 
 
Brugia Protein ID                                UniProt ID                                        Annotation 
 
BM-ACT-5                                             A8P5A0_BRUMA                             Actin 
Bm-HSP-1                                              A8P6Q6_BRUMA                             HSP70 
Bm5195                                                   A8PJ17_BRUMA                              Elongation  factor 1-alpha 
BM-EEF-2                                              A8PJV1_BRUMA                             Elongation  factor 2 
Bm4733                                                   A8PHP7_BRUMA                             Beta-tubulin 
BM-MEC-12                                           A8PN52_BRUMA                             Alpha-tubulin like 
BM-DPY-23                                           A8PZJ6_BRUMA                              Adaptin 
Bm13837                                                 A8QAR6_BRUMA                            ATP synthase subunit  alpha 
Bm-ATP-2                                              A8Q895_BRUMA                             ATP synthase subunit  beta 
Bm5931                                                   A8P4C6_BRUMA                             Alpha-1,4 glucan  phosphorylase 
BM-CPL-1                                              A8NCV6_BRUMA                            Cathepsin L-like cysteine protease 
BM-EAT-6                                              A8Q4C9_BRUMA                             Na+K+ATPase 
Bm-SCA-1                                              A8QET1_BRUMA                            Calcium-transporting ATPase 
BM-RAB-1                                             A8Q8U0_BRUMA                            Ras-related protein 
Bm4628                                                   A8NSV0_BRUMA                            Ubiquitin 
Bm5528                                                   A8NHQ1_BRUMA                           1,4-alpha-glucan branching enzyme 
BM-DLST-1                                           A8PU77_BRUMA                             2-oxoglutarate dehydrogenase 
Bm3206                                                   A8NHD8_BRUMA                           Histone  H2B 
Bm3425                                                   A8NHD2_BRUMA                           Histone  H3 
Bm4113                                                   A8Q1K1_BRUMA                            Histone  H4 
Ribosomal Proteins 
BM-RPS-16                                            A8P1D4_BRUMA                             40S ribosomal  protein S16 
Bm2853                                                   A8Q0J1_BRUMA                              40S ribosomal  protein S2 
Bm2320                                                   A8NXR7_BRUMA                            40S ribosomal  protein S3 
BM-SECS-1                                            A8PJH5_BRUMA                              40S ribosomal  protein S5 
BM-RPS-9                                              A8P2X1_BRUMA                             40S ribosomal  protein S9 
Bm13774                                                 A8PTY7_BRUMA                             60S ribosomal  protein L10 
Bm13718                                                 A8NKQ0_BRUMA                           60S ribosomal  protein L11 
BM-RPL-3                                              A8P136_BRUMA                              60S ribosomal  protein L3 
BM-RPL-9                                              A8QHP9_BRUMA                            60S ribosomal  protein L9 
Bm3930                                                   A8ND23_BRUMA                            Ribosomal protein 
BM-RPL-1                                              A8NG31_BRUMA                            Ribosomal protein 
 
Homology-based annotation of B. malayi ELV proteins  reveals hallmarks  of mammalian exosomes, 
including HSP70 and translation elongation factors.  Ribosomal proteins, histones, ras-related proteins, 
cathepsins, ATP synthase subunits, and other homologs of identiﬁed Brugia ELV proteins have  also been 
reported in exosomes derived  from various  cell types. 
 
doi:10.1371/journal.pntd.0004069.t001 
 
 
 
UniProt-GOA and quickGO were used to sort proteins into functional groups based on 
assigned gene ontology (GO) terms [38, 39], as shown in Fig 3. Based on GO annotations, 20% 
of the proteins identified are involved in binding of bioactive molecules including nucleic acids 
and other proteins, 16% function in the transport of various ions and proteins and 14% are 
ribosomal proteins. In addition, a large fraction of proteins identified (21%) appear to be 
involved in various metabolic processes including hydrolase and transferase activities while the 
remaining 29% comprises proteins with translational, cytoskeletal and other functions.
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004069  September 24, 2015  
Brugia malayi Secretes Exosome-Like Vesicles 
 
 
141 
 
 
 
 
 
Fig 3. Protein content of B. malayi exosome-like vesicles. GO functional annotation of 32 proteins  identified in ELVs isolated from B. malayi L3 stage 
parasites. 
 
doi:10.1371/journal.pntd.0004069.g003 
 
 
 
Included in the list of Brugia ELV proteins are potential effector molecules. Bm-CPL-1 is a 
cathepsin L-like cysteine protease robustly expressed across the B. malayi life cycle [40]. Upre- 
gulation of Bm-cpl-1 expression coincides with transition between life cycle stages and an 
important role in the modulation of parasite molting has been confirmed [41–43]. This is the 
first demonstration that B. malayi secretes CPL-1 although other cathepsin-like cysteine prote- 
ases have been identified in the B. malayi secretome [14, 37] and a cathepsin L-like molecule is 
secreted by intra-mammalian stage Haemonchus contortus [44]. The exogenous function of 
exosomal Bm-CPL-1 is not clear but evidence points to some manipulation of the host-parasite 
interface. In a previous study, we suppressed Bm-cpl-1 expression using in vivo RNAi during 
the mosquito life stages [42]. Loss-of-function reduced prevalence of infection in mosquitoes 
by nearly 40%, suggesting Bm-CPL-1 is important for establishing or maintaining parasitemia. 
In flatworms, an immunomodulatory role for secreted cathepsin L-like proteases is better 
established [45]; in Fasciola infection cathepsin L contributes to the permissive polarized 
Th2 > Th1 host response.
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Fig 4. Isolation of Small RNAs from larval  and adult B. malayi ELV fractions. Bioanalyzer data are shown for RNAs isolated  from L3, adult male, and 
adult female Brugia preparations. L3 ELVs contain significant amounts of small RNAs in the 25–200  nt range (25 and 200 nt reference peaks labeled),  while 
adult male and female vesicle preparations yield fewer RNAs. Vesicle fractions were prepared from 300 L3 and 30 adults in 24 hr culture incubations. Despite 
the much higher total tissue  amounts used in adult culture, we detect much higher levels of small RNAs in L3-derived ELVs. 
 
doi:10.1371/journal.pntd.0004069.g004 
 
 
 
 
The proteomic profiles of parasitic helminth exosomes are broad in range; for example, over 
350 proteins were identified in the putative exosomes secreted by Heligmosomoides polygyrus 
[26] whilst 45 and 79 proteins were identified in exosome-like vesicles from Echinostoma 
caproni and Fasciola hepatica, respectively [46]. The B. malayi L3 stage profile identified here 
is relatively scant but consistent with this broad distribution. It may be that this is a stage- 
specific observation and ELV secreted by other B. malayi life stages display a more complex 
and abundant protein cargo tailored to distinct functional demands. Reflecting the small RNA 
component of these ELVs (see later sections), it may also be that larval stage Brugia ELVs are 
primarily vehicles for protected RNA secretion. Replication of the experiments conducted here 
might add depth to the MS data set and identify further ELV-associated proteins. 
 
B. malayi ELVs contain small RNA including miRNAs 
with potential host targets 
We probed larval and adult microvesicle preparations for the presence of small RNA species. 
Exosomes have been found to contain both non-coding RNAs (ncRNAs) and messenger RNAs 
(mRNAs) in a diverse range of species and cell types. Of particular interest to us was the poten- 
tial presence of small non-coding RNAs, including microRNAs (miRNAs), that could poten- 
tially mediate parasite-parasite communication or modulate host gene expression. Small RNA 
species were preferentially isolated from putative ELV-containing pellets and examined with 
an Agilent Bioanalyzer. The microvesicle fractions of L3 B. malayi (24 hr incubations of 300 
worms) revealed an abundance of small RNA species in the 25–200 nt range (Fig 4). Much less 
RNA was detected from incubations of adult male and female B. malayi (24 hr incubations of 
30 adult worms), despite the much higher mass of tissue in adult stage culture media. This lack
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Fig 5. Discovery and profiling of miRNAs in B. malayi exosome-like vesicles. (A) Comparative abundance of miRNAs in L3 ELV and tissue-derived 
samples. miRNA discovery and abundance estimation was carried out using the mirDeep2 pipeline. The 20 miRNAs with highest expression in each sample 
were retained for comparison and abundance was normalized with respect to total miRNA-mapping reads within each sample. Normalized read count is 
plotted on a log scale for ELV and tissue  miRNAs to provide a relative ordering of fractional abundance. Bma-let-7 only appears in the highly expressed 
subset, and a number of miRNAs with perfect mature sequence identity to host homologs are highlighted (outer blue circle). (B) Sequence conservation 
between B. malayi ELV-origin miRNAs and the host ( H. sapiens ) miRNA complement. Reduced heat map showing one-to-one homology between a 
given B. malayi miRNA and its nearest matching  human  counterpart in terms of percent identity. Bma-let-7, bma-miR-1, bma-miR-9, bma-miR-92, and bma- 
miR-100b (white asterisks) share 100% identity with a host miRNA, while bma-miR-34 shows  high identity with a host miRNA (21/23 nucleotides). This B. 
malayi miRNA subset (shown in blue) contains potential modulators of host gene expression. (C) Sequence conservation between B. malayi ELV-origin 
miRNA seed sites and host ( H. sapiens ) miRNA seed sites. miRNAs sharing  perfectly conserved seed sites,  defined here as nucleotides 2–8 of the 
mature miRNA, are marked  (blue circles). 
 
doi:10.1371/journal.pntd.0004069.g005 
 
 
 
of correlation between total parasite tissue material and RNA yield, coupled to the differential 
quality of larval and adult microvesicle preparations as evaluated by EM, further indicates that 
ELV release is primarily a characteristic of larval-stage parasites and perhaps more biologically 
relevant to early parasite infection. 
To more fully investigate the nucleic acid contents of these newly discovered vesicles, we 
carried out RNA-Seq with both L3 ELV and tissue-derived small RNAs. Reads generated by 
Illumina sequencing were processed and used to seed an miRNA discovery and abundance 
estimation pipeline using miRDeep2 [47] (read statistics and raw miRNA abundances can be 
found in S1 Table). To compare ELV and cellular RNA abundance, miRNA expression was 
normalized to the total miRNA read count within each sample. miRNA discovery and profiling 
was augmented with data from previously discovered miRNAs in closely related nematode spe- 
cies to help overcome gaps in the B. malayi draft genome assembly (see Methods). Fig 5A com- 
pares normalized miRNA expression between ELV and tissue for the 20 most abundant
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Fig 6. Brugia malayi ELV miRNA sequence homology to nematode and mammalian host miRNAs. 
miRNAs from B. malayi, A. suum, C. elegans, H. sapiens, and M. musculus were grouped by seed site 
sequence identity (nucleotides 2–8) for multiple sequence alignments. Alignments are shown for bma-let-7, 
bma-miR-9 and bma-miR-993. bma-let-7 is shown as an example of a Brugia ELV miRNA that exhibits both 
seed site and full length sequence conservation extending to other parasitic and free-living nematodes, as 
well as to mammalian host species. bma-miR-9 and bma-miR-993 are presented as examples where 
conserved parasite miRNAs have clear host homologs, yet lack one-to-one C. elegans orthologs.  The 
complete set of alignments can be found in S1 Fig. 
 
doi:10.1371/journal.pntd.0004069.g006 
 
 
 
 
 
miRNAs in each sample. Although there is considerable conservation in relative miRNAs 
abundances, there are some notable observations and exceptions. 
Bma-let-7 is significantly enriched in L3 ELVs as compared to L3 tissue, where it does not 
appear among the 20 most abundant miRNAs. Bma-let-7, along with four other B. malayi 
mature miRNAs found in ELVs (bma-miR-1, bma-miR-9, bma-miR-92, and bma-miR-100b), 
share perfect sequence identity with host (Homo sapiens) mature miRNAs, as shown in Fig 5B. 
Additionally, bma-miR-34 shares near perfect sequence identity with its H. sapiens homolog. 
11 B. malayi miRNAs also share common seed sites with H. sapiens miRNAs (Fig 5C). Brugia 
ELV miRNA sequences were more broadly clustered by putative seed site and aligned to miR- 
NAs from the soil-transmitted parasitic nematode Ascaris suum, the free living model nema- 
tode Caenorhabditis elegans, and mammalian host species H. sapiens and Mus musculus (Fig 6 
and S1 Fig). In all cases, Brugia ELV miRNAs that share common seed sites with host miRNAs 
have one-to-one A. suum orthologs. In some cases, parasite miRNAs are better conserved in 
mammalian hosts than in C. elegans (e.g., bma-miR-9, bma-miR-993, and bma-miR-100b/c). 
We examined the complement of the most abundant Brugia ELV-associated miRNAs with 
respect to very recent investigations of miRNAs released by other parasitic nematode species 
and found circulating in host biofluids [26, 48–50]. Common markers include let-7, lin-4, 
miR-34, miR-71, miR-92, and miR-100c (Fig 7A and 7B). While all members of this subset 
share seed site sequence identity with mammalian host miRNAs, lin-4, miR-34, miR-71, and 
miR-100c are sufficiently diverged from host miRNAs over their full length mature miRNA 
sequence and can potentially serve as biomarkers of filarial infection. Additionally, we com- 
pared the complements of the 20 most abundant Brugia ELV and H. polygyrus exosomal [26] 
miRNAs, identifying six miRNAs shared between these vesicles and a large number of miRNAs 
unique to each species (Fig 7C).
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Fig 7. Comparison of the B. malayi ELV miRNA complement to miRNAs secreted by other parasitic nematodes species. (A & B) Comparison of the 
20 most abundant B. malayi ELV miRNAs with the complements of miRNAs found circulating in the serum  and plasma of definitive and model mammal hosts 
burdened with filarial infection (Litomosoides sigmodontis [26], Dirofilaria immitis [48], Loa loa [49], Onchocerca volvulus [48, 50], and Onchocerca ochengi 
[49]). The D. immitis miRNAs in (A) are restricted to the 20 most abundant miRNAs, and the O. volvulus miRNAs in (B) represent the combination of two non- 
overlapping sets arising from separate reports. (C) Comparison of the 20 most abundant miRNAs identified in B. malayi ELVs and H. polygyrus exosomes. 
These analyses reveal sets of common markers and a number of miRNAs unique to each species. 
 
doi:10.1371/journal.pntd.0004069.g007 
 
 
 
 
 
Enrichment of bma-let-7 and the high fractional presence of other parasite miRNAs sharing 
perfect or high homology to host miRNAs, leads us to speculate about a potential ELV- 
mediated mechanism by which parasite RNAs can be used to efficiently direct aspects of gene 
expression in host cells. Targets of endogenous let-7 family miRNAs in vertebrates include 
oncogenes, as well as genes involved in proliferation, apoptosis, and innate immunity [51–53]. 
Let-7 is intricately involved in macrophage polarization and responses to pathogen challenge 
[31, 33, 54], and the altering of host let-7 expression therefore represents a potentially advanta- 
geous point of intervention for an invading parasite. Live pathogens down-regulate the expres- 
sion of let-7 family miRNAs, and let-7 miRNAs act on toll-like receptors (e.g. TLR4) that 
directly mediate macrophage responses [54–56]. Clearly, there is an important association 
between macrophage response to pathogens and let-7 expression. Our observation that 
B. malayi secrete let-7 and other potential modulators of host gene expression identifies a 
mechanism by which this host immune response might be manipulated. Supporting this 
hypothesis, let-7 and other miRNAs with host conservation have been identified in immuno- 
modulatory H. polygyrus adult stage exosomes [26]. To fully dissect this hypothesis, a broad 
investigation of the interaction of ELV miRNAs and host immune cells in vivo is needed. 
 
Brugia ELVs are internalized by host macrophages 
 
Macrophages are critical mediators of the early immune response to invasive Brugia parasites 
[8]. To test the hypothesis that secreted Brugia ELVs interact with host macrophages, we used 
fluorescent lipophilic dyes to visualize the interaction between J774A.1 murine macrophages 
and ELVs. This cell line was chosen because it is commercially available, can be cultured readily 
and because it recapitulates the biology of primary macrophages and dendritic cells [57]. ELVs 
were labeled with PKH67, a green fluorescent dye, and incubated with J774A.1 labeled with 
PKH26, a red fluorescent dye. Confocal microscopy revealed efficient internalization of the
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004069  September 24, 2015  
Brugia malayi Secretes Exosome-Like Vesicles 
 
 
146 
 
 
 
 
 
Fig 8. Brugia exosome-like vesicles (ELVs) are internalized by J774A.1 macrophages. (A and D) J774A.1 macrophages were labeled with PKH26 (red) 
and counterstained with DAPI (blue) to visualize nuclei. (B and E) B. malayi L3 stage ELVs were purified from a 24 hr parasite culture and labeled  with PKH67 
(green). 3 × 105 J774A.1 were co-incubated with approximately 3 × 107 labeled  ELVs for 6 hrs at 37°C and washed repeatedly to remove  unbound ELVs. 
Vesicles internalized by macrophages appear diffusely throughout cytoplasm and focused in discrete puncta  associated with the cell membrane. (C and F) 
Merged images showing internalization of parasite ELVs. All images were acquired using a using a Leica TCS SP5 X Confocal/multiphoton microscope 
system with 20X (A-C) or 60X (D-F) objectives. Scale bars: 10 μm (A-C) and 25 μm (D-F). 
 
doi:10.1371/journal.pntd.0004069.g008 
 
 
 
 
ELVs by this macrophage cell line (Fig 8). Internalization was observed diffusely throughout 
the cell cytoplasm with focus around membrane-rich puncta associated with the surface of the 
macrophages (Fig 8B). This pattern of internalization is consistent with other studies describ- 
ing a phagocytic route of vesicle internalization [58, 59]. Macrophages were counterstained 
with DAPI to determine the efficiency of cell labeling and ELV uptake. PKH26-labeling of 
J774A.1 was very efficient and all cells were visualized although intensity of labeling was vari- 
able (Fig 8D). Approximately 40–50% of macrophages internalized labeled ELVs to some 
degree (Fig 8E) with approximately 10% of macrophages internalizing ELVs at markedly 
higher levels (Fig 8E). There was no correlation between strong PKH 26-labelling of macro- 
phages and vesicle uptake indicating internalization is not a factor of receptiveness to labeling.
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Brugia ELVs elicit a classically  activated phenotype in host 
macrophages 
Macrophage activation is dichotomous; classically activated macrophages (CAMF) are elicited 
by LPS or IFN-γ and have a generally pro-inflammatory phenotype whereas alternatively acti- 
vated macrophages (AAMF), driven by IL-4 and IL-13, appear immunosuppressive or anti- 
inflammatory. Helminth infection is typically associated with the AAMF pathway although 
both CAMF and AAMF are involved in the immune response to, and immunopathology 
caused by, Brugia infection. Experiments demonstrate different Brugia preparations can gener- 
ate both CAMF and AAMF activation phenotypes; dead and moribund worms and worm 
lysates produce CAMF [60] but live worms and complete excretory/secretory  (ES) prepara- 
tions drive AAMF [61–63]. To test the hypothesis that ELVs activate host macrophages, 
J774A.1 were treated with purified ELV preparations and their cytokine/chemokine responses 
monitored. J774A.1 were treated for 48 hrs with approximately 4 × 10
8 
L3 stage vesicles, puri- 
fied from in vitro culture medium by ultracentrifugation. The macrophage response was 
assayed using the Milliplex MAP Mouse Cytokine/Chemokine kit (EDM Millipore) interfaced 
with a Bio-Plex System (Bio-Rad) utilizing Luminex xMAP technology, a platform capable of 
simultaneously identifying and quantifying 32 cytokines/chemokines. Vesicle treatment effec- 
tively activated J774A.1 macrophages with significant increases in G-CSF, MCP-1, IL-6 and 
MIP-2 levels compared to control macrophages treated with naïve RPMI 1640 culture media, 
(p    0.001)(Fig 9A). Smaller increases in LIX, RANTES and TNF-α were also noted. Healthy, 
viable L3 stage parasites produced an almost identical response (Fig 9A), the only difference 
being a modest but significant enhancement of G-CSF stimulation by the viable parasites 
(p < 0.001), suggesting that the dominant parasite immunogen(s) are found in the vesicle pel- 
let. Finally, parasite culture media from which the ELVs had been removed by centrifugation 
did not produce this response, nor did live schistosomes  (S. mansoni cercaria) or their secreted 
vesicles (S2 Fig) suggesting the Brugia-associated activation is specific to this parasite and not a 
general response to helminths or their secreted vesicles. 
The activation profile observed would be considered more indicative of a CAMF response 
than AAMF; to confirm the response was CAMF-like, we compared it to the response elicited 
by LPS (200 ng/mL). The only significant differences were that ELV treatment stimulated 
G-CSF and IL-6 less effectively (p < 0.001) and stimulated MCP-1 more effectively (p < 0.001) 
than LPS (Fig 9B). The overall conservation of response, however, indicates these ELVs gener- 
ate a CAMF phenotype. Since Wolbachia, the endosymbiont present in filarial nematodes, 
lack LPS biosynthetic capacity it seemed unlikely our CAMF-like response was driven by LPS- 
like contamination but to rule this out, endotoxin levels in our vesicle preparation were deter- 
mined commercially (Lonza, Walkersville, MD). LPS-like activity was present (0.003 ng/mL) 
but at a concentration several orders of magnitude lower than the minimum dose required to 
stimulate J774A.1 macrophages [64]. As expected, treatment of macrophages with this low LPS 
dose was insufficient for activation (Fig 9C) indicating that the CAMF response we observe is 
not due to an LPS-like component in our preparation. 
Since the stimulation of an AAMF phenotype by live Brugia and ES preparations thereof in 
vivo and in vitro has been well established [61–63] it might be expected that Brugia ELV prepa- 
rations also stimulate a AAMF phenotype, especially since complete Brugia ES preparations 
are likely to include ELVs similar to those examined here, albeit at reduced concentrations. We 
observed a response consistent with a CAMF phenotype, however, although without the acute 
elevation in IL-β and TNF-α production others have seen in response to LPS [60]. One inter- 
pretation is that the CAMF > AAMF phenotype may be a somewhat artificial function of the 
homogenous J774A.1 monoculture used here as other studies describing a AAMF phenotype
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Fig 9. Brugia exosome-like vesicles (ELVs) elicit a classically activated phenotype in J774A.1 
macrophages. (A) J774A.1 (5 × 105) were treated with approximately 4 × 108 purified L3 stage ELVs, live L3 
stage parasites (10 worms) or naïve culture media (control) and supernatents collected  after 48 hr. The 
presence of 32 cytokines/chemokines was simultaneously assayed using the Milliplex MAP Mouse Cytokine/ 
Chemokine kit (EDM Millipore) interfaced with a Bio-Plex System (Bio-Rad) utilizing Luminex xMAP 
technology (Luminex). The quantification of identified cytokines is presented. The cytokine profile generated 
by ELV treatment is consistent with a classically activated phenotype. (B) Cytokine response to ELV 
treatment is compared to LPS (200 ng/mL). The close correlation of responses indicates ELV treatment 
generates a classically activated phenotype. (C) J774A.1 (5 × 105) were treated with high dose LPS (200 ng/ 
mL), low dose LPS (0.003 ng/mL), ELV or naïve culture media (control) for 24 hr, supernatant collected  and 
assayed for G-CSF using a Mouse G-CSF Quantikine ELISA kit (R&D Systems). The absence of response to 
low dose LPS suggests the classically activated response is not due to LPS-like contamination. 
 
doi:10.1371/journal.pntd.0004069.g009 
 
 
 
 
 
often use PBMC or other heterogeneous primary cell types. It would be instructive to monitor 
the responses of such mixed cell populations to the ELV preparation. Additionally, although 
the murine model is regarded as valuable for illuminating both how parasites establish them- 
selves and the early host immune response, J774A.1 may not be optimal for studying this par- 
ticular Brugia-host interaction and optimization with other murine or human cells may be 
required. Another interpretation, however, is that the purified ELVs examined here should be 
considered a distinct and specific fraction of the highly complex immunogenic facade pre- 
sented by filarial parasites and may elicit a genuine CAMF phenotype when examined in isola- 
tion. Supporting this interpretation, exosomes isolated from other biological systems effectively 
generate a CAMF phenotype [59, 65, 66]. A key mediator of this pro-inflammatory response is 
Hsp70 [65], which was identified in our ELV proteomic profile. In summary, irrespective of 
the polarity of macrophage activation phenotype, our results unequivocally identify secreted 
ELVs as distinct parasite-derived structures capable of activating the host immune system. 
A picture is emerging that parasitic helminths secrete functional exosome-like vesicles. The 
protein and small RNA cargo of these vesicles have putative effector functions at the host- 
parasite interface and potentially serve to create conditions favorable to the establishment or 
maintenance of infection. The identification of these cell-to-cell effector structures is exciting 
and prompts further investigation of their functional relevance. In particular, it will be impor- 
tant to describe the roles of individual miRNAs and proteins contained within the ELVs, to 
identify the host molecular targets being manipulated in vivo, and reveal any conserved or 
stage-specific effectors secreted across the parasite life cycle. Another intriguing question is 
whether or not there is any specificity or selectivity in host cells or tissues targeted and if so, 
what molecular mechanisms underscore this specificity. Addressing such questions will illumi- 
nate the fundamental interactions that occur between parasite and host, and may open previ- 
ously unexploited opportunities for parasite control and diagnostics. 
 
 
 
Materials and Methods 
Mosquito maintenance 
 
Aedes aegypti (Black eyed Liverpool strain, LVP), previously selected for susceptibility to infec- 
tion with Brugia malayi [67], were maintained in controlled conditions (27°C ± 1°C and 75% ± 
5% relative humidity) with a 16:8 photoperiod. Adult mosquitoes were fed a diet of 10% 
sucrose. Approximately 4,000 and 2,600 mosquitos were used for proteomics and RNA 
sequencing, respectively.
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Establishing Brugia malayi infection 
 
For proteomics and transcriptomics, B. malayi microfilaria (mf) infected cat blood was 
obtained from the University of Georgia NIH/NIAID Filariasis Research Reagent Resource 
Center (FR3). Blood containing the parasites was diluted with defibrinated sheep’s blood 
(Hemostat Laboratories, CA, USA) to achieve a concentration of 80–100 mf per 20μL. To 
establish infection, 3- to 5-day-old Ae. Aegypti (LVP) were allowed to feed for one hour on a 
glass membrane feeder. Mosquitoes were sucrose-starved for 24 hrs prior to blood feeding and 
those that did not take a blood meal were removed. Infected mosquitoes were maintained in 
the above described conditions for 13–15 days post infection (dpi) to allow development of 
parasites. 
 
Brugia malayi maintenance and collection of vesicle-containing media 
 
In exploratory studies, larval (300 L3) and adult (30 male or 30 female) B. malayi were pro- 
cured from the FR3. On arrival, parasites were cultured in 50 mL RPMI 1640 (Sigma-Aldrich, 
St. Louis, MO) at 37°C (5% CO2). Cell culture media was collected and replaced at 24 hr inter- 
vals for up to 72 hrs to collect secreted ELVs. For downstream sequencing and proteomics, B. 
malayi (13–15 dpi) were locally collected using methods described by FR3. Briefly, infected 
mosquitoes were immobilized by cooling to 4°C for 15 minutes. Immobilized mosquitoes were 
crushed in a mortar containing 5 ml of chilled Hanks’ balanced salt solution (HBSS, pH 7.0) 
containing pen-strep (0.4 units penicillin/ml, 0.4 mcg streptomycin/ml). Mosquitoes were then 
rinsed onto a 150 mesh sieve contained in a deep well plastic petri dish and washed 3–4 times 
using fresh chilled HBSS + pen-strep. Sieves were then placed into petri dishes containing 
warm (40°C) HBSS + pen-strep to allow infective larvae to migrate out. Sieves were transferred 
to new deep well petri dishes containing fresh warm HBSS every 30 minutes. Collected para- 
sites were washed twice with warm HBSS + pen-strep, placed into 25 mL RPMI 1640 contain- 
ing pen-strep (0.4 units penicillin/ml, 0.4 mcg streptomycin/ml) and held at 37°C, 5% CO2 for 
24 hrs to collect secreted ELVs. 
 
 
Exosome-like vesicle purification 
 
Differential centrifugation was used to isolate ELVs from 25 or 50 mL aliquots of Brugia cul- 
ture media. Aliquots were collected from 24 hr incubations of larval or adult worms in culture 
media. Lower speed centrifugation and filtration steps were used to remove contaminating 
cells (300 × g, 10 mins) and cellular debris (10,000 × g, 15 mins). The resulting supernatants 
underwent filtration through 0.22 μm filters and ultracentrifugation at 105,000 × g for 90 mins 
to pellet ELVs. Pellets were then washed with cold phosphate-buffered saline (PBS) and a final 
spin was carried out at 105,000 × g for 90 mins. Supernatants were discarded and pellets were 
resuspended in small volumes (30–250 uL) of PBS for imaging, sequencing, and proteomics, 
and RPMI for immunological assays. Samples were kept on ice and centrifugation steps were 
carried out at 4°C. Resuspended ELVs were stored at −80°C. 
 
Electron microscopy and nanoparticle tracking analysis 
 
Small aliquots of ELV suspension (3 μl) were applied to carbon coated 200 mesh copper grids 
and negatively stained with 2% uranyl acetate. Images were taken using a JEOL 2100 scanning 
and transmission electron microscope (Japan Electron Optics Laboratories, Akishima, Japan) at 
the Microscopy and NanoImaging Facility (Iowa State University). Nanoparticle tracking anal- 
ysis was carried out with the NanoSight LM10 (NanoSight Ltd., Amesbury, UK) to ascertain 
the size and frequency distribution of individual vesicle preparations, assayed in triplicate. The
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Brownian motion of particles in solution is related back to particle sizes and numbers, allowing 
better statistical resolution of vesicle size and concentration [68]. 
 
LC-MS/MS and proteomic  analysis 
 
Protein was isolated from purified exosome-like vesicles for proteomic analysis (System Biosci- 
ences). Briefly, samples were modified with 10% SDS to a final concentration of 2% SDS, 
heated at 100°C for 15 minutes and clarified by centrifugation. Protein concentration was 
determined using a Qubit fluorometry assay (Invitrogen). 15 μg of material was processed by 
SDS-PAGE using a 10% Bis-Tris homogeneous gel and the MES buffer system. In-gel digestion 
with trypsin was done at 37°C for 4 hrs using a ProGest robot (DigiLab, Marlborough, MA). 
The digested sample was analyzed by nano LC-MS/MS analysis using a Waters NanoAcquity 
HPLC system interfaced to a ThermoFisher Q Exactive. Data were searched against a copy of 
the B. malayi UniProt database (taxon ID: 6278) using a locally running copy of MASCOT 
(Matrix Science Ltd., London, UK). The search was restricted using the following parameters; 
maximum missed cleavages = 2, fixed modifications = carbamidomethyl (C), variable 
modifications = Oxidation (M), Acetyl (N-term), Pyro-Glu (N-term Q) and Deamidation (N, 
Q), a peptide mass tolerance of 10 ppm, and a fragment mass tolerance of 0.02 Da. Mascot 
DAT files were parsed into the Scaffold software for validation, filtering and to create a nonre- 
dundant list per sample. Data were filtered using a minimum protein value of 90%, a minimum 
peptide value of 50% (Prophet scores) and requiring at least two unique peptides per protein. 
 
RNA isolation and sequencing 
 
For detection of RNA species in ELV preparations, small RNAs were preferentially isolated 
from vesicle-containing pellets using the miRCURY RNA Isolation Kit (Exiqon, Vedbaek, 
Denmark) and RNA samples were examined with an Agilent 2100 Bioanalyzer using the RNA 
6000 Nano Kit. For small RNA sequencing (RNA-Seq), total RNA was isolated from ELVs 
released by *5,000 L3s over a 24 hr incubation period using the Total RNA and Protein Isola- 
tion Kit (Invitrogen, Carlsbad, CA). In parallel, total RNA was isolated from whole worm tissue 
using a TRIzol (Invitrogen) protocol, where a 6 hr precipitation step was carried out at -80°C 
to improve small RNA recovery. RNA NGS libraries were constructed using modified Illumina 
adapter methods using SBI’s XRNA Sample Preparation Kit (System Biosciences, Mountain 
View, CA) and indexed with separate bar codes for multiplex sequencing on an Illumina 
MiSeq v3 instrument using a 2 × 75 bp paired end run setting. 
 
miRNA discovery and abundance estimation 
 
Raw reads were trimmed to remove adapter sequences, filtered by quality score, and de-multi- 
plexed using the FASTX-Toolkit [69] (sequencing data are deposited with the NCBI SRA 
under project number PRJNA285132). The miRDeep2 pipeline was used to map short RNA 
reads (>15 nt) to the B. malayi genome for miRNA discovery, and to estimate and normalize 
miRNA abundances with respect to total miRNA read count. Nematode precursor and mature 
miRNA sequences deposited into miRBase [70] were used in the pipeline, including known B. 
pahangi, Caenorhabditis elegans, Ascaris suum, Haemonchus contortus, and Strongyloides ratti 
miRNAs. Non-mapped reads were ranked by abundance, filtered for homology against known 
miRNAs in the phylum Nematoda using BLASTn [71], and incorporated for final quantifica- 
tion of abundance with the miRDeep quantifier script, allowing for capture of miRNAs that 
did not map to the B. malayi assembly due to sequencing gaps. The ggplot2 package [72] of the 
statistical programming language R was used to organize and visualize comparisons between 
vesicular and tissue RNA samples.
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Cell culture 
 
J774A.1 murine macrophages (ATCC, Manassas, VA) were maintained in complete tissue cul- 
ture medium (Dulbecco’s modified Eagle’s medium, 25 mM HEPES, pH 7.4 supplemented with 
2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 0.05 μM 2-mercaptoethanol, 
and 10% heat-inactivated fetal bovine serum) at 37°C and 5% CO2. 24 hrs prior to assays, 400 
μL cells were plated in standard 24-well plates at a density of 5 × 105 cells/well. 
 
Vesicle labeling and uptake 
 
Exosome-like vesicles were purified from a 24 hr culture of 300 Brugia malayi L3 parasites as 
described above and labeled with the green fluorescent dye, PKH67 (Sigma-Aldrich, St Louis, 
MO,USA), according to the manufacturer’s instructions. ELVs were incubated with PKH67 for 
5 min at room temperature and the reaction terminated by addition of 1% BSA in PBS. RPMI 
1640 media was added, mixed and centrifuged at 105,000 × g for 1 hr to separate ELV-bound 
PKH67 from excess PKH67. Labeled ELV were washed again then resuspended in an appropri- 
ate volume of complete tissue culture medium (Dulbecco’s modified Eagles medium, 25 mM 
HEPES, pH 7.4 supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL strep- 
tomycin, 0.05 μM 2-mercaptoethanol and 10% heat-inactivated fetal bovine serum). 
J774A.1 were labeled with red fluorescent lipophilic dye, PKH26 (Sigma-Aldrich, St Louis, 
MO), according to the manufacturer’s instructions. Macrophages were incubated with PKH26 
for 5 min at room temperature and the reaction terminated by addition of 1% BSA. To remove 
excess unbound dye, samples were centrifuged at 400 × g for 10 minutes at room temperature 
and the supernatant discarded. Centrifugation was repeated three more times using 10 ml of 
complete media to ensure full removal of unbound dye and the cells were re-suspended in 
1 mL of complete medium. Approximately 3 × 10
5 
labeled cells were plated onto sterile cover- 
slips and incubated overnight at 37°C/5% CO2. Labeled ELV suspension (approximately 
3 × 107 per coverslip) was added to labeled J774A.1 and incubated for 6 hrs. Cells were washed 
5 times with ice-cold PBS to remove excess labeled ELVs, the cells fixed in 4% paraformalde- 
hyde (Sigma-Aldrich), washed and counterstained with DAPI before mounting and storage at 
4°C. Preparations were visualized using a Leica TCS SP5 X Confocal/multiphoton microscope 
system (Leica Microsystems Inc., Buffalo Grove, IL). 
 
Detection of macrophage modulation by Luminex assay 
Triplicate wells of adhered J774A.1 were treated with approximately 4 × 10
8 
purified L3 stage 
ELVs. The ELVs were purified by ultracentrifugation as previously described, resuspended in 
RPMI 1640 medium (Gibco/Life Technologies, Carlsbad, CA) and quantified by nanoparticle 
tracking analysis. Other treatments were similar volumes of vesicle depleted L3 culture 
medium (supernatant created following pelleting of ELV fraction from spent parasite culture 
medium), live B. malayi L3 parasites (10 worms/well), lipopolysaccharide (LPS; final concen- 
tration 200 ng/mL)(Sigma-Aldrich,  St. Louis, MO), naïve RPMI 1640 culture medium and var- 
ious combinations of these conditions. Supernatants from these cell cultures (400 μL/well) 
were collected 24 or 48 hrs post-treatment and centrifuged briefly (2,000 × g for 10 min) to 
remove non-adhered cells and cell debris before being analyzed for the presence of cytokines/ 
chemokines. The Milliplex MAP Mouse Cytokine/Chemokine kit (EDM Millipore, Billerica, 
MA) interfaced with a Bio-Plex System (Bio-Rad, Hercules, CA) utilizing Luminex xMAP tech- 
nology (Luminex, Austin, TX) allowed the simultaneous identification and quantification of 
the following analytes in the cell culture supernatant: Eotaxin, G-CSF, GM-CSF, IFNγ, IL-1α, 
M-CSF, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12(p40), IL-13, IL-15, IL-17, IP-10, 
MIP-2, KC, LIF, LIX, MCP-1, MIP-1α, MIP-1β, MIG, RANTES, TNFα, IL-12(p70), VEGF,
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IL-9. Briefly, experimental samples, background, standards and controls were added to a 
96-well plate and combined with equal volumes of pre-mixed, antibody coated magnetic beads; 
the plate was sealed and incubated overnight at 4°C. Following washing, 25 μL of detection 
antibody was added and the plate incubated for one hour at room temperature with shaking. 
Streptavidin-Phycoerythrin (25 μL) was added to each well and the plate incubated for a fur- 
ther hour at room temperature before washing. Finally, 150 μL assay buffer was added to all 
wells and fluorescence immediately recorded. Median fluorescent intensity data were analyzed 
as recommended using a five-parameter logistic curve-fitting method for calculating cytokine/ 
chemokine concentration. 
 
 
G-CSF ELISA 
 
Triplicate wells of adhered J774A.1 cells, prepared as described above, were treated with LPS 
(final concentration 200 ng/mL or 0.003 ng/mL), approximately 4 × 10
8 
purified L3 stage ELVs 
as described above, or RPMI 1640 as negative control. Cell culture supernatants were collected 
24 hrs after treatment, cleared via centrifugation as described previously and assayed for 
G-CSF using a Mouse G-CSF Quantikine ELISA kit (R&D Systems, Minneapolis, MN). Stan- 
dard curves were generated using Prism 6 software (GraphPad Software, San Diego, CA) and 
sample G-CSF concentrations determined by regression analysis. 
 
 
Statistical analysis 
 
For analysis of Luminex data, Tukey’s test was used to compare overall treatments while multi- 
ple t-tests, incorporating the Holm-Sidak method to correct for multiple comparisons, were 
used to compare individual chemokines/cytokines following treatments. t-tests were used to 
compare treatment groups following ELISA analysis. All statistical analyses were performed 
using Prism 6 for Mac (Graphpad). 
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S1 Video. Brugia malayi L3 ELVs recorded via NanoSight. 
(MP4) 
 
S1 Table. Small RNA-Seq miRNA abundances and read statistics. 
(XLSX) 
 
S1 Fig. Brugia malayi ELV miRNA sequence homology to nematode and mammalian host 
miRNAs. miRNAs are grouped by putative seed site and aligned. 
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S2 Fig. Macrophage activation is a specific function of Brugia ELVs. (A) J774A.1 macro- 
phages (5 × 10
5
) were treated with approximately 4 × 10
8 
purified L3 stage ELVs, an equivalent 
volume of culture media supernatant from which ELVs had been depleted by centrifugation 
(SN Treated) or naïve culture media (control). The presence of 32 cytokines/chemokines was 
simultaneously assayed using the Milliplex MAP Mouse Cytokine/Chemokine kit (EDM Milli- 
pore) interfaced with a Bio-Plex System (Bio-Rad) utilizing Luminex xMAP technology (Lumi- 
nex). The quantification of identified cytokines is presented. ELV treatment, but not the ELV 
depleted culture media, generates a classically activated phenotype. (B) J774A.1 macrophages 
were treated with approximately 4 × 10
8 
ELVs collected from a culture of Schistosoma mansoni 
invasive stage schistosomules as described for Brugia (Sm ELV), live S. mansoni schistosomules 
(300 per well; Sm) and naïve RPMI 1640 culture media (control). Macrophages were not
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